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1InTRODUCTIOn
Rheumatoid arthritis
Rheumatoid arthritis (RA) is one of the most prevalent chronic inflammatory diseases 
(1). Incidence in Western countries ranges from 9 to 45 cases per 100000 per year, with 
lower incidence observed in South European countries (2). Estimated prevalence ranges 
from 0.3% to 0.8% (2) and females are about three times more often affected than males 
(3).
The etiology of the disease is not completely understood. Increased concordance rates 
in twins and an increased risk associated with a positive family history suggest genetic 
factors play a role in the pathogenesis (1). In addition, genome-wide association studies 
have identified more than a hundred loci associated with RA risk, most of which implicate 
immune mechanisms (1). Environmental factors have been linked to the disease as well. 
Smoking, lower socioeconomic status and periodontal disease have been associated with 
an increased risk of RA (1).
Impact
As a chronic disease, RA carries a substantial burden for both individual patients and so-
ciety (1, 4). RA is a systemic disease that primarily involves inflammation of the joints (1). 
If left untreated, chronic inflammation of the joints causes articular destruction and bone 
erosions, leading to decline and functional disability. (5) Extra-articular manifestations 
may occur as well, among which rheumatoid nodules, pulmonary involvement, vasculitis 
and systemic comorbidities (1).
At the individual level, RA is not only associated with pain and disability due to joint 
inflammation, but also carries a burden extending beyond the joints and has been associ-
ated with an increased risk of several comorbidities (5). An approximately 2-fold higher 
cardiovascular risk has been reported for patients with RA compared with the general 
population (6), that cannot be entirely explained by shared risk factors (7) and is likely a 
consequence of systemic inflammation (8). A 2-fold increased risk of hip and vertebral 
fractures has been reported (9), which can be contributed to bone loss due to disease 
activity, physical inactivity and glucocorticoid use (8). In addition, an approximately 8-fold 
increased risk for developing interstitial lung disease was found in an inception cohort 
of RA patients compared with controls (10). Infection risk is increased in RA patients as 
well, which may be attributed either to an impaired immune system due to the disease or 
to effects of immunosuppressive therapy (5). An increased risk for certain malignancies 
has been associated with RA, among which lymphomas and lung cancer (11). Use of 
TNF-inhibitors has been reported to increase the risk of melanoma and non-melanoma 
skin cancer (12, 13).
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At the level of society, RA has a large impact and leads to increased costs, both due to 
direct and indirect medical costs, such as reduced work capacity and decreased societal 
participation (1, 14).
Psychosocial aspects
Apart from physical comorbidities, RA has been associated with increased levels of 
psychosocial distress, such as fatigue, anxiety, depression and cognitive impairment (5). 
Compared to the general population, prevalence of depression is about 1.5 times higher 
in RA patients (15) and is estimated to occur in 13-20% of patients (16). The prevalence 
may be as high as 40% when mild depressive symptoms are included (17). Anxiety 
often overlaps with depression and occurs 2-4 times more frequently in patients with 
RA (18). Apart from the burden depression and anxiety inflict by themselves, they also 
affect disease activity and treatment response. Higher anxiety and depression scores 
have been associated with significantly less remission rates at follow-up visits (19, 20). 
Fatigue is a common symptom in inflammatory disease. Also in RA patients, fatigue is 
significantly more pronounced compared with controls (21, 22) and tends to have a 
non-resolving character (23). Despite the association between fatigue and inflammation, 
negative associations have been found between baseline erythrocyte sedimentation rate 
and fatigue 1 year later (24) and two meta-analyses concluded that biologicals only have 
a small effect on reducing fatigue (25, 26). Associations have also been found for fatigue 
with pain, depression, anxiety and lack of social support (27-29).
Decreased work performance and work disability are observed in patients with RA (14, 
30) and have been related to worse treatment response (31). Taking all aspects together, 
the burden of RA leads patients to experience a significantly impaired quality of life (5). 
Compared to age- and sex-matched controls, RA patients have lower scores on both the 
physical and mental domains as measured by the Short Form-36 (SF36) (5, 8). Although 
treatment results in improvements in health-related quality of life, scores in both physical 
and mental domains remain below those of age- and sex-matched healthy controls (5).
Overall, we may conclude that there is evidence that RA is associated with higher levels 
of psychological distress, which likely contributes to the lower levels of health-related 
quality of life of RA patients experience. There is also some evidence for an association 
between anxiety and depression and disease activity. However, the body of evidence 
is not yet complete. Most studies focused on single psychosocial factors only or were 
performed in established RA patients. Also, the nature of the relationship between 
psychosocial factors such as anxiety and depression and disease activity score (DAS) 
remains unclear. Therefore, in this work, we aim to study the impact of a broad range of 
psychosocial factors (anxiety, depression, fatigue, coping style) on patients with early RA, 
with a special interest on DAS.
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1Management
Therapeutic management of RA consists of the application of disease-modifying anti-
rheumatic drugs (DMARDs). These agents target inflammation and, by definition, also 
reduce structural damage progression in RA (1). There are two major classes of DMARDs: 
Synthetic DMARDs and biological DMARDs. Synthetic DMARDs can be further divided 
into conventional synthetic and targeted synthetic DMARDs (1). Conventional synthetic 
DMARDs are the oldest class of agents, examples of which are methotrexate, sulphasala-
zine and hydroxychloroquine. Use of these agents has evolved empirically and their 
modes of action are still largely unknown (1). On the contrary, biological and targeted 
synthetic DMARDs have been developed to modulate specific targets in the inflamma-
tion process (1).
Current EULAR recommendations (32) for treatment of RA are based on the following 
principles:
1. Early treatment
2. Treat-to-target
3. Tight control
Early treatment means that therapy with DMARDs should be initiated as soon as the 
diagnosis of RA is made. Treat-to-target implies that treatment should be aimed at 
reaching a target of remission or low disease activity in every patient. Tight control is 
the frequent monitoring of patients for disease activity, so that treatment can be timely 
adjusted.
For newly diagnosed patients, the guidelines state that treatment should be initiated 
with a (combination of) conventional synthetic DMARDs, of which methotrexate should 
be part. Low dose glucocorticoids should be considered as a part of the initial treatment 
strategy for up to 6 months, but should be tapered as rapidly as clinically feasible (32). 
In case the treatment target is not achieved with the first DMARD strategy, guidelines 
recommend the addition of a biological DMARD if poor prognostic factors are present. 
In the absence of such factors, another conventional synthetic DMARD strategy should 
be attempted first. In case a first biological DMARD has failed, patients should be treated 
with another biological DMARD (in case of a failed TNF-inhibitor a second TNF-inhibitor 
may be attempted) (32). Whether or not starting with combination of synthetic DMARDs 
leads to improved outcomes over starting with methotrexate alone remains controversial 
(1) and current guidelines accept both strategies (32). An important argument against the 
use of a combination strategy are the increased toxicity and discontinuations compared 
to methotrexate alone, while several studies show no differences in disease activity 
scores are observed at 6 months and beyond (1). On the other hand, in tREACH it was 
observed that patients initiating with combination DMARD therapy achieve remission 
more quickly, resulting in less biological use and improved functional outcomes at 1 year 
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of follow-up (33). At last, it should be noted that, even if detailed guidelines are available, 
rheumatologists may not fully adhere to them in clinical practice. For instance, the IRIS 
study reported that over 96% of participating rheumatologists stated to agree with the 
EULAR recommendations to start DMARD treatment as early as possible after diagnosis 
and that MTX should be part of the first treatment strategy (34). However, when measur-
ing the actual performance, the rheumatologists only applied these guidelines in 67% 
and 60% of the recorded patients respectively (34). The recommendation that composite 
measures should be recorded regularly was agreed upon by 83% of rheumatologists, but 
only in 54% of patients were composite scores actually recorded in ≥50% of patient visits 
(34).
Remission and tapering
Conceptually, remission has been defined as the total absence of all articular and extra-
articular inflammation and immunologic activity related to rheumatoid arthritis (35). As 
the assessment of such a state is not feasible, instead the concept of clinical remission 
is used in practice. (36) Both in clinical practice and in clinical trials, a cut-off point of 
<2.6 on the 28-joint Disease Activity Score, or <1.6 on the original DAS is often used to 
define remission. However, use of these definitions has been criticized, as signs of joint 
inflammation may clearly be present despite a score indicating remission (36). For this 
reason, the ACR/EULAR committee has advocated the use of more stringent remission 
criteria for use in clinical trials (36).
Still, regardless of the definition used, disease control can be obtained in an increasing 
number of patients (37). For example, in Norwegian patients registered in the NOR-
DMARD registry, remission rates have doubled over the past decade to 40% (38). Similar 
patterns have been observed in the ESPOIR cohort, in which 50% of early RA patients 
were in DAS28 remission and 65% in DAS28 low disease activity 5 years after disease 
onset. The growing population of patients with RA in remission can be attributed for 
a great part to a paradigm shift that has taken place over the past two decades in the 
treatment of RA, in which concepts early diagnosis, tight-controlled treatment and treat-
to-target are central (39). Another important factor has been the rapid development of 
new anti-rheumatic drugs, especially the biological DMARDs (37).
As a consequence of this success, a new question has emerged whether de-escalation 
or even stopping of DMARD therapy should be considered in patients that have reached 
long-standing remission (37). This question is important for several reasons (37). First, in 
case of a symptom-free disease state, the benefits of continuous treatment should still 
outweigh the risks associated with long-term use of that treatment, both of which may 
be difficult to establish. Second, the costs of DMARDs, in particular bDMARDs, are high. 
As healthcare resources are under growing economic pressure, potential overtreatment 
of patients in remission should be avoided. This could make resources available for other 
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1patients in need of expensive treatments. Third, a potential cure of RA could can only 
be distinguished from mere suppression of inflammation by DMARDs after therapy has 
been de-escalated. (37) Due to the potential benefits, the option to de-escalate treat-
ment in patients in sustained remission has also been included into recent treatment 
guidelines (32). However, treatment de-escalation may come with certain risks as well. 
A systematic review and meta-analysis on the withdrawal of biological agents in RA 
found that withdrawing biologics decreased the probability of maintaining low disease 
activity and remission and found a small but significantly increased risk for radiographic 
progression (40). Identification of patients that would gain most benefit, or harm, from 
treatment de-escalation would therefore be preferable, but is not yet possible (37).
To further optimize the management of RA patients, rheumatologists need to be able 
to make informed decisions based on the best available evidence. Therefore, a second 
aim of this work is to study the effects of treatment de-escalation in patients with low 
disease activity or remission to aid rheumatologists in making informed decisions. A spe-
cial focus will be on the tapering of conventional synthetic DMARDs, as recent literature 
on this topic is lacking.
summary and aims
Despite the advances that have been made in the medical treatment of RA (39), chal-
lenges to further optimize care for patients remain. Two of these challenges will be the 
focus of this work: First, despite the better medical outcomes the burden of disease in 
RA patients is still higher compared to the general population, which may be attributed, 
at least in part, to higher levels of psychological distress patients experience (5). Second, 
continuous medical drug treatment for patients in remission is only justified if the ben-
efits outweigh the disadvantages such as potential overtreatment, safety considerations 
and treatment costs (37). These challenges resulted in the main objectives of this thesis:
1. To study the impact of psychosocial factors on patients with early RA, with special 
interest in the relationships between psychosocial factors and disease activity score 
and achievement of treatment goals
2. To study the effects of treatment de-escalation in patients with low disease activity 
or remission and aid rheumatologists in making informed decisions with regard to 
treatment de-escalation
Overview
In chapter 2, we will describe the burden of disease, quality of life and health care con-
sumption of patients diagnosed with RA during the first year of follow-up and compare 
them to patients diagnosed with joint complaints without synovitis.
In chapter 3 we will evaluate the associations between psychosocial factors and disease 
activity at subsequent visit during the first 15 months of follow-up.
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In chapter 4, we will describe the prevalence and pattern of fatigue in patients diag-
nosed with early RA during the first year after diagnosis. Factors associated with worsen-
ing and recovering of fatigue over time in patients with low or high levels of fatigue at 
baseline are investigated.
In chapter 5, predictors for attaining remission within the first 6 months of treatment 
and sustained remission at 6 and 9 months are explored.
In chapter 6, we will investigate the tapering of conventional synthetic DMARDs in 
patients with early arthritis in sustained remission during 2-year follow-up of the tREACH 
trial.
In chapter 7, we will present a systematic literature review of publications on RA 
patients tapering or discontinuing synthetic or biologic DMARDs. Main focus will be on 
reported flare rates, radiographic progression and time to achieve re-remission after 
flare.
In chapter 8, we will explore doctor’s preferences for de-escalating DMARDs in rheu-
matoid by means of a discrete choice experiment. In this study, we will investigate which 
factors rheumatologists deem important in their decision to de-escalate medication and 
the relative importance. Differences between rheumatologists will be explored as well.
In chapter 9, we will provide a general discussion of the main findings of this thesis and 
their relevance to clinical practice. Methodological considerations and their potential im-
plications on the findings will be discussed. Finally, several recommendations for future 
research will be presented.
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AbsTRACT
Objective
To compare the burden of disease and its development over time in patients being 
referred to an early arthritis cohort being diagnosed either as having arthralgias without 
synovitis or as having rheumatoid arthritis (RA).
Methods
Patients being diagnosed as having arthralgias without synovitis or RA were selected 
from the REACH cohort. Data were collected on clinical and psychological characteristics, 
demographics, pain scores (Rheumatoid Arthritis Disease Activity Index), functional 
ability (Health Assessment Questionnaire), health related quality of life (HRQOL, Short 
Form-36), fatigue (Visual Analogue Scale and Fatigue Assessment Scale) and health care 
utilization (HCU) at baseline, 6 and 12 months of follow-up. Burden of disease measures 
(pain, functional ability, fatigue and HRQOL) and HCU levels were plotted over time for 
both groups. A Poisson regression model for repeated data was used to identify determi-
nants of HCU for both groups.
Results
At baseline, 330 patients with arthralgias without synovitis (non-synovitis, NS group) and 
244 RA patients (RA group) were included. Overall, burden of disease measures and HCU 
levels were very similar between groups. Both groups showed improvement over time 
with respect to pain scores, functional ability, HRQOL and HCU levels. Independent pre-
dictors for high HCU were identified: More pain, worse physical health and external locus 
of control in the NS group and longer duration of complaints, chance locus of control and 
worse physical functioning in the RA group.
Conclusion
Despite the absence of an inflammatory diagnosis, patients with arthralgias without 
synovitis experience a similar burden of disease compared to RA patients.
Quality of life and health care use in arthralgia patients without synovitis
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InTRODUCTIOn
Over the past decade, early arthritis clinics have been established around the world (1). 
Main goal of these clinics is the early detection and treatment of rheumatoid arthritis, 
which has been shown to result in a more favorable course of disease (2-4). Although 
many of the patients referred to early arthritis clinics are diagnosed as having early 
rheumatoid arthritis (RA) and benefit from early treatment of their condition, another 
part of the referred patients do not show any physical signs of an underlying inflamma-
tory disease and are unlikely to develop RA in the future. Patients in this second group 
are referred to the rheumatologist with complaints that very much resemble those of 
early arthritis, but for whom no signs of arthritis can be found at physical examination. 
However, despite the absence of an underlying inflammatory condition, a previous study 
suggested that these patients experience a similar burden of disease as early RA patients 
or patients with other inflammatory joint conditions do (5). Formal diagnoses, as well as 
a clear understanding of the processes underlying the complaints, are usually lacking in 
this patient group. As a result, the consequences on functional ability, health and gen-
eral well-being, as well as the progression of health complaints over time are unknown. 
Furthermore, despite the high burden of disease, standardized treatment regimens are 
usually absent for this category of patients. It is unclear what strategies these patients 
adopt to deal with their complaints after visiting the rheumatologist being diagnosed as 
non-synovitis.
Aim of the present study was to to compare the burden of disease and its development 
over time in patients being referred to an early arthritis clinic being diagnosed either as 
having arthralgias without synovitis or as having rheumatoid arthritis (RA). To do this, we 
set out to answer to the following questions:
1. What are the quality of life, perceived pain, perceived fatigue, functional ability and 
health care consumption levels in patients with arthralgias without clinical synovitis 
compared to those of RA patients and how do these domains evolve over time?
2. Which factors are associated with higher health care consumption levels in patients 
with arthralgias without clinical synovitis and patients with RA?
PATIenTs AnD MeTHODs
study population
Patients in this study were selected from the Rotterdam Early Arthritis CoHort (REACH) 
(5). All patients participating before June 2009 that gave permission to send question-
naires were included. Patients were excluded if diagnosed with non-RA arthritis at any 
moment during the 12 months of follow-up (Figure 1). 
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Patients in REACH
Included before June 2009
Permission to send questionnaires
n = 1216
Diagnosis RA at all time 
points (baseline, 6 months 
and 12 months)
n = 244
Diagnosis inflammatory 
arthralgias without synovitis 
at all time points (baseline, 
6 months and 12 months)
n = 346
Diagnosis non-RA arthritis 
at any time point (baseline, 
6 months or 12 months)
n = 626
figure 1. Inclusion and follow-up of patients with RA and patients with arthralgias without synovitis.
The REACH is a prospective inception cohort set up in the greater Rotterdam area 
in July 2004. Patients were recruited at their first consultation either via the general 
practitioner or via the outpatient rheumatology clinic of 5 hospitals. 
Patients in the REACH cohort were included if they fulfilled either or both of the fol-
lowing criteria:
1) having synovitis in at least one joint on clinical examination
2) having pain, stiffness or loss of function in at least two joints accompanied by at least 
two of the following criteria: morning stiffness > 1 hour; unable to clench a fist in the 
morning; pain when shaking someone’s hand; pins and needles in the fingers; dif-
ficulties wearing rings; difficulties wearing shoes; a family history of RA; unexplained 
fatigue lasting less than one year.
Patients were excluded if their symptoms existed for more than 12 months, or if 
symptoms resulted from trauma or overuse. This study was approved by the ethics com-
mittees of the 5 participating hospitals. All patients gave written informed consent.
Measures for burden of disease
Pain
Pain was assessed using the Rheumatoid Arthritis Disease Activity Index (RADAI) ques-
tionnaire (6). The RADAI was modified so that two questions regarding the activity of 
joint inflammation were excluded. Sumscores were calculated on a scale of 0-10, higher 
values indicating more symptomatic disease.
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Functional ability
Functional ability was assessed by the Health Assessment Questionnaire (HAQ) (7). The 
HAQ ranges from 0 to 3, higher scores indicating more disability.
Health related quality of life
Health related quality of life (HRQOL) was assessed by the Medical Outcome Study Short 
Form-36 Health Survey (SF-36). The SF-36 is a generic 36-item questionnaire covering 
8 dimensions: physical functioning (PF), physical role functioning (RP), bodily pain (BP), 
general health (GH), vitality (VI), social functioning (SF) and mental health (MH) (8, 9). 
To provide a global measure of physical and mental functioning, component summary 
scores (physical component scale (PCS) and mental component scale (MCS) respectively) 
were calculated from the 8 separate dimensions of the SF-36. The 8 dimensions and 2 
summary scores may range from 0 to 100, a higher score indicating a better HRQOL.
Fatigue
Fatigue was measured by questionnaire using 2 different scales: A visual analogue scale 
(VAS) and the Fatigue Assessment Scale (FAS). The VAS is a continuous scale, ranging 
from 0 to 100. Total FAS scores can range from 10 to 50 (10). On both the VAS and the 
FAS, higher scores indicate higher levels of fatigue.
Health care use
Health care utilization (HCU) was assessed by a questionnaire at baseline, 6 months and 
12 months of follow-up. At each point, patients were asked to report the number of visits 
for joint complaints for general practitioners, medical specialists, physiotherapists, nurse 
specialists, occupational physicians and other health care providers (to be specified by 
the patient). If any health care provider was consulted, patients were asked to report the 
number of visits.
To evaluate overall use of care, a combined HCU measure was constructed as follows: 
visits to GP + visits to a medical specialist + visits to a physiotherapist / 5 + visits to 
alternative health care providers. Since generally, multiple sessions for physiotherapy are 
prescribed we chose a correction factor of 5 (based on the distribution of our data, 15% 
had more than 5 visits to a physiotherapist at baseline) to be applied for its contribution 
to the combined measure.
Clinical and demographic characteristics
Clinical characteristics
A trained research nurse took a standardized history and conducted a physical examina-
tion at baseline, after 6 months and after 12 months. Tender and swollen joint counts 
were computed evaluating 53 joints and 44 joints respectively (as required to calculate 
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the original Disease Activity Score (DAS) (11)). The presence or absence of synovitis was 
confirmed by the treating rheumatologist. Diagnoses were obtained directly from the 
treating rheumatologists or chart reviews. 
Demographic characteristics and lifestyle
Patients were asked about their age, sex and ethnicity. Education was categorized as low 
(primary school, lower and intermediate secondary schooling or intermediate vocational 
training), intermediate (higher secondary schooling or intermediate vocational training), 
and high (higher vocational training or university). Employment status was defined as 
having paid employment (yes/no). Living status was ascertained and patients were clas-
sified as living alone or with others. Body mass index was categorized into obese (≥ 30 
kg/m2) or non-obese (< 30 kg/m2).
Psychosocial characteristics
Coping style
Coping style was assessed using the Coping of Rheumatic Stressors (CORS) questionnaire 
(12-14). The questionnaire consists of 2 scales: “decreasing activities to cope with pain” 
and “pacing to cope with limitations”. Sum scores were computed. A higher sum score 
indicates more frequent use of the coping strategy.
Locus of control
Perceived control over health outcomes was measured by the Multidimensional Health 
Locus of Control Questionnaire (MHLC). The MHLC assesses 3 different dimensions of 
perceived health control by means of 3 scales: “internal”, “external” and “chance” (15, 
16). The “internal” scale reflects the belief that people are personally responsible for 
their own health. The physician scale reflects that a physician is responsible for one’s 
health. The “chance” scale reflects the belief that health depends on chance, luck or fate. 
The subscale scores range from 6 to 36, a higher score indicating that a patient’s belief 
is stronger in that particular health locus of control. The scales are not opposite ends of 
the same spectrum. Thus, it is possible to have, for example, both internal and physician 
beliefs about health status at the same time.
Anxiety / depression
Anxiety and depression were ascertained using the Hospital Anxiety and Depression Scale 
(HADS) (17, 18). The HADS was originally developed to identify anxiety disorders and 
depression among patients in non-psychiatric hospital clinics. Both the anxiety and depres-
sion subscales range from 0 to 21, higher scores indicating more anxiety or depression.
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statistical analysis
Characteristics of the study population were described using simple descriptive analysis 
techniques. Baseline differences between groups among continuous variables were 
tested with the unpaired t-test or with the Wilcoxon rank-sum test if data were not 
normally distributed. Categorical variables were tested using Pearson’s chi-square test.
Determinants of HCU were evaluated using Poisson regression analyses for repeated 
data. A 6-month time-lag model was chosen, implying that the measurement of a risk 
factor was related to the outcome measured 6 months later. For variables that measured 
overlapping constructs (HADS and SF-36 MCS, HAQ and SF-36 PCS, Tender Joint Count 
and RADAI) or were highly correlated (coping with pain and coping with limitations), one 
variable was selected for inclusion into the model. Covariates that were collected solely 
at baseline were included into the model as time-independent covariates. All univariate 
analyses were performed taking into account the evolution of HCU over time. For the 
multivariable models, first variables were selected based on their level of significance 
in the univariate analysis (p ≤ 0.20). Then backwards stepwise selection was performed, 
while covariates month, age and sex were included by default. Missing covariates were 
imputed with their corresponding individual value at 6 or 12 months of follow-up. If 
neither of these were available the group mean was imputed. Subsequently, missing 
values at 6 months of follow-up were imputed with their corresponding baseline values 
and missing values at 12 months of follow-up were imputed with their corresponding 
values at 6 months. All statistical analyses were performed with the statistical package 
STATA (12.0 SE) using p ≤ 0.05 as level of statistical significance.
ResUlTs
General characteristics
At baseline, 330 patients with inflammatory arthralgias without synovitis (non-synovitis, 
NS group) and 244 rheumatoid arthritis patients (RA group) were included. Of 244 pa-
tients in the RA group, 166 (68.0%) fulfilled the ACR1987 criteria and 171 (70.1%) fulfilled 
ACR2010 criteria. One-hundred-twenty-four patients (50.8%) fulfilled both criteria, 42 
(17.2%) fulfilled ACR1987 criteria only, 47 (19.3%) fulfilled ACR2010 criteria only and 31 
(12.7%) fulfilled neither criteria.
On average, patients in the RA group were older (54.0 years versus 45.0 years), were 
more often males, had lower education, were more often unemployed, had a shorter 
duration of complaints (103 versus 136 days), had more tender joints (9 versus 4), had 
higher pain scores (RADAI, 3.3 versus 2.5) and had higher functional disability scores 
(HAQ, 1 versus 0.6) than patients in the NS group (Table 1).
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Table 1. Baseline clinical, demographic and psychosocial characteristics of non-synovitis (n=330) and 
rheumatoid arthritis (n=244) patients.
non-synovitis
(n=330)
Rheumatoid arthritis
(n=244)
P-value
Clinical and demographic characteristics
Age, mean [n] (sd) 45.0 [330] (12.4) 54.0 [244] (13.7) < 0.001a
Female, n (%) 282/330 (85) 165/244 (68) < 0.001b
Dutch ethnicity, n (%) 251/309 (81) 188/229 (77) 0.823b
Education, n (%) 0.008b
Low 154/310 (50) 145/230 (59)
Intermediate 96/310 (31) 54/230 (22)
High 60/310 (19) 31/230 (13)
Living alone, n (%) 40/312 (13) 38/231 (16) 0.266b
Paid employment, n (%) 204/313 (65) 127/231 (52) 0.017b
BMI, mean [n] (sd) 26.8 [321] (5.1) 26.4 [219] (4.6) 0.376a
Duration of complaints, 136 [329] (7 – 380) 103 [244] (7 – 373) < 0.001c
median days, [n] (range)
Tender joint count, median [n] (range) 4 [328] (0- 26) 9 [241] (0 – 45) < 0.001c
RADAI (0-10), median [n] (range) 2.5 [304] (0 – 8.4) 3.3 [225] (0 - 9.5) 0.004c
HAQ (0-3), median [n] (range) 0.6 [310] (0 - 2.3) 1 [229] (0 - 2.9) < 0.001c
Fatigue (FAS), median [n] (range) 22 [307] (10 – 48) 21 [225] (10 – 47) 0.177c
Diagnosis, n(%) N/A
Tendinopathy 48/330 (15)
Joint complaints (other) 201/330 (61)
Fibromyalgia 11/330 (3)
Osteoarthrosis 70/330 (21)
Comorbid conditions, n (%) 0.382b
None 83/320 (26) 76/232 (31)
1 124/320 (39) 80/232 (33)
2 66/320 (21) 44/232 (18)
3 or more 47/320 (15) 32/232 (13)
Psychosocial characteristics
Coping with pain (8-32), 14 [310] (8 – 29) 15 [229] (8 – 30) <0.001c
median [n] (range)
Coping with limitations (8-40), 20 [310] (10 – 37) 23 [229] (10 – 40) <0.001c
median [n] (range)
Locus of control, median [n] (range)
Internal (6-36) 21 [307] (7 – 32) 21 [231] (6 – 34) 0.541c
External (6-36) 17 [307] (6 – 34) 20 [231] (9 – 35) <0.001c
Quality of life and health care use in arthralgia patients without synovitis
27
2
Psychosocial characteristics, functional ability and fatigue
Psychosocial characteristics were very similar between groups (Table 1). Although 
significant differences were found on coping with pain and limitations (CORS), physical 
health (SF-36 PCS) and external locus of control, differences are too small to have clinical 
relevance. Pain scores (RADAI) decreased over time in both groups (Figure 2A) from 2.9 
(95%-CI 2.7-3.1) to 2.1 (95%-CI 1.8-2.3) and 3.4 (95%-CI 3.1-3.7) to 1.8 (95%-CI 1.6-2.0) 
in the NS and RA group respectively. A trend was seen for higher pain scores at baseline 
and lower pain scores after 6 and 12 months in the RA group. Baseline functional ability 
(HAQ) scores were worse in the RA group but decreased over time (Figure 2B). HAQ 
scores remained more or less constant over time in the non-synovitis group. Fatigue 
scores, as measured with the fatigue assessment scale (FAS), were similar in both groups 
and remained constant over time (Figure 2C). Fatigue scores measured on a visual analog 
scale (VAS), were similar in both groups and decreased from 55 (95%-CI 52-57) and 51 
(95%-CI 48-54) at baseline to 47 (95%-CI 44-51) and 42 (95%-CI 38-46) after 12 months 
in the NS group and RA group respectively (Figure 2D). HRQOL (SF-36 subscales) was 
comparable or somewhat lower for the RA group, improving over time for both groups 
(Figure 3). However, HRQOL remained considerably lower than the population average 
in both groups.
Table 1. Baseline clinical, demographic and psychosocial characteristics of non-synovitis (n=330) and 
rheumatoid arthritis (n=244) patients. (continued)
non-synovitis
(n=330)
Rheumatoid arthritis
(n=244)
P-value
Chance (6-36) 19 [307] (6 – 35) 20 [231] (6 – 36) 0.585c
Anxiety (HADS (0-21)), 6 [309] (0 – 21) 5 [231] (0 – 18) 0.151c
median [n] (range)
Depression (HADS (0-21)), 3 [309] (0 – 18) 4 [229] (0 – 18) 0.067c
median [n] (range)
SF36
PCS (0-100), median [n] (range) 39 [306] (12 – 59) 32 [225] (9 - 58) <0.001c
MCS (0-100), median [n] (range) 54 [306] (20 – 70) 54 [225] (21 – 74) 0.343c
a Student t-test
b Fisher’s exact test
c Wilcoxon rank-sum test
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figure 2. Evolvement of pain scores (RADAI) (panel A), functional ability (HAQ) (panel B), fatigue mea-
sured with the FAS (panel C) and fatigue measured with the VAS (panel D) over time in patients with 
arthralgias without synovitis and patients with rheumatoid arthritis. Dotted lines indicate 95%-confi-
dence intervals.
figure 3. Health related quality of life in patients with arthralgias without synovitis (panel A) and pa-
tients with rheumatoid arthritis (panel B), as measured by the SF-36 components physical functioning 
(PF), physical role functioning (PR), bodily pain (BP), general health (GH), vitality (VI), social functioning 
(SF), emotional role functioning (RE), and mental health (MH). Averages for the general Dutch popula-
tion aged >25 years are shown.
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Health care utilization
HCU decreased over time in both groups and was similar in both groups, except for more 
visits to medical specialists in the RA group, which one would expect (Figure 4). In the 
NS group, high levels of HCU were associated in the multivariable Poisson analysis with 
increased pain (IRR 1.10, 95%-CI 1.02–1.17), worse physical health (IRR 0.98, 95%-CI 
0.96-0.99) and external locus of control (IRR 1.04, 95%-CI 1.01-1.07) (Table 2) and in 
the RA group with shorter duration of complaints (IRR 1.53, 95%-CI 1.17-2.00), worse 
physical functioning (IRR 0.98, 95%-CI 0.97- 0.99) and low chance locus of control (IRR 
1.03, 95%-CI 1.01-1.05) (Table 2).
figure 4. HCU in patients with arthralgias without synovitis (panel A) and patients with rheumatoid ar-
thritis (panel B) during the 6 months prior to baseline, 6 and 12 months of follow-up, by type of health 
care provider.
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Table 2. Multivariable Poisson regression for repeated datab: Determinants for combined HCU over the 
first year for non-synovitis and rheumatoid arthritis patients.
Multivariable model Multivariable model
non-synovitis Rheumatoid arthritis
IRR p 95%-CI IRR p 95%-CI
Month 0.944 0.000 0.922 – 0.967 0.962 0.000 0.942 – 0.982
Agea 1.001 0.858 0.990 – 1.013 1.000 0.992 0.992 – 1.008
Female sex 1.110 0.597 0.755 – 1.630 1.085 0.465 0.872 – 1.348
Duration of complaints
90-180 days 0.922 0.476 0.737 – 1.153
>180 days 0.653 0.002 0.500 – 0.852
Pain (RADAI) 1.095 0.009 1.023 – 1.172
External locus of controla 1.036 0.018 1.006 – 1.066
Chance locus of controla 0.972 0.004 0.953 – 0.991
SF36 PCS 0.975 0.000 0.963 – 0.987 0.980 0.000 0.971 – 0.988
a baseline
b backwards selection was applied; variables month, age, sex were included by default
DIsCUssIOn
Overall, we observed that the burden of disease, as measured by pain, disability, fatigue 
and quality of life, and health care consumption levels are very similar between patients 
with arthralgias without synovitis compared to patients with rheumatoid arthritis. Our 
results indicate that, despite the absence of an underlying inflammatory process, patients 
with arthralgias without synovitis experience a burden of disease that is similar to that of 
patients diagnosed with early rheumatoid arthritis, at least during the first year of follow-
up. Pain scores, functional ability, HRQOL and health care consumption levels improved 
over time in both groups. Fatigue scores improved only marginally (VAS fatigue) or not 
at all (Fatigue Assessment Scale) in both groups. Groups differed most with respect to 
baseline disability scores (HAQ), which were higher in the RA group. Small differences 
were observed with respect to health care consumption levels, that were somewhat 
higher in the RA-group, and HRQOL scores (SF-36 subscales), that were either similar or 
somewhat worse in the RA group. The finding that HCU levels in the NS-group are quite 
similar to those observed in the RA-group is surprising. RA patients are actively being 
treated for their disease and have regularly scheduled visits with their rheumatologist, 
which accounts for a large part the health care consumption levels observed. Patients 
in the NS-group, on the other hand, probably seek care for different reasons. Possibly 
searching for a diagnosis and relief for their symptoms. 
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In existing literature, studies on burden of disease measures and health care consump-
tion in RA patients are sparse and absent in patients with arthralgias without synovitis. 
In a prospective cohort study of 183 patients with early rheumatoid arthritis included 
between 1985 and 1989, Lindqvist et al. found that median HAQ scores increased from 
0.8 at baseline to 1 after one year of follow-up (19). In contrast, we found that median 
HAQ scores decreased in the RA group from 1.0 at baseline to 0.6 after 12 months. These 
differences are probably a consequence of the availability of more effective treatment 
regimens nowadays. In accordance to our findings, a study comparing four cohorts of 
patients with early rheumatoid arthritis found that pain scores (VAS) decreased in all 
cohorts during the first year of follow-up (20). In the Dutch cohort, pain scores decreased 
from 3.9 at baseline to 2.6 at 1 year of follow-up (20).
Despite substantial improvements in pain, functional ability and HRQOL scores, we 
only observed a modest improvement in fatigue scores as measured on the visual analog 
scale (VAS), while no improvement in fatigue scores was seen on the FAS. Possibly, the 
FAS is less sensitive than the VAS for the detection of subtle changes in fatigue. We did 
not find any studies investigating levels of fatigue in NS patients in current literature. 
However, in line with our findings, studies investigating the effect of treatment with con-
ventional or biologic DMARDs on VAS fatigue scores in RA patients, found improvements, 
but with small effect sizes, as well (21, 22).
Second aim of this study was to identify factors associated with high HCU levels in pa-
tients with arthralgias without synovitis and patients with RA. Our multivariable Poisson 
regression analyses showed that overall HCU was associated with worse physical health 
in both groups. Differences between the groups were found for duration of symptoms at 
baseline (>6 months) and high chance locus of control, that were associated with lower 
HCU in the RA group, while higher pain scores and external locus of control were associ-
ated with higher HCU in the non-synovitis group. We could not find any previous studies 
in which HCU was assessed in an early arthritis cohort. In a cross-sectional study among 
1200 patients with established RA, Jacobi et al. found that overall high use of care was 
associated with younger age, female sex, longer disease duration and having 2 or more 
comorbidities (23). We could not confirm a relationship for age, sex and comorbidity. 
These discrepancies could be explained by the smaller sample size of our study, or the 
difference between patients in the two studies (long standing RA in the Jacobi study 
versus newly diagnosed RA in our study). Moreover, Jacobi found increased disease dura-
tion to be associated with high HCU, while we found a longer duration of complaints to 
be associated with less HCU.
This study has several strengths and weaknesses. Strong points include the fact that 
data were obtained prospectively and repeatedly within an early arthritis cohort. De-
terminants for HCU were analysed using a Poisson model for repeated data, taking into 
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account progression of the outcome over time. Possible weaknesses of this study are the 
relatively small sample sizes of the two patient groups. Possible determinants for HCU 
might not have been detected due to this. Also, HCU was measured using questionnaires, 
introducing a potential for recall bias. Recall bias could have led to both an over- and an 
underestimation of HCU, although underreporting was found to be the more common 
problem when using questionnaire data (24). In either case, as disease burden is very 
similar among groups, we would expect that if recall bias indeed is present, it would 
be similar among groups. This would then lead to non-differential misclassification of 
health-care use, resulting in a dilution of effect sizes for determinants of HCU in our Pois-
son regression models. Therefore, the relatively weak effect sizes observed in the mul-
tivariable analyses for determinants of HCU might be a consequence of non-differential 
misclassification of HCU due to recall bias. Another limitation might be that some patients 
diagnosed with fibromyalgia (n=10) were among the patients in the non-synovitis group, 
because fibromyalgia was not an a priori exclusion criterion. This could have biased the 
results for the group. However, excluding the 10 patients with fibromyalgia (3.6% of total) 
from the analysis of determinants of HCU in the non-synovitis group did not substantially 
change the results as previously found (data not shown). Also, the finding that HRQOL is 
similar between groups pertains only to the first year of follow-up. Further observation 
is required to see if this is still true later on. Another limitation could be that patients 
in the non-synovitis group were selected on the basis that they did not develop any 
form arthritis during the first 12 months of follow-up, while they might be developing 
arthritis later on. Patients in our cohort were followed-up for 24 months. Therefore, we 
checked whether patients in the NS-group had developed any form of arthritis at 24 
months of follow-up or beyond. At 24 months of follow-up, 4 patients in the NS-group 
had developed arthritis. Two patients were diagnosed with RA, 1 patient was diagnosed 
with polyarthtritis and 1 patient was diagnosed with oligoarthritis. Beyond 24 months of 
follow-up, 8 more patients developed a form of arthritis. Five patients were diagnosed 
with RA, 2 patients were diagnosed with psoriatic arthritis, and one patient was diag-
nosed with synovitis due to osteoarthritis. However, excluding the 12 patients developing 
arthritis beyond 12 months of follow-up from the analysis did not significantly change the 
results (data not shown).
COnClUsIOn
In conclusion, we found that the burden of disease, as well as health care use (HCU), in 
patients with arthralgias without synovitis is comparable to that of patients with rheu-
matoid arthritis. Although both groups show improvements in pain scores, quality of life 
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and reduction of HCU over time, only a modest improvement was seen for fatigue in 
both groups.
Health related quality of life in the non-synovitis group remains substantially lower 
compared to the general population. We therefore believe that, after synovitis is suf-
ficiently ruled out by the rheumatologist, patients should be offered further support and 
monitoring by their general practitioner. Depending on the burden of health complaints, 
the emphasis could lie on helping patients to better cope with their complaints, for 
instance through psychological interventions. However, if any joint swelling does occur in 
the future, patients should be referred back to a rheumatologist for further examination. 
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AbsTRACT
Objectives
To investigate 1) whether psychosocial factors have an additional effect on disease activ-
ity and 2) which compounds of psychosocial factors are the most influencing ones during 
the first year of RA treatment.
Methods
Fifteen months follow-up data were used from patients included in tREACH; an RCT 
comparing initial triple DMARD therapy (iTDT) to methotrexate monotherapy (iMM) 
with glucocorticoid bridging in both groups. Patients were evaluated every 3 months and 
treated-to-target. Associations between DAS at 3, 9 and 15 months and psychosocial fac-
tors anxiety, depression, fatigue and coping with pain at the previous visit were assessed 
by multivariable linear regression correcting for demographic, clinical and treatment 
related factors.
Results
N=265, 251 and 162 patients were available for analysis at 3, 9 and 15 months of follow-
up respectively. Baseline anxiety and coping with pain were associated with DAS at 3 
months. Coping with pain at 6 months was associated with DAS at 9 months. Fatigue at 
12 months was associated with DAS at 15 months. Psychosocial factors were moderately 
correlated to each other. Effects on DAS were mainly through DAS components tender 
joint count and global health.
Conclusion
Psychosocial factors have an additional effect on DAS throughout the first year of treat-
ment in early RA. A change in pattern was observed from anxiety and coping with pain 
being associated with subsequent DAS at baseline towards fatigue being associated with 
subsequent DAS at 12 months. Due to the explorative nature of this study, more research 
is needed to confirm this pattern.
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InTRODUCTIOn
Rheumatoid arthritis is a common autoimmune disease and is associated with progressive 
disability, early death and socioeconomic costs (1). Disease progression can be tackled by 
early treatment with DMARDs, using tightly controlled and treat-to-target strategies (2, 
3). This target has been proposed in guidelines as remission or low disease activity, which 
is commonly measured in clinical practice by composite scores such as DAS and DAS28 
(4). Recently published studies show that with this regime a response rate between 40-
80% can be reached within 1 year (5, 6). Several patient and disease characteristics, such 
as baseline disease activity (7, 8), age (7, 9) and sex (7-9) have been reported that may 
explain part of the variability in response rates. However, a large part of the variability 
remains unexplained, suggesting that other, unidentified, factors may be at play as well. 
Recent interest has gone out to the influence of psychosocial factors. Several studies 
have reported significant associations between baseline levels of anxiety and/or depres-
sion and subsequent disease activity scores or its components (10-12). However, effects 
of psychosocial factors after treatment has been initiated on disease activity have not 
been extensively studied. Knowing and understanding the effect of psychosocial factors 
underlying disease activity and treatment response could provide important information 
for selection of therapy, evaluation of response, and even targeted psychological inter-
ventions aimed at optimizing patient outcome (13). In this study, we aimed to answer 
the following questions: 1) Is there, apart from an effect by patient and disease related 
factors, an additional effect of psychosocial factors on the disease activity during the first 
year of treatment in an early RA population. 2) Which compounds of psychosocial factors 
are the most influencing ones during the disease course?
MeTHODs
study population
Fifteen months follow-up data were used from the tREACH cohort, for which a detailed 
description of the inclusion criteria and protocol can be found in the original tREACH paper 
(6). In short, patients with early arthritis (duration of complaints < 1 year) and a high risk 
of developing persistent arthritis (score >6 points on Visser model (14)) were eligible. Of 
the included patients, 97% fulfilled the ACR/EULAR 2010 criteria for RA (4). Patients were 
randomized to the following induction treatment strategies: Triple DMARD therapy (iTDT; 
methotrexate (MTX) 25 mg/week, sulphasalazine 2000 mg/day and hydroxychloroquine 400 
mg/day or MTX monotherapy 25 mg/week (iMM). Both groups received bridging therapy 
with glucocorticoids (triamcinolone acetonide 80 mg or methylprednisolone 120 mg once 
by intramuscular injection or oral prednisone 15 mg for 4 weeks, thereafter tapered by 5 
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mg/week). Patients were evaluated every 3 months. In case DAS was >2.4, patients were 
switched to a TNF-blocker combined with MTX 25 mg/week. If sustained remission (DAS<1.6 
at 2 consecutive visits) was achieved, medication was tapered according to protocol. Detailed 
information on the medication scheme can be found in the original tREACH paper (6).
Outcomes
Outcomes were the disease activity scores (DAS) at 3, 9 and 15 months of follow-up.
Psychosocial factors
Psychosocial factors, measured at baseline, 6 and 12 months of follow-up, included 
anxiety and depression (hospital anxiety and depression score (HADS)), fatigue (Fatigue 
Assessment Scale (FAS)) and coping with pain (Coping with Rheumatic Stressors) and are 
explained in more detail below:
Coping with pain: Coping with pain was measured by the Coping with Rheumatic 
Stressors (CORS) questionnaire. The list contains 8 questions about coping with pain 
(Cronbach’s alpha 0.88). Scores range from 8-40 (15).
Depression and anxiety: The Hospital Anxiety and Depression Scale (HADS) was used to 
measure depression and anxiety. The scores for depression and anxiety range between 
0 to 21, higher scores indicating symptoms related to more anxiety or depression (16).
Fatigue: Fatigue was assessed using the Fatigue Assessment Scale (FAS). Questions 
were asked about the fatigue status of the patient. The score ranges from 10 to 50, 
higher score indicating higher levels of fatigue (17).
Demographic, disease related and treatment related factors
Age, sex, rheumatoid factor (RF) and anti-citrullinated protein (ACPA) status were as-
sessed at baseline. For this study, initial treatment strategy was included as a binary 
variable, indicating methotrexate monotherapy with GC bridging (coded 1) versus initial 
triple DMARD therapy with either oral or intramuscular GC bridging (coded 0). At follow-
up visits, medication increase was defined as a dose increase or switch towards other 
medication. Medication decrease was defined as a dose decrease or discontinuation of 
medication. Medication increase and decrease included as binary variables also.
statistical analyses
Missing data
In those patients having an outcome DAS available, missing values in covariates at the 
previous visit (see Supplemental Table 1) were completed using multiple imputation with 
chained equations (mi impute chained procedure in STATA). Given that the largest miss-
ing rate observed was 42.3% (Supplemental Table 1) , a number of m=50 imputations 
was chosen, taking into consideration the rule of thumb that the number of imputations 
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should at least be equal to the percentage of incomplete cases (18). To avoid bias, impu-
tation models were constructed such that all variables used in the analysis models were 
included in the imputation models (18). Before imputation, continuous variables were 
transformed to normality using the “nscore” package for STATA by Mark Lunt (19) and 
transformed back to their original scale afterwards, ensuring imputed values cannot lie 
outside the observed data range (19). The complete specification of imputation models 
can be found in Supplement 1.
Analyses
Multivariable linear regression analyses were performed for psychosocial factors, mea-
sured at baseline, 6 months and 12 months of follow-up, on outcome disease activity 
score (DAS) at 3, 9 and 15 months of follow-up respectively and correcting for demo-
graphic, disease-related and treatment-related factors. 
First, DAS was regressed against each individual psychosocial factor, controlling for 
DAS and medication change at previous visit and baseline factors age, sex, RF and ACPA 
positivity. Then a full model was build containing all 4 psychosocial factors together and 
controlling for the same factors. Backward elimination was performed on the full model 
until remaining psychosocial factors were significant. Statistical analyses were performed 
using STATA 14.1 (StataCorp, 4905 Lakeway Drive College Station, Texas, USA). P-values 
<0.05 were considered statistically significant.
ResUlTs
Two-hundred-eighty-one patients were available for analysis, 161 of whom had outcome 
DAS available at all three visits (completers) Overall, mean age was 53 years, 190 (68%) 
were female (Table 1). Mean baseline DAS was 3.36 and 95% fulfilled the ACR/EULAR 
2010 criteria for RA (6) (Table 1). Completers and non-completers were similar with 
respect to baseline characteristics, except for a slightly higher percentage of completers 
being RF-positive and fulfilling the ACR/EULAR 1987 criteria (Table 1).
Association after 3 months of treatment
Analyses of each psychosocial factor individually, correcting for age, sex, RF, ACPA and 
baseline DAS, revealed that higher levels anxiety, coping with pain and depression were 
associated with a higher DAS at 3 months of follow-up. After applying backward elimina-
tion on the full model, anxiety and coping with pain were independent predictors for DAS 
at 3 months of follow-up. In sensitivity analysis by bootstrap samples, anxiety and coping 
with pain were selected in 65.3% and 56.7% of samples, whereas depression and fatigue 
were selected in <15% of samples (Table 2).
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Association after 9 months of treatment
In the per factor analysis of psychosocial factors, correcting for age, sex, RF, ACPA and 
DAS at 6 months, coping with pain was associated with DAS at 9 months and fatigue 
showed a borderline significant association. After backward elimination, coping with pain 
remained as significant predictor for DAS at 9 months of follow-up. In sensitivity analyses 
on bootstrap samples, coping with pain was selected in 59.2% of samples and fatigue in 
20.4% of samples.
Table 1. Baseline characteristics.
All patients
(n=281)
Completers
(outcome DAs 
available at 3, 9
and 15 months) 
(n=161)
non-completers
(outcome DAs 
missing at 3, 9
or 15 months)
(n=120)
P-value1
Demographic
Age 53 (14) 53 (14) 53 (14) 0.981
Sex, female, n(%) 190 (68) 104 (65) 86 (72) 0.210
Disease-related
Duration of complaints, days, mean (sd) 166 (91) 168 (87) 164 (97) 0.662
RF-positive 228 (81) 138 (86) 90 (75) 0.023
ACPA-positive 226 (80) 133 (83) 93 (78) 0.286
Fulfilling ACR/EULAR 1987 criteria 189 (67) 118 (73) 71 (59) 0.013
Fulfilling ACR/EULAR 2010 criteria 267 (95) 154 (96) 113 (94) 0.571
DAS, mean (sd) 3.36 (0.96) 3.39 (0.97) 3.33 (0.95) 0.648
HAQ, mean (sd) 1.00 (0.66) 0.97 (0.65) 1.03 (0.67) 0.496
tSvHs, median (IQR) 0 (0-0) 0 (0-0) 0 (0-0) 0.2662
anxiety (HADS), mean (sd) 5.8 (3.7) 5.8 (3.9) 5.8 (3.5) 0.861
depression (HADS), mean (sd) 4.6 (3.4) 4.5 (3.4) 4.6 (3.4) 0.843
fatigue (FAS), mean (sd) 22.2 (7.0) 22.6 (7.3) 22.0 (6.8) 0.542
coping with pain (CORS), mean (sd) 15.5 (5.2) 16.2 (5.2) 15.0 (5.1) 0.058
1  Differences between completers and non-completers were tested. Student’s t-test and Pearson’s Chi-
squared test were used as appropriate, unless specified otherwise
2  Wilcoxon rank-sum test
Abbreviations:
- ACPA: Anti-Citrullinated Protein Antibodies
- ACR: American College of Rheumatology
- CORS: Coping with Rheumatic Stressors
- DAS: Disease Activity Score
- EULAR: European League against Rheumatism
- FAS: Fatigue Assessment Scale
- HADS: Hospital Anxiety and Depression Scale
- HAQ: Health Assessment Questionnaire
- IQR: Interquartile range
- RF: Rheumatoid Factor
- sd: standard deviation
- tSVHS: total Sharp van der Heijde Score
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Association after 15 months of treatment
Per factor analysis showed that only fatigue was significantly associated with DAS at 15 
months when correcting for age, sex, RF, ACPA and DAS at 12 months. This was also 
the case in the backward elimination model. Sensitivity analyses on bootstrap samples, 
fatigue was selected in 51.5% of instances, whereas other psychosocial factors were 
selected in <20% of samples.
Table 3. Association of psychosocial factors at baseline, 6 and 12 months on DAS components at 3, 
9 and 15 months respectively by zero-inflated negative binomial regression or linear regression. All 
analyses are corrected for age, sex, RF, ACPA, initial treatment group, medication change at previous 
visit and DAS at previous visit.
sJC441 ln esR2 RAI1 GH2
beta P beta P beta P beta2 p
DAS 3 months (n=252)
Anxiety (T0) 0.006 0.723 -0.005 0.752 0.033 0.031 1.728 <0.001
Depression (T0) -0.002 0.895 0.016 0.353 0.008 0.631 1.687 <0.001
Fatigue (T0) 0.014 0.129 -0.004 0.648 0.008 0.361 0.726 0.001
Coping with pain (T0) 0.046 <0.001 0.030 0.008 0.021 0.055 0.121 0.677
DAS 9 months (n=214)
Anxiety (T6) 0.004 0.859 -0.014 0.469 0.012 0.508 1.689 <0.001
Depression (T6) -0.020 0.371 -0.024 0.226 0.026 0.159 2.199 <0.001
Fatigue (T6) -0.002 0.821 -0.024 0.011 0.025 0.003 1.045 <0.001
Coping with pain (T6) -0.015 0.379 -0.015 0.275 0.029 0.025 0.900 0.008
DAS 15 months 
(n=141)
Anxiety (T12) 0.008 0.817 -0.010 0.636 0.020 0.458 0.499 0.334
Depression (T12) -0.041 0.247 0.013 0.547 0.041 0.078 0.717 0.172
Fatigue (T12) 0.001 0.952 -0.008 0.494 0.039 0.002 0.478 0.083
Coping with pain (T12) 0.017 0.462 -0.011 0.514 0.063 <0.001 -0.158 0.686
1 Zero-inflated negative binomial regression
2 Linear regression
Abbreviations:
ACPA: Anti-Citrullinated Protein Antibodies
DAS: Disease Activity Score
ESR: Erythrocyte Sedimentation Rate
GH: Global Health
ln: natural logarithm
RAI: Ritchie Articular Index
RF: Rheumatoid Factor
SJC44: 44 Swollen Joint Count
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Correlation between psychosocial factors
Pearson correlations between psychosocial factors for each time point are shown 
(Supplemental Table 2). Especially anxiety, depression and fatigue are highly correlated 
to each other with correlation coefficients around 50-70%. Coping with pain shows 
moderate correlations to the other factors with correlation coefficients around 25-50%.
Course over time of psychosocial factors
To gain further insight, development over time of psychosocial factors was investigated 
(Supplemental Figure 1). All scores showed significant decreases at 6 and 12 months with 
respect to baseline scores, except for coping with pain at 6 months.
Associations between psychosocial factors and DAs components
To evaluate which DAS components are associated with psychosocial factors at the previ-
ous visit, linear and zero-inflated negative binomial regression models were performed 
(Table 3). Most significant associations are observed for the subjective components 
Ritchie Articular Index (RAI) and Global Health (GH). Some significant associations 
for objective components are observed as well: Higher levels of baseline coping with 
pain was associated with both a higher 44 swollen joint count (SJC44) and erythrocyte 
sedimentation rate (ESR) at 3 months, while higher levels of fatigue at 6 months were 
associated with lower levels of ESR at 9 months (Table 3).
DIsCUssIOn
In this longitudinal study of rheumatoid arthritis patients starting with DMARD therapy, 
we found that psychosocial factors were independently associated with DAS at the next 
3-monthly visit during the first year of follow-up. The psychosocial factors associated with 
DAS changed over time: Coping with pain and anxiety influenced the disease activity in 
the first at 3 months, but anxiety did not appear to play a role anymore after 9 months of 
treatment. In the phase where disease activity is low only fatigue played a role. Although 
speculative, the change observed might indicate a change in the relative importance of 
psychosocial factors over the course of disease in newly diagnosed patients with RA. 
In the first months after diagnose, when disease is still active and optimal treatment 
effects has not yet been achieved, it is imaginable that anxiety and coping with pain play 
a more pronounced role, especially by affecting the more subjective components of DAS 
RAI and GH. Later on, when disease is under control and patients have adapted to living 
with the disease, fatigue could be more on the foreground. However, it should be noted 
that the psychosocial factors we investigated are highly correlated, which is in line with 
previous studies that found that symptoms of anxiety and depression often co-occur in 
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RA patients (20). Therefore, care should be taken in drawing definite conclusions with 
respect to the importance of one factor over the other and no definite conclusions of a 
change in relative importance should be drawn based on the results of this study alone. 
However, overall, our results do suggest that psychosocial factors in general appear to 
play an additional role in explaining response to treatment during the entire first year of 
follow-up. 
Several previous studies have investigated the effects of psychosocial factors on DAS 
at subsequent visits. In a secondary analysis of a clinical trial in early RA, Matcham et 
al. found that both baseline and persistent symptoms of depression/anxiety symptoms, 
measured on a combined scale of the EQ5D, were associated with increased DAS28 
scores over the first two years of follow-up. This is in part in agreement of our findings, 
in which we found both baseline anxiety and depression scores to be associated with 
higher DAS at 3 months of follow-up, but not at later moments (12). Differences may, at 
least in part, be explained by the use of a different instrument to measure depression/
anxiety symptoms and differences in analysis approach (linear mixed model averaging 
outcome over time) (12).
Previous studies have also looked into which components of the DAS are associated 
with psychosocial distress. In the COMET trial, significant associations between depres-
sion and both subjective (i.e. tender joint count and general health) and objective (i.e. 
swollen joint count and ESR) components of DAS were observed (10), whereas Matcham 
et al. only found associations for subjective components of DAS (11, 12). Regarding our 
own results, most associations are observed for the subjective components (Table 3). 
In patients with high levels of psychosocial distress, this might lead to overtreatment 
and higher costs if rheumatologists perform DAS-steered treatment without recognizing 
that the increased DAS is based on subjective components rather than inflammation. 
We therefore recommend that rheumatologists be aware of psychosocial distress and its 
impact on DAS when adjusting therapy.
Several strengths and limitations should be noted. Strong points include the fact that 
data were used from a prospective randomized clinical trial on early RA patients that 
were treated to target according to current guidelines (2, 3). Although not powered for 
this analysis, the sample size appears to be adequate for the scope of this analysis. The 
number of missing values in predictor variables was small at baseline, but increased at 
follow-up visits (Supplemental Table 1). To increase power and avoid bias in the analysis, 
we used multiple imputation to complete missing covariates for those patients having an 
outcome DAS available at the subsequent visit. Nonetheless, the complete case analysis 
for patients without missing covariates showed similar results (Supplemental Table 3). 
Few studies have assessed the additional effect of psychosocial factors on DAS and to our 
knowledge no previous studies have assessed them at specific time points after baseline.
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Several limitations should be mentioned as well. By the multiple imputation procedure, 
we completed missing covariates for those patients having an outcome DAS available at 
the subsequent visit. However, this does not take into account potential selection bias by 
patients completely dropping out from the study over time. Although selective drop-out 
cannot be ruled out, patients with complete and incomplete follow-up were similar with 
respect to most baseline characteristics (Table 1).
Data were used from a randomized clinical trial that was not designed for the purpose 
of these analyses. As the clinical trial setting differs from clinical practice, it cannot be 
ruled out that by selection bias different effects would have been observed if a similar 
study were performed in a clinical practice setting. Another potential limitation is the 
issue of multiple testing. Because of the explorative nature of the study and commonly 
available solutions like the Bonferroni method tend to be highly conservative, no formal 
methods were applied to account for this. Although under the null-hypothesis, it is still 
highly unlikely to obtain 5 out of 12 significant associations (multivariable per factor 
analysis, Table 2) by chance alone, it cannot be ruled out that some of these were due 
to chance.
COnClUsIOn
In conclusion, we found that psychosocial factors effect subsequent DAS during the first 
year of follow-up in patients newly diagnosed with RA. A change in pattern was observed 
from anxiety and coping with pain being associated with subsequent DAS at baseline 
towards fatigue being associated with subsequent DAS at 12 months of follow-up. Due 
to correlation of psychosocial factors and the explorative nature of this study, more 
research is needed to confirm this pattern.
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supplement  1. Multiple Imputation models
t0_das: regress t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_lim t0_cop_pain t0_
haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas t12_haq t6_PCS t6_
MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_lim t12_PCS 
t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
dur_complaints: regress dur_complaints t0_das t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_lim t0_cop_
pain t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas t12_haq t6_
PCS t6_MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_lim 
t12_PCS t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
t6_med_i: mlogit t6_med_i t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_lim t0_
cop_pain t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas t12_haq 
t6_PCS t6_MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_
lim t12_PCS t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos, augment
t9_med_i: mlogit t9_med_i t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_lim t0_
cop_pain t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas t12_haq 
t6_PCS t6_MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_
lim t12_PCS t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos, augment
t12_med_i: mlogit t12_med_i t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_lim t0_
cop_pain t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas t12_haq 
t6_PCS t6_MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_
lim t12_PCS t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos, augment
t0_SHS: regress t0_SHS t0_das dur_complaints t3_das Dutch t0_anxiety t0_depression t0_cop_lim t0_cop_pain t0_
haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas t12_haq t6_PCS t6_
MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_lim t12_PCS 
t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
t3_das: regress t3_das t0_das dur_complaints t0_SHS Dutch t0_anxiety t0_depression t0_cop_lim t0_cop_pain t0_
haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas t12_haq t6_PCS t6_
MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_lim t12_PCS 
t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
Dutch: logit Dutch t0_das dur_complaints t0_SHS t3_das t0_anxiety t0_depression t0_cop_lim t0_cop_pain t0_haq 
t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas t12_haq t6_PCS t6_MCS 
t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_lim t12_PCS t12_
MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos, augment
t0_anxiety: regress t0_anxiety t0_das dur_complaints t0_SHS t3_das Dutch t0_depression t0_cop_lim t0_cop_pain 
t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas t12_haq t6_PCS t6_
MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_lim t12_PCS 
t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
t0_depression: regress t0_depression t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_cop_lim t0_cop_
pain t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas t12_haq t6_
PCS t6_MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_lim 
t12_PCS t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
t0_cop_lim: regress t0_cop_lim t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_pain 
t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas t12_haq t6_PCS t6_
MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_lim t12_PCS 
t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
t0_cop_pain: regress t0_cop_pain t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_lim 
t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas t12_haq t6_PCS t6_
MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_lim t12_PCS 
t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
effects of psychosocial factors on monitoring treatment effect over time in RA
49
3
t0_haq: regress t0_haq t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_lim t0_cop_
pain t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas t12_haq t6_PCS t6_
MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_lim t12_PCS 
t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos 
t0_fat_vas: regress t0_fat_vas t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_lim 
t0_cop_pain t0_haq t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas t12_haq t6_PCS 
t6_MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_lim t12_
PCS t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
t0_fat_fas: regress t0_fat_fas t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_lim t0_
cop_pain t0_haq t0_fat_vas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas t12_haq t6_PCS t6_
MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_lim t12_PCS 
t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
t0_PCS: regress t0_PCS t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_lim t0_cop_
pain t0_haq t0_fat_vas t0_fat_fas t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas t12_haq t6_PCS t6_
MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_lim t12_PCS 
t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
t0_MCS: regress t0_MCS t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_lim t0_cop_
pain t0_haq t0_fat_vas t0_fat_fas t0_PCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas t12_haq t6_PCS t6_
MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_lim t12_PCS 
t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
t6_das: regress t6_das i.t3_med_i t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_lim 
t0_cop_pain t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t9_das t12_das t6_fat_vas t6_haq t6_fat_fas t12_haq t6_
PCS t6_MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_lim 
t12_PCS t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
t9_das: regress t9_das t0_das dur_complaints i.t6_med_i t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_lim 
t0_cop_pain t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t12_das t6_fat_vas t6_haq t6_fat_fas t12_haq t6_
PCS t6_MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_lim 
t12_PCS t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
t12_das: regress t12_das t0_das dur_complaints i.t9_med_i t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_
lim t0_cop_pain t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t6_fat_vas t6_haq t6_fat_fas t12_haq t6_
PCS t6_MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_lim 
t12_PCS t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
t15_med_i: mlogit t15_med_i t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_lim t0_
cop_pain t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas t12_haq 
t6_PCS t6_MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_
lim t12_PCS t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos , augment
t6_fat_vas: regress t6_fat_vas t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_lim 
t0_cop_pain t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_haq t6_fat_fas t12_haq t6_PCS 
t6_MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_lim t12_
PCS t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
t6_haq: regress t6_haq i.t3_med_i t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_lim 
t0_cop_pain t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_fat_fas t12_haq t6_
PCS t6_MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_lim 
t12_PCS t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
t6_fat_fas: regress t6_fat_fas t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_lim t0_
cop_pain t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t12_haq t6_PCS t6_
MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_lim t12_PCS 
t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
t12_haq: regress t12_haq t0_das dur_complaints i.t9_med_i t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_
lim t0_cop_pain t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas t6_
Chapter 3
50
PCS t6_MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_lim 
t12_PCS t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
t6_PCS: regress t6_PCS t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_lim t0_cop_
pain t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas t12_haq t6_
MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_lim t12_PCS 
t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
t6_MCS: regress t6_MCS t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_lim t0_cop_
pain t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas t12_haq t6_
PCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_lim t12_PCS 
t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
t12_fat_vas: regress t12_fat_vas t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_lim 
t0_cop_pain t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas 
t12_haq t6_PCS t6_MCS t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_lim 
t12_PCS t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
t12_fat_fas: regress t12_fat_fas t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_lim 
t0_cop_pain t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas 
t12_haq t6_PCS t6_MCS t12_fat_vas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_lim 
t12_PCS t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
t6_anxiety: regress t6_anxiety t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_lim t0_
cop_pain t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas t12_haq 
t6_PCS t6_MCS t12_fat_vas t12_fat_fas t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_lim t12_PCS 
t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
t6_depression: regress t6_depression t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_
lim t0_cop_pain t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas 
t12_haq t6_PCS t6_MCS t12_fat_vas t12_fat_fas t6_anxiety t12_anxiety t12_depression t6_cop_pain t6_cop_lim 
t12_PCS t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
t12_anxiety: regress t12_anxiety t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_lim 
t0_cop_pain t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas 
t12_haq t6_PCS t6_MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_depression t6_cop_pain t6_cop_lim 
t12_PCS t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
t12_depression: regress t12_depression t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_
cop_lim t0_cop_pain t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_
fas t12_haq t6_PCS t6_MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t6_cop_pain t6_cop_lim 
t12_PCS t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
t6_cop_pain: regress t6_cop_pain t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_
lim t0_cop_pain t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas 
t12_haq t6_PCS t6_MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_lim 
t12_PCS t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
t6_cop_lim: regress t6_cop_lim t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_lim 
t0_cop_pain t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas 
t12_haq t6_PCS t6_MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain 
t12_PCS t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
t12_PCS: regress t12_PCS t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_lim t0_cop_
pain t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas t12_haq t6_
PCS t6_MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_lim 
t12_MCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
t12_MCS: regress t12_MCS t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_lim t0_
cop_pain t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas t12_haq 
t6_PCS t6_MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain t6_cop_
lim t12_PCS t12_cop_lim t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
effects of psychosocial factors on monitoring treatment effect over time in RA
51
3
t12_cop_lim: regress t12_cop_lim t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_
lim t0_cop_pain t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas 
t12_haq t6_PCS t6_MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain 
t6_cop_lim t12_PCS t12_MCS t12_cop_pain t15_das age sex inital_MTX rf_pos acpa_pos
t12_cop_pain: regress t12_cop_pain t0_das dur_complaints t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_
lim t0_cop_pain t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas 
t12_haq t6_PCS t6_MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain 
t6_cop_lim t12_PCS t12_MCS t12_cop_lim t15_das age sex inital_MTX rf_pos acpa_pos
t15_das: regress t15_das t0_das dur_complaints i.t12_med_i t0_SHS t3_das Dutch t0_anxiety t0_depression t0_cop_
lim t0_cop_pain t0_haq t0_fat_vas t0_fat_fas t0_PCS t0_MCS t6_das t9_das t12_das t6_fat_vas t6_haq t6_fat_fas 
t12_haq t6_PCS t6_MCS t12_fat_vas t12_fat_fas t6_anxiety t6_depression t12_anxiety t12_depression t6_cop_pain 
t6_cop_lim t12_PCS t12_MCS t12_cop_lim t12_cop_pain age sex inital_MTX rf_pos acpa_pos
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* * * * 
* * 
* 
* * * * * 
supplemental figure 1. Mean levels of anxiety, depression, fatigue, coping with pain over time. Er-
ror bars indicate standard deviations. Psychosocial factors are plotted at the range of their respective 
scales. 
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supplemental Table 1. Missing values.
DAs 3 months
n=265/281 (94.3%)
DAs 9 months
n=251/281 (89.3%)
DAs 15 months
n=162/281 (57.7%)
age 281/281 (100%) 281/281 (100%) 281/281 (100%)
sex 281/281 (100%) 281/281 (100%) 281/281 (100%)
RF 281/281 (100%) 281/281 (100%) 281/281 (100%)
ACPA 281/281 (100%) 281/281 (100%) 281/281 (100%)
initial treatment 281/281 (100%) 281/281 (100%) 281/281 (100%)
medication change - 279/281 (99.3%) 274/281 (97.5%)
anxiety 263/281 (93.6%) 221/281 (78.6%) 220/281 (78.3%)
depression 263/281 (93.6%) 221/281 (78.6%) 220/281 (78.3%)
fatigue 256/281 (91.1%) 234/281 (83.3%) 226/281 (80.4%)
coping 262/281 (93.2%) 217/281 (77.2%) 215/281 (76.5%)
Abbreviations:
ACPA: Anti-Citrullinated Protein Antibodies
DAS: Disease Activity Score
RF: Rheumatoid Factor
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supplemental Table 2. Pearson correlation coefficients of psychosocical factors at baseline, 6 months 
and 12 months of follow-up.
baseline Anxiety Depression Fatigue Coping with pain
Anxiety - 0.61 0.51 0.25
Depression 0.61 - 0.54 0.39
Fatigue 0.51 0.54 - 0.40
Coping with pain 0.25 0.39 0.40 -
6 months Anxiety Depression Fatigue Coping with pain
Anxiety - 0.69 0.59 0.32
Depression 0.69 - 0.72 0.47
Fatigue 0.59 0.72 - 0.52
Coping with pain 0.32 0.47 0.52 -
12 months Anxiety Depression Fatigue Coping with pain
Anxiety - 0.71 0.58 0.26
Depression 0.71 - 0.69 0.32
Fatigue 0.58 0.69 - 0.46
Coping with pain 0.26 0.32 0.46 -
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supplemental Table 3. Multivariable linear regression analysis of psychosocial factors at baseline, 6 and 
12 months on DAS at 3, 9 and 15 months respectively. All analyses are corrected for age, sex, RF, ACPA, 
initial treatment group, medication change at previous visit and DAS at previous visit – complete case 
analysis.
Multivariable,
per factor
Multivariable,
full
Multivariable,
after backward 
elimination
beta P beta P beta P
DAS 3 months (n=242)
Anxiety (T0) 0.041 0.010 0.045 0.025 0.041 0.010
Depression (T0) 0.036 0.035 -0.004 0.848
Fatigue (T0) 0.013 0.132 -0.003 0.763
Coping with pain (T0) 0.027 0.019 0.023 0.063
DAS 9 months (n=204)
Anxiety (T6) 0.027 0.062 0.019 0.367
Depression (T6) 0.032 0.040 0.003 0.919
Fatigue (T6) 0.012 0.100 0.003 0.817
Coping with pain (T6) 0.023 0.032 0.017 0.145 0.023 0.032
DAS 15 months (n=146)
Anxiety (T12) 0.011 0.489 -0.009 0.681
Depression (T12) 0.027 0.104 0.011 0.689
Fatigue (T12) 0.020 0.022 0.016 0.228 0.020 0.022
Coping with pain (T12) 0.018 0.137 0.006 0.653
1 Selection rate of psychosocial factors after applying backward elimination in bootstrap samples
Abbreviations:
ACPA: Anti-Citrullinated Protein Antibodies
DAS: Disease Activity Score
Chapter 3
56
supplemental Table 4. Analysis of multicollinearity: Variance inflation factors for each covariate in the 
full models, as presented in Table 2.
Multivariable, full
beta P 95% CI VIf
DAS 3 months (n=265)
Anxiety (T0) 0.037 0.050 -0.000 – 0.075 1.75
Depression (T0) -0.001 0.963 -0.044 – 0.042 1.99
Fatigue (T0) 0.001 0.935 -0.189 – 0.020 1.70
Coping with pain (T0) 0.024 0.051 -0.000 – 0.048 1.41
DAS 9 months (n=251)
Anxiety (T6) 0.004 0.822 -0.034 – 0.043 2.04
Depression (T6) 0.001 0.975 -0.046 – 0.048 2.98
Fatigue (T6) 0.006 0.602 -0.015 – 0.026 2.54
Coping with pain (T6) 0.021 0.081 -0.003 – 0.044 1.62
DAS 15 months (n=162)
Anxiety (T12) -0.013 0.525 -0.055 – 0.028 2.04
Depression (T12) 0.011 0.669 -0.040 – 0.062 2.53
Fatigue (T12) 0.017 0.179 -0.008 – 0.041 2.45
Coping with pain (T12) 0.007 0.619 -0.019 – 0.033 1.46
Abbreviations:
ACPA: Anti-Citrullinated Protein Antibodies
DAS: Disease Activity Score
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AbsTRACT
Objective
Fatigue has a large impact on quality of life, and it is still unmanageable in many patients. 
The study aims were to i) describe the prevalence and pattern of fatigue over time in 
patients with early RA ii) identify predictive factors for worsening and recovering of 
fatigue over time.
Methods
Data on disease activity from the tREACH study were used. Patients completed patient 
reported outcomes on fatigue, quality of life and coping and were clinically assessed 
every 3 months. Descriptive techniques were used to describe fatigue and its associa-
tions with covariates. We assessed the evolution of fatigue over time in relation to the 
covariates using logistic regression.
Results
Almost half of all patients had high fatigue levels at baseline which decreased slightly 
over time from 45% at baseline to 43% after 1 year. However, at individual level patients 
showed fluctuating patterns after 1 year of follow-up. Of the initial fatigue patients, 23% 
showed a lower level of fatigue whereas in 15% of the low fatigued patients the fatigue 
level increased. Univariable analyses revealed tender joints, VAS global, DAS score, anxi-
ety and depression and the Mental Component summary of the SF-36 to be associated 
with developing fatigue, of which depression and coping remained in the multivariable 
analyses.
Conclusion
Despite strict treat-to-target strategy, fatigue remained an overall problem during the 
first year of treatment, however this fluctuated for the individual patient. Signaling signs 
of depression and coping may be important in managing fatigue.
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InTRODUCTIOn
Fatigue is known to be a common symptom in patients suffering from rheumatoid arthri-
tis (RA) (1, 2). Whether it is directly related to the disease itself, as a consequence of the 
disease or its treatment, a pre-existing feature unrelated to the disease or a combination 
is unknown. Despite its unclear mechanism, fatigue affects the lives of 40-80% of the 
RA patients depending on what fatigue instrument is used (1, 3, 4). Fatigue had a high 
impact on patient by influencing the social environment; the impact of fatigue perme-
ates through every aspect of their lives limiting work participation (5), family activities 
or social activities (6), sports and simply enjoying life as it is. Furthermore, the nature of 
fatigue, its variable and unpredictable nature requests unplanned anticipation which is 
for part of the patients difficult to (self-) manage (7).
Factors that might interact with fatigue in early rheumatoid arthritis suggest a possible 
role for disease related factors like disease activity (pain, functional ability and sleep), 
cognitive behavioral factors such as mental health and general health and personal fac-
tors like age, gender (8-12). Evolvement of fatigue over time on individual level is less 
well studied in both early and established RA. An 8 year study from the Netherlands 
suggested little change of fatigue levels over time on group level, while individual levels 
fluctuated over time (11). In contrast, a study in early RA revealed an improvement in 
fatigue for 40% of the patients, while another 24% worsened in their fatigue levels (9). 
Both these studies has been performed in cohort studies where treatment was not 
protocolled and therefore could have biased the results. Therefore, the objective of the 
present study was i) to describe the prevalence and pattern of the fatigue over time in 
patients with early RA under a treat-to-target strategy ii) identify predictive factors for 
worsening and recovering of fatigue over time.
MeTHODs
study participants
Patients fulfilling the ACR-EULAR 2010 criteria for RA participating in the tREACH study 
(treatment in the Rotterdam Early Arthritis Cohort, 2007-2013) were used for this analy-
sis. This multi-centered trial compared different initial treatment strategies in early RA 
patients. Inclusion criteria for the tREACH were: age ≥18 years, arthritis in one or more 
joint(s) and symptom duration <1 year. Patients were recruited from the outpatient clin-
ics of all participating centres between July 2007 and April 2011. Initial treatment arms 
consisted of either: I methotrexate, sulphasalazine, HCQ +GCs intramuscularly; II metho-
trexate, sulphasalazine (SASP), hydroxychloroquine HCQ+ oral GC tapering scheme; III 
MTX+ oral GC. Treatment was escalated to biologicals if DAS44 >2.4. Details can be found 
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in Claessen et al. (13). Medical ethics committees at each participating center approved 
the study protocol and all patients gave written informed consent before inclusion.
Data collection 
Demographic, clinical characteristics and frequency of erosions of each patient were 
recorded at baseline. Disease activity measures and its correlated treatment strategy 
took place every three months. Fatigue, coping strategies used to deal with pain and 
physical limitations, health related quality of life, symptoms of anxiety and depression 
were assessed every 6 months.
Clinical evaluation of disease activity
The disease activity was assessed by the DAS score, which may range from 0 to10 and is 
a composite score containing swollen joints, tender joints, VAS global and ESR, where a 
higher score indicates a higher disease activity (14).
Fatigue
Levels of fatigue were measured by Visual Analogue Scale (VAS) and the Fatigue Assess-
ment Scale (FAS). The VAS (100 mm) fatigue involves the severity of the fatigue over the 
past week with the anchors: no fatigue (0 mm) and extremely fatigued (100 mm). The 
scale is sensitive to change, valid and reliable, but no cut point has been determined 
(15, 16). Fatigue Assessment Scale (FAS) is a 10-item fatigue scale with a good internal 
consistency reliability and validity (17, 18). Five questions reflect physical fatigue and five 
questions reflect mental fatigue. The instruction is directed at how a person usually feels. 
Each item is scored on a 5-point rating scale ranging from 1 ‘never’ to 5 ‘always’. Scores 
on the FAS range from 10 to 50 and can be divided into 10-21 low fatigue; ≥ 22-34 tired, 
≥ 35-50 extremely fatigued as suggested by the developers (19, 20).
Patient reported outcome measures
Disease-related
The RADAI (Rheumatoid Arthritis Disease Activity Index) measures self-reported disease 
activity (21). It contains 5 items, global disease activity during the last month, today’s 
disease activity in terms of swollen and tender joints, today’s amount of arthritis pain 
and stiffness and self-assessed tender joints. It uses a scale ranging from 0 to 10, where 
higher scores indicate more disease activity (22).
General health
The health related quality of life (HRQOL) was scored with the SF-36 (range score 0-100). 
A higher score indicates a better HRQOL. It assesses eight health concepts: physical func-
tioning, bodily pain, role limitations due to physical health problems, role limitations due 
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to personal or emotional problems, emotional well-being, social functioning, energy/
fatigue, and general health perceptions which are summarized in a physical component 
summary (PCS) and mental component summary (MCS) score (23).
Psychosocial
Coping was measured via the Coping with Rheumatoid Stressors (CORS) scale. The sub-
scales dealing with pain, decreasing activities (range 8-32) and limitations (range10-40) 
were included in tREACH. A higher sum score indicates more frequent use of the coping 
strategy. Both scales have good internal consistency and high test-retest reliability (24, 
25).
Depression and anxiety were measured by the HADS. Two subscales with each 7 
items are calculated with higher scores indicating more severe symptoms of anxiety or 
depression (26). Categorical scores are available. Scores between 0 and 7 represent ‘no 
case’; 8 to 10 indicate ‘possible case’ and 11 to 21 suggest a ‘probable case of anxiety or 
depression’ (26, 27).
statistical analysis
Simple descriptive techniques were used to describe fatigue and its associations with 
other covariates at baseline. Fatigue evolution over time was plotted. Mean and SD or 
percentages were described, as appropriate.
As longitudinal fatigue evolvement was diverse we stratified the analysis into two 
clinically relevant patient samples: Those with low fatigue (FAS values 10-21) and those 
fatigued (FAS values 22-50) at baseline. This stratification allows for practical advice for 
rheumatologist on what to expect of the evolution of fatigue. The cut off value of 21 was 
chosen as recommended by the developers of the FAS questionnaire (18, 19). Logistic 
regression was used for the description of the differences between high and low fatigue 
at baseline on demographics, disease related variables and psychosocial variables. To 
investigate variables that are important for change of fatigue over time logistic regression 
analyses predicting fatigue status at 12 months by baseline covariates were performed 
for each stratum. First, univariable analyses were performed. Thereafter, starting with 
full models, backward elimination was performed until all remaining variables reached 
a significance level of p<0.10. Age and gender were forced into the models regardless 
of their levels of significance. Missing values were imputed by multiple imputation with 
chained equations using m=100 imputation datasets. P-values <0.05 were considered 
statistically significant.
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ResUlTs
A total of 270 individuals, of whom 220 patients had complete data of all variables were 
available at baseline, 178 at 6 months and 176 patients after 12 months of follow-up. 
The excluded 50 patients were older (p=0.02) and worked less often (p=0.02) but did 
not differ with respect to DAS score, the presence of erosions or in which treatment arm 
they were randomized (data not shown). The early RA population had a mean age of 53 
years (SD 14.3 years) and 67% were females (see Table 1). The presence of rheumatoid 
factor and anti-CCP antibodies at baseline were 73% and 77% respectively. Erosions were 
present in 18% of patients (Table 1).
Table 1. Baseline characteristics, total and high fatigue and low fatigue, mean (SD).
All patients
(n=246)
fatigued 
patients 
(n=113; fAs >21)
low fatigued 
patients 
(n=133; fAs ≤ 21)
P-value
Age, in years* 53.3 (14.30) 51.3 (14.09) 55.0 (14.3) 0.04
Sex, female, (%) 68% 75% 62% 0.03
Working status (%) 55% 52% 60% 0.21
Native, Dutch (%) 83% 81% 85% 0.35
Symptom duration(days) median, IQR 147.5 (91-213) 149 (92-236) 145.5 (88-198) 0.16
RF pos, % 73% 76% 69% 0.01
Anti CCP, % 77% 76% 80% 0.12
Das28 (range 0-10) 4.8 (1.2) 5.1 (1.2) 4.6 (1.2) 0.001
Tender joints (range 0-44) 11 (7.9) 13 (8.6) 9 (7.0) 0.002
Swollen joints (range 0-44) 9 (6.5) 10 (7.5) 8 (5.3) 0.02
ESR(median, IQR) 29 (21.0) 30 (21.7) 30 (20.4) 0.93
VAS global (range 0-100) 52 (22) 60 (19) 46 (23) <0.001
VAS fatigue (range 0-100) 51 (26) 67 (18) 38 (24) <0.001
FAS (range 10-50) 22 (7) 28 (5) 17 (3) <0.001
RADAI (range 0-10) 4.0 (1.7) 4.6 (1.7) 3.6 (1.6) <0.001
Coping with pain (range 8–32) 15.5 (5.2) 17.4 (5.1) 13.9 (4.7) <0.001
Coping with limitations (range 8–40) 22.9 (7.4) 24.9 (7.3) 21.3 (7.0) <0.001
HADS anxiety (range 0–21) 5.6 (3.7) 7.3 (3.5) 4.6 (3.3) <0.001
HADS depression (range 0–21) 4.6 (3.5) 6.2 (3.5) 3.2 (2.8) <0.001
Possible case depression (HADS-D≥ 8, n / %) 49 (19.9%) 37 (32.7%) 12 (9%) <0.001
SF-36 PCS (range 0-100) 39.98 (6.52) 37.81 (6.62) 41.90 (5.80) <0.001
SF-36 MCS (range 0-100) 45.42 (6.78) 43.08 (6.82) 47.51 (6.04) <0.001
SF-36 vitality (range 0-100) 54.86 (20.19) 40.97 (13.82) 66.93 (16.84) <0.001
P-value presented for parametric or non-parametric test as appropriate
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At baseline the mean score of the fatigue was VAS (0-100): 51 (sd 26) and FAS (10-50): 
22 (sd 7) and 45% of the patients were categorized as fatigued (FAS > 21).
Table 1 summarizes the baseline results for the two strata of fatigue; 113 fatigued 
and the 133 low fatigued patients. Younger females were most fatigued. The two groups 
differed in disease related and every patient reported outcomes (PROs) (Table 1). A 
significant trend was observed for the different categories of the HADS depression; in 
the fatigued patients 32% reached the clinical relevant levels for possible case for depres-
sions (Table 1).
evolution of fatigue
Over time, on average FAS fatigue decreased slightly for all patients with 1.4 points, with 
3.8 points for the fatigued patients and with 0.8 points increase for the low fatigued 
patients (Figure 1a, 1b). After 12 months 43% of all patients were still fatigued. Individual 
patient profiles showed varying patterns. 
A
B C
figure 1. Evolution of fatigue over time: Average for all, high fatigued and low fatigued patients (panel 
A) and individual profile plots for initially low fatigued (panel B) and high fatigued (panel C) patients.
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Of all fatigued patients (n=113) at baseline only 23% decreased to below the level of 
low fatigue and 15% of the low fatigued patients (n=133) became fatigued.
factors associated with the strata of fatigue at 12 months
Low fatigued patients
In the univariable analysis significant higher levels of fatigue over time were found for 
more tender joints, higher VAS global, higher DAS score, HADS anxiety and depression, 
Mental Component summary of the SF-36 (Table 2). In the multivariable analysis the 
HADS depression and limitation in coping were associated with developing fatigue over 
time.
High fatigued patients
No associated factors were found for the recovering of fatigue in the univariate analysis. 
Only a role for not having a Dutch nationality lead to a decrease of fatigue in the multi-
variable analysis (Table 2).
Table 2. Univariable and multivariable analysis for developing fatigue after 12 month for low fatigued 
and fatigued patients.
Univariable Odds ratio (CI95%) Multivariable Odds ratio (CI95%)
fatigue (≤21) fAs (>21) fatigue (≤21) fAs (>21)
Sex, female 2.60 (0.83-8.09) 1.28 (0.48-3.40) 3.01 (0.84-10.73) 1.83 (0.65-5.01)
Age, per year 0.98 (.095-1.02) 1.00 (0.97-1.04) 0.97 (0.93-1.01) 1.00 (0.97-1.04)
Education 1.01 (-0.03-2.07) -0.03 (-1.08-1.01)
Working status (Y/N) 1.89 (0.67-5.30) 1.28 (0.53-3.06)
Nationality Natively/Dutch 1.33 (0.29-6.01) 2.98 (0.89-9.95) 7.45 (0.74-74.83) 3.43 (0.99-11.82)*
DAS 1.96 (1.07-3.59) * 1.45 (0.93-2.25)
ESR 1.007 (0.98-1.02) 1.00 (0.98-1.02)
Tender joints  (0-44) 1.12 (1.01-1.23)** 1.03 (0.96-1.10)
Swollen joints (0-44) 1.03 (0.95-1.12) 1.02 (0.96-1.08)
VAS global (0-100) 1.02 (1.00-1.05)** 1.01 (0.99-1.04)
Radai (0-10) 1.19 (0.88-1.61) 0.97 (0.75-1.25)
Hads depression (0-21) 1.20 (1.03-1.40)** 1.04 ( 0.91-1.19) 1.33 (1.08-1.62)**
Hads anxiety (0-21) 1.15 (1.01-1.32)* 0.98 (0.86-1.12)
Coping limitations (8-40) 1.06 (0.99-1.14) 0.98 (0.92-1.04) 1.09 (1.00-1.18)*
Coping pain (8-32) 1.08 (0.98-1.19) 0.96 (0.87-1.05)
Physical health (SF36, 0-100) 0.94 (0.86-1.02) 1.00 (0.94-1.07)
Mental health (SF 36, 0-100) 0.87 (0.80-0.96)** 0.98 (0.92-1.05)
Level of significance *p=0.05/**p=0.01/***p=0.001 Cut point for FAS≤21 low fatigue/>21 fatigued
Multivariable analysis corrected for sex and age
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DIsCUssIOn
In this RCT where patient were treated by an early, intensive and tight controlled strategy, 
almost half of the early rheumatoid arthritis patients were fatigue over the first year 
after diagnosis. At group level fatigue only decreased slightly, while at the individual level 
fatigue fluctuated. In the low fatigue group 15% of the patients converted to fatigued, 
while in the fatigued group most of the patients (77%) remained fatigued despite im-
provement in disease activity. Literature on the course of fatigue in early RA has been 
conflicting. Some cohort studies in early RA observe recovery of fatigue over time (9). 
This was more often observed in studies evaluating biological treatment with patients 
having much longer RA (28, 29). But other cohort studies showed persistent fatigue 
over time with almost no change since diagnosis (11). Moreover, a recent meta-analysis 
found that, although statistically significant, treatment with biologicals only lead to a 
small improvement in levels fatigue (30). Since our RCT that was performed in early RA 
with induction of conventional DMARDs, it is interesting to see that a similar pattern was 
observed, where levels of fatigue decreased with 6%. This might indicate that fatigue 
stays an important burden of the disease irrespective of disease duration or therapy.
In line with other studies, our analysis showed an association between fatigue and 
depression. At baseline fatigued patients reported significant higher levels of depressive 
symptoms which almost reached levels indicative for clinical depression (26, 27). In ad-
dition, depression was also an independent predictor for developing fatigue after 1 year 
of diagnoses. This bidirectional relationship, thus is depression induced by fatigue or 
fatigue induced by depression, is under debate, both directions seemed to be possible 
(9,31). A dynamic conceptual model of RA fatigue showed the bi-directional relation for 
depression and fatigue (31). Irrespectively of the direction, we feel that the high levels 
of depression at baseline warrant monitoring over time and further examination by a 
psychologist if symptoms persist.
Another factor associated in the model with the evolution of fatigue was coping with 
limitations. Results from RA studies suggest that some coping strategies may be useful 
for patients to better manage the disease, while other are not (32). Maladaptive coping 
appears to be a risk factor for psychological comorbidity (33). Lower levels of active cop-
ing strategies were related to higher levels of depression (33). Thus, it might be that both 
coping and depression act upon fatigue. Whether they have the same affect or additional 
upon each other is not clear.
Several aspects of this study need further discussion. The Fatigue Assessment Scale 
and the VAS fatigue were both included to measure fatigue. This choice was made in 
2003 with not much specific RA fatigue instruments available. The Fatigue Assessment 
Scale (FAS) has a good internal consistency reliability and validity (19, 20). Although the 
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VAS fatigue was also included, the lack of a standardized VAS cut point for high and low 
fatigue prohibited a clear message about the VAS fatigue scores.
We were able to analyse a substantial number of covariates influencing fatigue, but 
some were not available such as sleep quality or the presence of symptoms of fibromy-
algia. Strength of this study include its longitudinal design and control for medication 
and tight-controlled treatment due to the trial design. This allowed us to study the lon-
gitudinal evolvement of fatigue and the development of fatigue among those patients 
with initial low fatigue levels at baseline and recovery of fatigue among those with initial 
high levels of fatigue, where medication had no effect on the decrease of fatigue in both 
groups (data not shown).
Given the observed fatigue levels in this early RA RCT and other cohorts, it may be valid 
to quantify fatigue, depression and coping in daily care. Early identification and interven-
tion may prevent acute fatigue from becoming chronic, but also development of fatigue 
over time. The results suggest that fatigue does not devolve by itself. Although there are 
no intervention studies published we suggest that this may be achieved by interventions 
such as teaching specific coping strategies and identification and follow-up of depression 
at baseline. Furthermore, it is important to provide patients with knowledge and insight 
in the course of symptoms of the disease. This may result in more self-management 
behaviour. Screening on fatigue at baseline and follow up and taking a positive approach 
to the (self-) management of fatigue may lead to benefits for the patient, feeling their 
fatigue is acknowledged, and may also improve patient satisfaction and treatment out-
comes.
COnClUsIOn
Irrespective of a strict treat to target strategy in patients with early RA, fatigue remains 
a problem for many patients. A part of the low fatigue patients developed fatigue later, 
while only a few fatigued patients improved. Higher levels depression and coping were 
associated with developing fatigue in initially low fatigued patients. Monitoring fatigue 
and depression at baseline and follow-up might be important to intervene in amenable 
factors.
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AbsTRACT
Objectives
Early disease control leads to better long term outcomes in RA. Identifying factors respon-
sible for an adequate treatment response might pave the way to a more personalized 
treatment of RA patients. Aim was to identify predictors of early remission on DMARD 
induction therapy.
Methods
Nine months follow-up data were used from patients included in tREACH; an RCT com-
paring initial triple DMARD therapy (iTDT) to methotrexate monotherapy (iMM) with GC 
bridging in both groups. Patients were treated in a treat-to-target fashion. Early remission 
was defined as DAS<1.6 at 6 months of follow-up and sustained remission as DAS<1.6 at 
6 and 9 months. Demographic, disease-related and psychosocial factors were considered 
as candidate predictors, analysed by univariable and multivariable logistic regression.
Results
Data from 281 patients were available. At 6 months 135/281 (48%) patients were in DAS 
remission. Younger age, male sex, lower baseline DAS, HAQ and lower levels of psycho-
social factors anxiety, depression and fatigue were associated with remission within 6 
months. Of these, age, sex, baseline DAS and anxiety were identified as independent 
predictors. Sustained remission at 9 months was independently predicted by age, sex, 
ACPA-negativity and fatigue.
Conclusions
In addition to the known demographic (age, sex) and disease related factors (DAS, HAQ), 
also psychosocial factors (anxiety, depression and fatigue) were identified as predictors 
for attaining early remission. Results may pave the way for personalized medicine by 
identifying patients who may benefit from interventions on psychosocial items.
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InTRODUCTIOn
Current guidelines for the treatment of rheumatoid arthritis recommend treatment 
should be steered towards remission, or at least low disease activity (LDA), within 6 
months using a treat-to-target strategy (1, 2). Adherence to this treat-to-target concept 
has been shown to lead to lower radiographic damage and better functional outcomes 
(3). Previous studies like tREACH showed that treatment goals were achieved more 
quickly and with fewer biological use in patients with initial triple disease modifying anti-
rheumatic drug (DMARD) therapy versus methotrexate alone (4). On the other hand, 
40% of patients in the initial methotrexate group were in remission within 6 months. 
Similar findings have been reported in studies comparing induction with methotrexate 
alone to expensive biologicals (5).
Hence, identification of factors responsible for an adequate response to treatment 
might pave the way to a more personalized treatment of RA patients. Although several 
studies have been performed to identify predictors for remission in early RA (6-8), most 
have focused on disease-related, treatment and / or genetic factors. Associations be-
tween psychosocial factors such as anxiety and depression and remission beyond the 
first year of treatment have been reported as well (9, 10). We therefore hypothesize that 
psychosocial characteristics may be of predictive value for attaining early remission as 
well. The primary aim of this study was to identify predictors associated with achieving 
remission (DAS<1.6) within 6 months of follow-up. To evaluate which patients remained 
in remission, secondary aim was to identify predictors associated with sustained remis-
sion (2xDAS<1.6 at 2 consecutive visits) at 9 months of follow-up.
MeTHODs
study population
Nine months follow-up data were used from the tREACH cohort, for which a detailed 
description of the inclusion criteria and protocol can be found in the original tREACH 
paper (4). In short, patients with early arthritis (duration of complaints < 1 year) and a 
high risk of developing persistent arthritis (score >6 points on Visser model (11)) were 
eligible. Of the included patients, 97% fulfilled the ACR/EULAR 2010 criteria for RA (4, 
12). Patients were randomized to the following induction treatment strategies: Triple 
DMARD therapy (iTDT; methotrexate (MTX) 25 mg/week, sulphasalazine 2000 mg/day 
and hydroxychloroquine 400 mg/day or MTX monotherapy 25 mg/week (iMM). Both 
groups received bridging therapy with glucocorticoids (triamcinolone acetonide 80 mg 
or methylprednisolone 120 mg once by intramuscular injection or oral prednisone 15 
mg for 4 weeks, thereafter tapered by 5 mg/week). Patients were evaluated every 3 
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months. In case DAS was >2.4, patients were switched to a TNF-blocker combined with 
MTX 25 mg/week. If sustained remission (DAS<1.6 at 2 consecutive visits) was achieved, 
medication was tapered according to protocol. Detailed information on the medication 
scheme can be found in the original tREACH paper (4). This study was approved by the 
Erasmus MC medical ethics committee, Rotterdam (NL-14580.078.06). All patients gave 
written informed consent before inclusion.
Outcome
Primary outcome was remission (DAS<1.6) within 6 months of follow-up.
Secondary outcome was sustained remission (2x DAS<1.6 at 2 consecutive visits) at 9 
months of follow-up.
Candidate predictors
Demographic, disease-related and psychosocial factors were included as candidate 
predictors into the model. Demographic characteristics included age, sex, ethnicity and 
having paid work at baseline. Disease-related factors included initial treatment strategy 
(initial triple DMARD therapy or MTX monotherapy), baseline disease activity (DAS), func-
tional ability (Health Assessment Questionnaire, HAQ), radiographic damage (Sharp-van 
der Heijde Score), Rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA) 
status, duration of complaints and physical functioning (SF36 physical component score 
(PCS)). Psychosocial factors included mental functioning (SF36 mental component scale), 
internal, external and chance locus of control (multidimensional health locus of control 
(MHLC), anxiety and depression (hospital anxiety and depression score (HADS)), fatigue 
(Visual Analogue Scale (VAS)) and coping with pain (Coping with Rheumatic Stressors). 
The demographic and disease related assessments are described in the original tREACH 
paper (4). Psychosocial questionnaires are explained in more detail below.
Locus of control: The locus of control was determined by the Multidimensional Health 
Locus of Control (MHLC) questionnaire, containing 18 questions about health and dis-
eases. The MHLC assesses 3 different loci of control: internal, external and chance (Cron-
bach’s alpha 0.68-0.78). An “internal” locus of control indicates that a patient beliefs he 
is responsible for his health, whereas someone with an “external” locus of control beliefs 
that the practitioner is responsible for his health status. The “chance” locus of control 
reflects that someone beliefs that his health depends on fate or luck. Each domain has a 
sum score ranging from 6 to 36, higher scores indicating a higher belief in that particular 
locus of control (13).
Coping style: Coping style was measured by the Coping with Rheumatic Stressors 
(CORS) questionnaire. The list contains 8 questions about coping with pain (Cronbach’s 
alpha 0.88) and 10 questions about coping with limitations (Cronbach’s alpha 0.91). 
Psychosocial factors are important predictors for meeting DAs remission criteria in early RA
77
5
Scores for coping with pain range from 8-40 and for coping with limitations between 
10-40. Higher scores indicate more passive coping (14).
Depression and anxiety: The Hospital Anxiety and Depression Scale (HADS) was used to 
measure depression and anxiety. The scores for depression and anxiety range between 
0 to 21, higher scores indicating symptoms related to more anxiety or depression (15).
Fatigue: Fatigue was assessed using a visual analog scale ranging from 0-100, higher 
scores indicating higher levels of fatigue.
statistical analyses
Missing values in baseline covariates (<10% missing, see Supplemental Table 1) were 
completed using multiple imputation with chained equations (mi impute chained pro-
cedure in STATA) with m=50 imputation models. Univariable logistic regression analyses 
were performed for all candidate predictors to assess their association with outcomes 
remission within 6 months and sustained remission at 9 months respectively. Candidate 
predictors with p<0.20 were entered into the multivariable models, after which back-
ward selection was applied until significance was reached for all remaining predictors. 
Statistical analyses were performed using STATA 14.1 (StataCorp, 4905 Lakeway Drive 
College Station, Texas, USA). P-values <0.05 were considered statistically significant.
ResUlTs
Data from 281 patients participating in tREACH were available for analysis. Overall, 68% of 
patients were female and mean age was 53.3 years. Mean baseline DAS was 3.35 (95%CI 
3.24-3.36) (Table 1). A flowchart of follow-up is shown in Figure 1. During 6 months of 
follow-up, remission was achieved by 135/281 (48%) of patients, while 96/281 (34%) of 
patients achieved sustained remission at 9 months of follow-up.
Predictors for remission within 6 months
Univariable analyses revealed older age and female sex were associated with a lower 
probability to attain remission within 6 months (Table 2). Of disease related factors, 
higher baseline DAS and HAQ scores resulted in a lower odds for remission, whereas 
higher scores on SF36 physical component scale (reflecting better physical health, were 
associated with a higher chance for remission. Of psychosocial factors, higher scores on 
SF36 mental component scale and internal locus of control were associated with a higher 
odds for attaining remission. On the contrary, higher levels of anxiety, depression and fa-
tigue were associated with a lower probability to attain remission within 6 months. In the 
final multivariable model, age, sex, baseline DAS and anxiety remained as independent 
predictors for remission within 6 months (Table 2).
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Predictors for sustained remission at 9 months (in remission at 6 and 9 months)
When considering patients in remission at both 6 and 9 months, univariable analyses 
revealed female sex to be associated with a lower probability to attain sustained remis-
sion. Of disease related factors, higher baseline DAS scores and HAQ scores resulted in 
a lower odds for remission, whereas higher scores on SF36 physical component scale 
was associated with a higher chance for remission. Of psychosocial factors, higher scores 
on internal locus of control were associated with a higher odds for attaining remission. 
On the contrary, higher levels of anxiety, depression, fatigue and passive coping with 
pain were associated with a lower probability to attain remission within 6 months. In the 
final multivariable model age, sex, ACPA positivity and fatigue remained as independent 
predictors for sustained remission at 9 months (Table 2).
Table 1. Baseline characteristics of all patients and patients by remission status.
All patients (n=281)
Remission within 6 months
no (n=146) Yes (n=135)
Demographic
Age 53 (14) 55.0 (13) 51.3 (15)
Sex, female, n (%) 190 (68) 108 (74) 82 (61)
Disease-related
Duration of complaints, days, mean (sd) 166 (91) 171 (95) 162 (88)
RF-positive 228 (81) 113 (77) 115 (85)
ACPA-positive 226 (80) 119 (82) 107 (79)
Fulfilling ACR/EULAR 1987 criteria 189 (67) 95 (65) 94 (70)
Fulfilling ACR/EULAR 2010 criteria 267 (95) 140 (96) 127 (94)
DAS, mean (sd) 3.36 (0.96) 3.66 (0.87) 3.03 (0.94)
HAQ, mean (sd) 1.00 (0.66) 1.12 (0.66) 0.87 (0.64)
tSvHs, median (IQR) 0 (0-0) 0 (0-0) 0 (0-0)
Abbreviations:
- ACPA: Anti-Citrullinated Protein Antibodies
- ACR: American College of Rheumatology
- DAS: Disease Activity Score
- EULAR: European League against Rheumatism
- HAQ: Health Assessment Questionnaire
- IQR: Interquartile range
- RF: Rheumatoid Factor
- sd: standard deviation
- tSVHS: total Sharp van der Heijde Score
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T3 
n=265 
T0 
n=281 
time-point 
skipped: 
n=5 
Drop out: n=11 
- Patient refusal (n=6) 
- Problems with communication (n=1) 
- Incorrect randomization (n=1)  
- Adverse event: 
 - Colon carcinoma (n=1) 
 - Myocardial infarction (n=1) 
 - MTX related (n=1) 
T6 
n=255 
time-point 
skipped: 
n=8 
Drop out: n=7 
- Patient refusal (n=5) 
- Non-compliance (n=2) 
 
T9 
n=252 
time-point 
skipped: 
n=6 
Drop out: n=5 
- Patient refusal (n=3) 
- Non-compliance (n=1) 
- Adverse event: 
 - Lung carcinoma (n=1) 
 
T12 
n=249 
time-point 
skipped: 
n=2 
Drop out: n=7 
- Patient refusal (n=6) 
- Deceased (n=1) 
 
figure 1. Flow-chart of follow-up.
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Table 2. Predictors for attaining remission (DAS<1.6) within 6 months and sustained remission (DAS<1.6 
at 2 consecutive visits) at 9 months by logistic regression.
Remission within 6 months
(n=135 cases)
sustained remission at 9 months
(n=83 cases)
Univariable Multivariable* Univariable Multivariable*
OR P OR P OR P OR P
Demographics
Age (years) 0.982 0.032 0.978 0.026 0.988 0.183 0.965 0.002
Sex (female) 0.544 0.018 0.538 0.033 0.373 <0.001 0.372 0.001
Dutch ethnicity 1.128 0.707 1.294 0.488
Paid work 1.198 0.465 1.529 0.125
Disease
MTX monotherapy 0.657 0.098 0.642 0.122
DAS (baseline) (0-10) 0.447 <0.001 0.495 <0.001 0.582 0.001
HAQ (baseline) (0-3) 0.565 0.003 0.549 0.006
tSvHS (baseline) 0.939 0.241 0.940 0.339
RF positive 1.679 0.098 1.762 0.123
ACPA positive 0.867 0.635 0.612 0.119 0.441 0.018
Duration of complaints (days) 0.999 0.421 0.999 0.324
Physical functioning (SF36 PCS) (0-100) 1.055 0.007 1.068 0.004
Psychosocial
Mental functioning
(SF36 MCS) (0-100)
1.038 0.045 1.032 0.128
Internal locus of control (MHLC) (6-36) 1.054 0.056 1.088 0.006
External locus of control (MHLC) (6-36) 1.010 0.726 0.992 0.788
Chance locus of control (MHLC) (6-36) 1.005 0.842 0.994 0.814
Anxiety (HADS) (0-21) 0.886 0.001 0.907 0.015 0.886 0.004
Depression (HADS) (0-21) 0.882 0.001 0.881 0.005
Fatigue (VAS) (0-100) 0.983 0.001 0.978 <0.001 0.973 <0.001
Coping with pain (CORS) (8-40) 0.960 0.093 0.945 0.040
*  Backward selection, variables with p<0.20 in univariable analysis were entered
Abbreviations:
- ACPA: Anti-Citrullinated Protein Antibodies
- ACR: American College of Rheumatology
- CORS: Coping with Rheumatic Stressors
- DAS: Disease Activity Score
- EULAR: European League against Rheumatism
- FAS: Fatigue Assessment Scale
- HADS: Hospital Anxiety and Depression Scale
- HAQ: Health Assessment Questionnaire
- IQR: Interquartile range
- MCS: Mental Component Scale
- MHLC: Multidimensional Health Locus of Control
- MTX: Methotrexate
- OR: Odds Ratio
- PCS: Physical Component Scale
- RF: Rheumatoid Factor
- sd: standard deviation
- SF36: Short Form 36
- tSVHS: total Sharp van der Heijde Score
- VAS: Visual Analog Scale
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DIsCUssIOn
In our analyses of predictors for attaining remission within 6 months after starting 
DMARD therapy in early RA patients, we found that besides the known factors age, sex 
and disease related factors (baseline DAS and HAQ), also physical functioning and several 
psychosocial factors (mental functioning, internal locus of control, anxiety, depression 
and fatigue) were associated. We found similar results for sustained remission at 9 
months.
Several recently published studies on predictors for attaining remission focused on 
specific treatment regimens or used different definitions of remission, both of which have 
been shown to influence the identification of predictors (16, 17). Furthermore, these 
studies were performed in patients with established rather than early RA. Although this 
heterogeneity makes direct comparison difficult, we identified several recent (> the year 
2010) studies in early RA patients on predictors for remission initiating treatment with 
conventional DMARDs that we will discuss shortly (8-10, 18-21). In line with our findings, 
five studies reported that males respond better to treatment (8, 18-21). Men have been 
reported to have both lower levels of ESR (22) and pain scores (16) compared to women, 
which may explain why achieving remission is more difficult for women. Younger age was 
found to be a predictor for remission in two studies as well (8, 20), but 4 studies reported 
insignificant associations (9, 10, 19, 21). Therefore, whether age is truly a predictor for 
remission remains unclear. Baseline DAS (21) or its components tender joint count (8, 
20), swollen joint (20) count or CRP (10) have been reported as predictors, as well as 
baseline HAQ (8). Treatment with combination DMARD therapy compared to MTX alone 
was identified as a predictor by Kuriya et al. (19) ACPA status was evaluated in 3 studies 
(8, 10, 21), none of which found a significant association. Although few studies assessed 
psychosocial factors, lower depression scores were identified as independent predictors 
for remission both in the EUPA cohort (10) and the COMET trial (9). The latter study also 
found an association between baseline anxiety and remission, which is in line with our 
findings (9).
In addition to the factors just mentioned, genetic factors have been associated with at-
taining remission as well. Fransen et al. proposed a prediction rule for attaining DAS<2.4 
within 6 months of follow-up with methotrexate alone based on clinical and genetic 
factors (6). This model was able to correctly classify 75% of patients as (non-)responders 
in its own sample (6).
Comparing predictors for attaining point remission within 6 months to the more strin-
gent criterion of attaining sustained remission (remission at both 6 and 9 months), we 
observe that baseline DAS is an independent predictor for remission within 6 months, 
whereas ACPA-negativity is an independent predictor for being in sustained remission 
at 9 months. Likely, the impact of baseline DAS on disease activity diminishes over 
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time by the treat-to-target regimen, whereas ACPA-positive status reflects a tendency 
for a higher DAS that remains present. We also observe that anxiety was identified as 
an independent predictor for point remission and fatigue as an independent predictor 
for sustained remission within 6 months. This finding does not necessarily implicate 
a real difference. As measures anxiety, fatigue and depression are correlated to each 
other (Pearson correlation coefficients: anxiety-depression 0.59, anxiety-fatigue 0.43, 
depression-fatigue 0.46), they likely measure, at least in part, a common domain that is 
reflected by patient well-being.
Several strengths and limitations should be noted. Strong points include the fact that 
data were used from a prospective randomized clinical trial on early RA patients that 
were treated to target according to current guidelines (1, 2). Although not powered for 
this analysis, the sample size appears to be adequate as for many candidate predictors 
significant results were obtained. The number of missing values in predictor variables 
were small <10%. Nonetheless, we used multiple imputation to increase power of the 
analysis. Nonetheless, the complete case analysis showed similar results (Supplemental 
Table 1). Few studies have assessed the predictive value of psychosocial factors and to 
our knowledge no previous studies have assessed them as predictors for attaining early 
remission.
Limitations can be noted as well. Data were used from a randomized clinical trial that 
was not designed for the purpose of these analyses. As the clinical trial setting differs from 
clinical practice, it cannot be ruled out that by selection bias different predictors would 
be identified if a similar study were performed in a clinical practice setting. Treatment in 
tREACH was steered to low disease activity (DAS<2.4) rather than remission (DAS<1.6) 
as used in our analysis. It is possible that, if treatment were steered towards remission 
rather than LDA, more patients would have achieved sustained remission and different 
factors would have been identified. On the other hand, treatment in clinical practice is 
often steered on DAS28 remission, which is a less stringent criterion than DAS remission. 
Therefore steering on DAS LDA may better reflect clinical practice and make our results 
more generalizable to this setting.
In this analysis, we specifically looked at predictors for remission within 6 months, as 
this is the recommend treatment goal (1, 2). However, this does not mean that patients 
achieving remission at a later point in time do not still have a better prognosis than 
patients not achieving remission at all. The course of disease for all patients achieving 
sustained remission within the first 2 years in tREACH has been published before (23).
Results from our study suggest that psychosocial factors like anxiety, depression and 
fatigue are associated with a decreased probability of meeting DAS criteria for remission. 
Whereas age and sex may be regarded as predictors that cannot be modified, interven-
tions aimed to increase the efficiency of drug therapy or to relieve symptoms of anxiety, 
depression and fatigue may be feasible. Therefore we suggest these factors might be used 
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for personalized treatment strategy. A systematic review on the effects of interventions 
aimed at self-regulation in RA found that psychological interventions utilizing more self-
regulation techniques reduced depressive symptoms and anxiety significantly more than 
interventions utilizing fewer such techniques, especially in those with early disease. Also 
person-centered physical therapy in RA patients was found to give significant improve-
ments in fatigue and anxiety (24). Whether such personalized interventions, in addition 
to a treat-to-target regimen, lead to improvements in remission rates as well should be 
further investigated. At last, results of our study may guide development of a prediction 
model as well. Addition of psychosocial factors to existing models based on clinical and 
genetic factors (6, 20) may improve the predictive ability. However, as the psychosocial 
factors likely act mostly through the subjective components of DAS (25), addition may 
not be warranted if the model is used for the purpose of identifying patients who need 
more intensive DMARD therapy.
COnClUsIOn
In conclusion, we identified male sex, younger age, lower baseline DAS and less symp-
toms of anxiety as independent predictors for attaining remission within 6 months. 
Results suggest that features of fatigue, anxiety and depression may prevent patients 
from attaining remission despite treatment according to a tight control and treat-to-
target strategy. Future studies may be addressed at evaluating the (cost-)effectiveness of 
early personalized treatment and psychological interventions in early RA patients starting 
DMARD therapy.
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supplemental Table 1. Number of patients with missing values in covariates of 281 patients included 
in the analysis.
Missing, n (%) Regression method for 
imputation
Demographics
Age 0 (0) -
Sex (female) 0 (0) -
Dutch ethnicity 16 (6) logistic
Paid work 24 (9) logistic
Disease
MTX monotherapy 0 (0) -
DAS (baseline) 1 (0.4) truncated
HAQ (baseline) 19 (7) truncated
tSvHS (baseline) 14 (5) ordered logistic
RF positive 0 (0) -
ACPA positive 0 (0) -
Duration of complaints 2 (0.7) truncated
Physical functioning (SF36 PCS) 26 (9) truncated
Psychosocial
Mental functioning (SF36 MCS) 26 (9) truncated
Internal locus of control (MHLC) 22 (8) truncated
External locus of control (MHLC) 22 (8) truncated
Chance locus of control (MHLC) 23 (8) truncated
Anxiety (HADS) 18 (6) truncated
Depression (HADS) 18 (6) truncated
Fatigue (VAS) 21 (7) truncated
Coping with pain (CORS) 19 (7) truncated
Abbreviations:
ACPA: Anti-Citrullinated Protein Antibodies
CORS: Coping with Rheumatic Stressors
DAS: Disease Activity Score
HADS: Hospital Anxiety and Depression Score
HAQ: Health Assessment Questionnaire
MCS: Mental Component Scale
MHLC: Multidimensional Health Locus of Control
MTX: Methotrexate
PCS: Physical Component Scale
RF: Rheumatoid Factore
tSvHS: total Sharp-van der Heijde Score
VAS: Visual Analog Scale
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supplemental Table 2. Complete case analysis of predictors for attaining remission (DAS<1.6) within 
6 months and sustained remission (DAS<1.6 at 2 consecutive visits) at 9 months by logistic regression.
Remission within 6 months
(n=135 cases)
sustained remission at 9 months,
(n=83 cases)
Univariable Multivariable* Univariable Multivariable*
OR P OR P OR P OR P
Demographics
Age (years) 0.982 0.032 0.978 0.027 0.988 0.183 0.969 0.006
Sex (female) 0.544 0.018 0.512 0.025 0.373 <0.001 0.362 0.001
Dutch ethnicity 1.193 0.584 1.421 0.348
Paid work 1.220 0.432 1.400 0.230
Disease
MTX monotherapy 0.657 0.098 0.642 0.122
DAS (baseline) (0-10) 0.447 <0.001 0.518 <0.001 0.583 0.001
HAQ (baseline) (0-3) 0.550 0.002 0.545 0.006
SvH (baseline) 0.935 0.216 0.943 0.354
RF positive 1.679 0.098 1.762 0.123
ACPA positive 0.867 0.635 0.612 0.119 0.451 0.025
Duration of complaints (days) 0.999 0.414 0.998 0.302
Physical functioning (SF36 PCS) (0-100) 1.054 0.008 1.075 0.002
Psychosocial
Mental functioning (SF36 MCS) (0-100) 1.042 0.029 1.037 0.087
Internal locus of control (MHLC) (6-36) 1.056 0.049 1.094 0.004
External locus of control (MHLC) (6-36) 1.012 0.674 0.997 0.935
Chance locus of control (MHLC) (6-36) 1.004 0.855 0.996 0.872
Anxiety (HADS) (0-21) 0.886 0.001 0.908 0.015 0.881 0.002
Depression (HADS) (0-21) 0.881 0.001 0.877 0.004
Fatigue (VAS) (0-100) 0.982 0.001 0.977 <0.001 0.973 <0.001
Coping with pain (CORS) (8-40) 0.964 0.128 0.946 0.050
*  Backward selection, variables with p<0.20 in univariable analysis were entered
Abbreviations:
- ACPA: Anti-Citrullinated Protein Antibodies
- ACR: American College of Rheumatology
- CORS: Coping with Rheumatic Stressors
- DAS: Disease Activity Score
- EULAR: European League against Rheumatism
- FAS: Fatigue Assessment Scale
- HADS: Hospital Anxiety and Depression Scale
- HAQ: Health Assessment Questionnaire
- IQR: Interquartile range
- MCS: Mental Component Scale
- MHLC: Multidimensional Health Locus of Control
- MTX: Methotrexate
- OR: Odds Ratio
- PCS: Physical Component Scale
- RF: Rheumatoid Factor
- sd: standard deviation
- SF36: Short Form 36
- tSVHS: total Sharp van der Heijde Score
- VAS: Visual Analog Scale
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AbsTRACT
Objectives
With early and intensive treatment many early RA patients attain remission. Aims were 
to investigate 1) the frequency and time to sustained remission and subsequent tapering 
in patients initially treated with conventional synthetic (cs)DMARD strategies and 2) the 
frequency and time to flare and regained remission in patients tapering csDMARDs and 
biologic (b)DMARDs during 2 years of follow-up.
Methods
Two year follow-up data from the tREACH cohort were used. Patients were randomized 
to initial treatment with triple DMARD therapy (iTDT) with glucocorticoid (GC) bridging 
or methotrexate monotherapy (iMM) with GC bridging. Patients were evaluated every 3 
months. In case Disease Acitivity Score (DAS) was >2.4 treatment was switched to a TNF-
blocker. In case DAS<1.6 at 2 consecutive time points, tapering was initiated according 
to protocol. Outcomes were rates of sustained remission (DAS<1.6 at 2 consecutive time 
points), flare (medication increase after tapering) and remission after flare (DAS<1.6). 
Data were analyzed using Kaplan-Meier analyses.
Results
During 2 years of follow-up, sustained remission was achieved at least once by 159 (57%) 
of patients, of whom 118 and 23 patients initiated tapering of csDMARDs and bDMARDs 
respectively. Thirty-four patients achieved drug-free remission. Flare rates were 41% and 
37% and within 1 year respectively. After flare, 65% of patients tapering csDMARDs re-
achieved remission within 6 months after treatment intensification.
Conclusions
Regardless of initial treatment strategy, 56% of patients achieved sustained remission 
during 2 years of follow-up. Flare rates were 41% and 37% within 12 months in patients 
tapering csDMARDs and bDMARDs respectively.
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InTRODUCTIOn
Several studies (1-3), among which the tREACH study (1), have shown that by early 
and intensive treatment remission can be achieved in many early RA patients. Current 
evidence suggests that once remission has been achieved, treatment de-escalation may 
be considered (4, 5), but most recent studies have focused on de-escalation of biological 
(b)DMARDs only (4).
In this follow-up study of tREACH (1), we investigated the frequency and time to remis-
sion and subsequent tapering of conventional synthetic (cs)DMARDs and bDMARDs and 
the frequency and time to flare and regained remission in patients tapering csDMARDs 
and bDMARDs.
MeTHODs
Data were used from the tREACH cohort, a detailed description of the inclusion criteria 
and protocol can be found in the original tREACH paper (1). In short, patients with early 
arthritis (duration of complaints < 1 year) and a high risk of developing persistent arthritis 
(score >6 points on Visser model (6)) were eligible. Of included patients, 97% fulfilled the 
ACR/EULAR 2010 criteria for RA (1, 7). Patients were randomized for induction treatment 
strategies with triple DMARD therapy (iTDT; methotrexate (MTX) 25 mg/week, sulphasala-
zine 2000 mg/day and hydroxychloroquine 400 mg/day or MTX monotherapy 25 mg/
week (iMM). Both groups received bridging therapy with glucocorticoids (triamcinolone 
acetonide 80 mg or methylprednisolone 120 mg once by intramuscular injection or oral 
prednisone 15 mg for 4 weeks, thereafter tapered by 5 mg/week). For this analysis, the 2 
groups receiving iTDT with oral or intramuscular glucocorticoids were combined (n=184). 
Patients were evaluated every 3 months and treated in a treat-to-target fashion. If DAS 
was >2.4 on initial treatment, patients were switched to a TNF-blocker combined with 
MTX 25 mg/week. If sustained remission (DAS<1.6 at 2 consecutive visits) was achieved, 
medication was tapered according to protocol (expert opinion of project group) while 
remission remained: (1) iTDT: Sulphasalazine stop, half dose MTX, quarter dose MTX, 
stop MTX, stop hydroxychloroquine; iMM: half dose MTX, quarter dose MTX, stop MTX; 
Combination of MTX and TNF-blocker: Randomization to taper MTX first (aforementioned 
regimen) or TNF-blocker first: doubling of interval, then half dose, then stop. In case MTX 
or TNF-blocker had been completely tapered, the remaining agent was tapered accord-
ing aforementioned scheme (also see Supplement 1). Flare was defined as an increase 
in medication after initiation of tapering. Initially, duration of follow-up was 12 months, 
which was soon extended to ≥24 months after the trial had started. For this reason 76 
(27%) of patients missed one or more visits during the second year of follow-up. Groups 
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were compared using simple descriptive statistics. Sustained low disease activity (LDA) 
was defined as DAS<2.4 at 2 consecutive visits. Drug-free remission was defined as 
DAS<1.6 without using DMARDs. Rates of sustained remission, flares and time to regain 
remission between groups were analysed using Kaplan-Meier analyses. Baseline predic-
tors for drug-free remission were evaluated using logistic regression. Statistical analyses 
were performed using STATA 14.1 (StataCorp, 4905 Lakeway Drive College Station, Texas, 
USA). P-values <0.05 were considered statistically significant.
ResUlTs
Data from 281 patients participating in tREACH were available for analysis. Overall, 68% of 
patients were female and mean age was 53.3 years. Mean baseline DAS was 3.35 (95%CI 
3.24-3.36). At baseline, groups were similar with respect to demographic and disease-
related characteristics (Table 1). A flowchart of follow-up is shown in Figure 1. During two 
years of follow-up, sustained remission was achieved in the iTDT and iMM groups in 108 
(59%) and 51 (53%) of patients and sustained low disease activity (LDA) in 148 (80%) and 
76 (78%) of patients respectively. Remission was achieved with a biological in 12 (11%) 
and 13 (26%) patients in the iTDT and iMM groups respectively. After sustained remission 
had been achieved, 94 (87%) and 47 (92%) initiated tapering in the iTDT and iMM groups 
respectively. Tapering involved a conventional DMARD in 84% (n=118) and a biological 
DMARD in 16% (n=23) of cases.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T21 
n=163 
T15 
n=162 
T0 
n=281 
T3 
n=265 
T6 
n=255 
T9 
n=252 
T12 
n=249 
T12 
n=249 
T18 
n=164 
T24 
n=202 
time-point 
skipped: 
n=5 
time-point 
skipped: 
n=8 
time-point 
skipped: 
n=6 
time-point 
skipped: 
n=2 
time-point 
skipped: 
n=52 
time-point 
skipped: 
n=48 
time-point 
skipped: 
n=46 
time-point 
skipped: 
n=3 
Drop out: n=11 
- Patient refusal (n=6) 
- Problems with communication (n=1) 
- Incorrect randomization (n=1)  
- Adverse event: 
 - Colon carcinoma (n=1) 
 - Myocardial infarction (n=1) 
 - MTX related (n=1) 
Drop out: n=7 
- Patient refusal (n=5) 
- Non-compliance (n=2) 
 
Drop out: n=5 
- Patient refusal (n=3) 
- Non-compliance (n=1) 
- Adverse event: 
 - Lung carcinoma (n=1) 
 
Drop out: n=7 
- Patient refusal (n=6) 
- Deceased (n=1) 
 
Drop out: n=37 
- Patient refusal (n=11) 
- Reached second year before 
   protocol was implemented (n=24)  
- Adverse event: 
 - Cerebral tumour (n=1) 
 - MTX related lung (n=1) 
Drop out: n=2 
- Patient refusal (n=2) 
Drop out: n=3 
- Patient refusal (n=2) 
- Adverse event: 
 - Malignancy (n=1) 
Drop out: n=4 
- Patient refusal (n=4) 
First year Second year 
figure 1. Flow-chart of follow-up.
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Time to remission
Of patients achieving sustained remission, 56 (52%) and 19 (37%) achieved this within 6 
months (p=0.09) and 91 (84%) and 39 (76%) within 1 year (p=0.27) in the iTDT and iMM 
groups respectively. Therefore, a trend for higher frequency of sustained remission and 
subsequent tapering was observed in the iTDT group compared to the iMM group, but 
this trend became less prominent over time (Figure 2A). Kaplan-Meier analysis over two 
years also revealed no significant difference between groups (Figure 2A). 
Table 1. Baseline characteristics of all patients initiating with csDMARD therapy and the subset of pa-
tients tapering DMARDs (synthetic and/or biologic).
All patients
(n=281)
Tapering DMARDs 
(n=141)
Demographic
Age, mean (sd) 53 (14) 52 (15)
Sex, female, n(%) 190 (68) 79 (56)
Disease-related
Duration of complaints, days, mean (sd) 166 (91) 167 (88)
RF-positive, n(%) 228 (81) 17 (83)
ACPA-positive, n(%) 226 (80) 108 (77)
Fulfilling ACR/EULAR 1987 criteria, n(%) 189 (67) 96 (68)
Fulfilling ACR/EULAR 2010 criteria, n(%) 267 (95) 134 (95)
DAS, mean (sd) 3.36 (0.96) 3.18 (1.03)
SJC44, median (IQR) 7 (4-12) 8 (4-12)
ESR , median (IQR) 24 (14-42) 22 (12-39)
CRP, median (IQR) 9 (4-23) 10 (5-26)
TJC44, median (IQR) 9 (4-14) 7 (3-13)
Global Health, median (IQR) 53 (33-69) 50 (28-67)
HAQ, mean (sd) 1.00 (0.66) 0.88 (0.62)
tSvHs, median (IQR) 0 (0-0) 0 (0-0)
Complete follow-up at 2 years, n(%) 248 (88) 133 (94)
Abbreviations:
ACPA: Anti-Citrillunated Protein Antibody
CRP: C-Reactive Protein
DAS: Disease Activity Score
ESR: Erythrocyte Sedimentation Rate
HAQ: Health Assessment Questionaire
RF: Rheumatoid Factor
SJC44: 44 Swollen Joint Count
TJC44: 44 Tender Joint Count
tSvHs: total Sharp – van der Heijde Score
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figure 2. Survival analysis of patients initiating with triple DMARD therapy (iTDT, blue line) versus pa-
tients initiating with MTX monotherapy (iMM, red line) with respect to sustained remission (panel A), 
of patients achieving early remission (light blue line) versus late remission (orange line) with respect 
to occurence of flare (panel C), of patients tapering csDMARDs (green line) or bDMARDs (+csDMARDs) 
(purple line) with respect to occurrence of flare (panel C), and time to regain remission after flare of 
patients tapering csDMARDs (green line) or bDMARDs (+csDMARDs) (purple line) (panel D).
Remission duration
Sustained remission at ≥3 consecutive visits was achieved by 123 patients (3 visits: n=27, 
4: n=40, 5: n=22, 6: n=11, 7: n=7, 8: n=16). After tapering DMARDs 34 patients achieved 
drug-free remission, of whom 11 and 7 remained in drug-free remission for at least 3 and 
6 months respectively. Nine and 7 patients failed drug-free remission or were censored 
after 3 months respectively. Baseline predictors male sex, lower DAS and HAQ and not 
having paid work were associated with achieving drug-free remission (Supplemental 
Table 1).
flare
For all 141 patients tapering any DMARD, no difference in flare rate was observed for 
patients achieving remission early (≤6 months) or thereafter (figure 2B). Of 118 patients 
tapering csDMARDs, 52 (44%) experienced a flare during the 2-year follow-up period. 
Kaplan-Meier analysis revealed a flare rate of 41% (95%CI 32%-50%) within 1 year and 
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51% (95%CI 42%-62%) within 18 months after initiation of tapering (figure 2C). Of 23 
patients tapering bDMARDs, 7 (30%) experienced a flare during 2 years of follow-up. 
Kaplan-Meier analysis revealed a flare rate of 37% (95%CI 19%-64%) within 1 year after 
initiation of tapering (figure 2C). Upon medication increase after a flare, Kaplan-Meier 
analysis revealed that 53% (95%CI 40%-68%) of patients tapering csDMARDs regained 
DAS-remission within 3 months and 65% (95CI 50%-79%) within 6 months (figure 2D). 
Of five patients tapering bDMARDs , three regained DAS-remission within 6 months after 
flare.
DIsCUssIOn
In this study of early rheumatoid arthritis, a trend for a higher frequency of achieving sus-
tained remission, with less use of biologicals, was observed in patients with initial triple 
DMARD therapy compared to initial methotrexate monotherapy. We found that 57% 
of patients reached sustained remission and 78% sustained LDA at least once during 2 
years of follow-up. This is in line with findings by others. Previous studies found sustained 
remission rates of 50% during 2 years of follow-up in patients initiating with MTX mono-
therapy (8) and an LDA rate of 78% at 2 years of follow-up in early RA patients initiating 
with combination csDMARD therapy with tapered high dose prednisone (9). Although 
in recent years, many clinical trials and observational studies on tapering DMARDs have 
emerged (4), most deal with the de-escalation of biologic DMARDs (4, 10-12) or report 
mixed results for groups in which both bDMARDs and csDMARDs were tapered (13, 14). 
A recent publication on data from a Dutch registry study found that de-escalation of MTX 
in patients using concomitant TNFi did not influence average DAS and drug survival (15). 
However, studies that specifically focus on de-escalation of conventional DMARDs gener-
ally date from the nineties or before and were performed in patients with established 
RA (4). Results from this study on the tapering of conventional DMARDS may therefore 
provide additional value to current literature. The 1-year flare rates after tapering csD-
MARDS (41% (95% CI 32% - 50%)) and bDMARDS (37% (95%CI 19% - 64%)) appear to be 
comparable to the pooled flare rate found for studies de-escalating TNF-blockers of 33% 
(95%CI 23% - 45%) (4). Also in line with the findings of the systematic review, we found 
that the majority of patients (65% (95%CI 50-79%) regained a state of remission within 6 
months after treatment intensification.
This study has several strengths and limitations. Strong points of this study include the 
fact that we performed an analysis in a large clinical trial population of early RA patients 
treated in a treat-to-target fashion. Some limitations in the analysis should be noted as 
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well. First of all, follow-up with respect to the outcome measures used in this analysis 
was not complete. Especially during the second year of follow-up we had a substantial 
amount of missing observations. This had to do with the fact that initially the trial was 
set up to have a follow-up duration of 12 months. Only after the trial had started, the 
follow-up was extended to 36 months. Hence, part of the patients have only been fol-
lowed for 1 year. This problem was addressed by using Kaplan-Meier estimates, which 
allowed to correctly analyse censored data. The tapering of medication was performed 
largely according to protocol, however this protocol was not always exactly followed by 
the rheumatologists in practice. Reasons may vary from unfamiliarity with the protocol 
to deviation on purpose because the disease status as indicated by the DAS did not 
agree with the rheumatologists’ opinion. Although this may be seen as a limitation, it 
may also be a strong point as our results are likely to better reflect the way in which 
tapering is performed in clinical practice. Another potential limitation is that the flare 
rates in this study may depend on the tapering scheme used. We used stepwise tapering 
as long as sustained remission was maintained. It is possible that more patients would 
have remained in sustained remission if only dose reduction of csDMARDs were applied, 
which has already been shown for TNF-inhibitors. (16, 17) Considering the DMARDs 
patients received at the moment flare occurred (Supplement 1), we observe that 15/32 
of patients having a flare while tapering combination DMARD therapy experienced the 
flare during the first 2 steps (tapering sulphasalazine and methotrexate, arguably cutting 
dose in half) and 6/15 patients when tapering MTX to half dose. Possibly, dose reduction 
is more difficult to achieve in patients receiving csDMARDs only than in patients treated 
with bDMARDs. It should be noted that after flare, the majority of patients regained 
remission within 6 months which is similar to re-remission rates observed in studies de-
escalating biological DMARDs (4). At last it should be noted that data are from an early RA 
population with relatively mild disease. Results may not be generalizable to populations 
with established RA for which rates of remission and successful tapering may be lower.
In conclusion, we found a trend for earlier achievement of sustained remission, with 
less use of biologicals, in early RA patients initiating with triple DMARD therapy compared 
to MTX monotherapy. Regardless of initial treatment strategy, 56% of patients achieved 
sustained remission during 2 years of follow-up. Of patients tapering csDMARDs, 41% 
experienced a disease flare within 12 months. After flare, 65% of patients tapering 
csDMARDs regained a state of remission within 6 months after treatment intensification.
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supplement 1. Treatment de-escalation steps for patients in sustained remission. Numbers in boxes 
indicate the number of flares on each respective step.
Flare after tapering combination DMARD therapy (MTX25 mg/week, Sulphasalazine 2000 mg/day, Hy-
droxychloroquine (HCQ) 200 mg/day), n=32/84§
Step 1
MTX 25 mg/week
HCQ 200 mg/day
Step 2
MTX 12.5 mg/week
HCQ 200 mg/day
Step 3
MTX 7.5 mg/week
HCQ 200 mg/day
Step 4
HCQ 200 mg/day
Step 5
No DMARDs
n=8 n=7 n=6 n=8 n=3
Flare after tapering MTX25 mg/week, n=15/29§
Step 1
MTX 12.5 mg/week
Step 2
MTX 7.5 mg/week
Step 3
No DMARDs
n=6 n=6 n=3
Flare after tapering Enbrel 50 mg/week and MTX 25 mg /week, Enbrel first, n=6/12§
Step 1
Enbrel 
50mg/2weeks
MTX 25 mg/
week
Step 2
Enbrel 
25mg/2weeks
MTX 25 mg/
week
Step 3
MTX 25 mg/
week
Step 4
MTX 12,5 mg/
week
Step 5
MTX 7.5 mg/
week
Step 6
No DMARDs
n=3 - n=2 n=1 - -
Flare after tapering Enbrel 50 mg/week and MTX 25 mg /week, MTX first, n=1/7§
Step 1
Enbrel 50mg/
week
MTX 12.5 mg/
week
Step 2
Enbrel 50mg/
week
MTX 7.5 mg/
week
Step 3
Enbrel 50 mg/
week
Step 4
Enbrel 
50mg/2weeks
Step 5
Enbrel 
25mg/2weeks
Step 6
No DMARDs
n=1 - - - - -
Flare after tapering other medication/dosages: n=5/9§
§ Note: Due to right-censored nature of data ratios should be interpreted with caution
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supplemental Table 1. Predictors for attaining drug-free remission.
Drug-free remission
(logistic regression)
Univariable Multivariable*
OR P OR P
Demographics
Age 0.995 0.709
Sex (female) 0.373 0.008 0.352 0.010
Dutch ethnicity 3.316 0.110
Paid work 0.438 0.037 0.404 0.030
Disease
MTX monotherapy 1.589 0.212
DAS (baseline) 0.590 0.014 0.587 0.022
HAQ (baseline) 0.515 0.038
SvH (baseline) 0.993 0.870
RF positive 1.399 0.511
ACPA positive 0.636 0.283
Duration of complaints 1.001 0.801
Physical functioning (SF36 PCS) 1.056 0.085
* Backward selection, variables with p<0.20 in univariate analysis were entered.
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AbsTRACT
Objective
To evaluate the risk of having a disease flare in rheumatoid arthritis patients with low 
disease activity or remission, when de-escalating (tapering or stopping) DMARD therapy.
Methods
A search in medical databases including publications from January 1950 to February 2015 
was performed. Included were trials and observational studies in adults with rheumatoid 
arthritis with low disease activity or remission, evaluating ≥20 patients tapering or stop-
ping DMARDs. Flare rates had to have been reported. A meta-analysis was performed on 
studies de-escalating TNF-blockers.
Results
Four studies evaluated synthetic DMARDs. Flare rates ranged from 8% at 24 weeks to 
63% at 4 months after de-escalation. Fifteen studies reported on TNF-blockers. Esti-
mated flare rates by meta-analysis on studies tapering or stopping TNF-blockers were 
0.26 (95% CI 0.17-0.39) and 0.49 (95% CI 0.27-0.73) for good and moderate quality 
studies, respectively. Flare rates in three studies stopping tocilizumab and three studies 
de-escalating abatacept ranged from 41% at 9 months - 87% at 1 year and 34% at 1 
year - 75% at 6 months, respectively. Five studies evaluating radiographic progression in 
patients de-escalating treatment all found limited to no progression.
Conclusion
Results suggest that more than one third of patients with RA in low disease activity or 
remission may taper or stop DMARD treatment without experiencing a disease flare 
within the first year.
Dose reduction of TNF-blockers results in lower flare rates than stopping and may 
be non-inferior to continuing full dose. Radiological progression after treatment de-
escalation remains low, but may increase slightly.
Tapering or stopping DMARDs in patients in low disease activity or remission – a systematic review
105
7
InTRODUCTIOn
The treatment of rheumatoid arthritis (RA) has advanced greatly. Combination therapy 
with disease modifying anti-rheumatic drugs (DMARDs), early, tight controlled treatment, 
and biologic agents improve outcomes in patients (1). Increasing numbers of patients 
reach and maintain a state of low disease activity or remission. The issue rises whether 
then DMARD therapy should be continued unchanged (infinitely) to keep the disease 
under control. De-escalation (tapering or stopping) of one or more anti-rheumatic agents 
could yield several benefits, such as less drug toxicity, less adverse reactions and less 
medical costs. However, it would then be important to know the risk of flare, radiographic 
progression and whether disease control can be easily regained after flare.
Objective of this review was to assess the course of disease after tapering or stopping 
synthetic DMARD (sDMARD) or biologic DMARD (bDMARD) therapy in patients with 
rheumatoid arthritis in remission or low disease activity. To do this, we set out the fol-
lowing goals:
1. To assess the risk of having a disease flare after tapering or stopping DMARDs.
2. To evaluate the mean or median time to flare (time-to-flare) after tapering or stop-
ping DMARDs.
3. To evaluate the rate of radiographic progression after tapering or stopping DMARDs.
4. To assess how much time is needed to regain a state of low disease activity or remis-
sion (time-to-remission) after a disease flare has occurred.
MATeRIAls AnD MeTHODs
search strategy and selection criteria
This systematic review was conducted in accordance with the PRISMA (Preferred Report-
ing Items for Systematic reviews and Meta-Analyses) guidelines (2).
The search strategy developed and performed in collaboration with two medical librar-
ians, was performed in the digital databases of Ovid-SP, Embase, PubMed and the Cochrane 
library for articles published up to February 2015. Keywords included terms and synonyms 
for rheumatoid arthritis, specific types of disease modifying anti-rheumatic drugs (e.g. 
methotrexate, etanercept) and stopping/tapering. One investigator (TMK) manually 
searched through cited references of published reviews of de-escalation of DMARDs in 
rheumatoid arthritis. The complete search strategy can be found in Supplement 1.
We included both clinical trials and observational studies on adult patients with rheu-
matoid arthritis in low disease activity or remission (as defined by any available criteria 
or on clinical grounds), tapering down or stopping DMARDs, reporting a flare rate at ≤ 
1 year of follow-up. A minimum sample size of 20 patients de-escalating DMARDs was 
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required to be included. Patients needed to have equal lengths of follow-up in studies 
that reported flare rates as percentage or alternatively reported flares per person years 
in case patients had unequal length of follow-up. Studies were excluded if published 
only in the form of congress abstracts and studies reporting only combined flare rates 
for DMARDs with different modes of action (e.g. TNF-inhibitors and tocilizumab) were 
excluded. As most disease flares would be expected to occur within the first 3-6 months 
after treatment de-escalation, we believe a follow-up time of up to 1 year to be adequate.
Data extraction
One investigator (TMK) reviewed titles and abstracts and selected potential manuscripts 
for retrieval. After retrieval of potential manuscripts, the same investigator established 
study eligibility applying the selection criteria specified above. In case of he was doubt, 
the study was discussed with the co-investigators (FBGL, JWGJ, JMWH) until consensus 
was reached. We used a standardized data collection form to extract the following infor-
mation: Type of study, patient definition, number of patients tapering down or stopping 
medication, the DMARD that was tapered down or stopped, co-medication, definition of 
low disease activity / remission used, manner in which medication was tapered down or 
stopped, definition of flare, number of flares per follow-up time, mean/median time to 
flare, radiological progression and time to regain disease control after a flare.
Risk of bias assessment
We used a modification of Black’s list to perform a quality assessment on observational 
studies (3). The original list contains 27 items, distributed over five subscales: reporting, 
external validity, bias, confounding and power. Some minor modifications were made 
to the original list to suit it better use on treatment de-escalation studies: Items 6, 10, 
16 and 25 from the original list were omitted, while item 17 was extended with two 
sub-items addressing the adequateness of follow-up for the outcomes flare rate and ra-
diographic progression. Item 27 was modified to: “Was the sample size used to calculate 
the flare rate larger than n=100?”, ensuring an adequate precision (95%-CI < 0.2). The 
modified list is available (Supplement 2). Two investigators (FBGL and JJL) independently 
rated each study. Disagreements were resolved by consensus. A table with item scores 
for each study was generated (Supplement 3), so that readers can easily identify design 
flaws introducing a potential for bias among studies. 
Pooling of data
Because of small numbers and differences in study design, meta-analysis was deemed 
inappropriate for studies on abatacept, tocilizumab and sDMARDs. A meta-analysis was per-
formed on studies de-escalating TNF-blockers, reporting a flare rate at 1 year of follow-up.
The software Comprehensive Meta-Analysis version 2.2 (Biostat Inc., 14 North Dean 
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Street, Englewood, USA) was used. A random effects model was chosen based on the as-
sumption that there are 2 sources of variability in effects observed in the various studies, 
i.e. sampling error and variability introduced by doing studies in different populations. 
Subgroup analyses by study quality were performed using a moderator variable. First, a 
quality score was generated using the items scores from the quality assessment as follows: 
Quality score = (#items “yes” + 0.5* #items “partly”) / total #items. Then, based on the 
median score of the studies selected for meta-analysis, a dichotomous moderator variable 
was created to compare the results of studies according their quality. In case one or more 
studies had exactly the median score these studies were classified as having good quality.
ResUlTs
The search in electronic databases yielded 8147 publications, of which 7909 articles were 
excluded based on title and abstract (Figure 1). After full text assessment of the remaining 
238 publications, 25 studies remained that were eligible for inclusion (Figure 1). 
0 additional articles identified through 
other sources 
10424 potentially relevant articles 
identified through database searching 
8147 potentially relevant articles after removing 
duplicates, screened on title and abstract 
25 studies included in 
systematic review 
7909 articles 
excluded 
238 full-text articles 
assessed for eligibility 
219 articles excluded 
 
90 no original data/ congress abstract 
41 no primary outcome 
44 no tapering/discontinuation study 
15 small numbers (<20 patients 
tapering/stopping DMARDs) 
13 no low disease activity/remission 
3 no RA 
4 unclear which DMARDs are tapered 
1 flare rate reported at ≥ 1year 
2 same data as included study 
figure 1. Flow diagram of study selection.
Included studies showed a large heterogeneity in the specific DMARDs, the concomi-
tant treatment with other DMARDs, the remission criteria used to initiate tapering and 
follow-up time (Table 1). Sample sizes were relatively small (median 65, range 22-717). 
Chapter 7
108
Table 1. Overview of included studies.
first Author, 
year of 
publication
study design Disease 
duration
Patients Criteria used 
to initiate 
tapering / 
discontinuation
Medication 
tapered/
stopped 
Co-
medication
# patients 
tapered/
stopped
flare 
definition
flare % (n)
/ follow-up
Median / 
mean time 
to flare
Time to 
remission 
after flare
Radiological 
progression
study 
limitations 
(items)#
biological DMARDs: Tnf inhibitors
Smolen, 
2013 
(PRESERVE) 
(17)
RCT mean 6.9 
years
RA, 18-70 years 
old; etn+MTX 36 
weeks
DAS28≤3.2 for 
24 weeks
etn 50 mg / 
week + MTX, 
randomized 
1:1:1 to
A) etn 50 mg/
week +MTX, 
B) etn 25 mg/
week +MTX
 C) pbo + MTX
MTX ± gcs 202 (full 
dose etn), 
202 (half 
dose etn), 
200 (pbo)
DAS28>3.2 at 
52 weeks
50 mg: 
17.4% (35)
25 mg: 
20.9% (42)
placebo: 
57.4% (113) 
/ 1 year
- - group A: -0.06 
u/year, B: 0.05 
u/year, C: 0.60 
u/year; A vs C 
was significant 
9, 11, 12,26; 
partly: 1
van der 
Maas, 2012 
(21)
single-arm 
trial
median 
12 years
RA, 1987 ACR DAS28<3.2 for 6 
months
ifx, down- 
titration 3 mg/
kg every 8-12 
weeks
± sDMARDs 51 reversed 
EULAR 
response 
criteria¶
54% (28)
/ 1 year
200 days 
(median)
- - 9, 12,15,19, 26
Heimans, 
2013 
(IMPROVED) 
(5)
single-arm 
trial
8 months early RA (ACR 
2010) or 
undifferentiated 
arthritis
DAS44<1.6 for 4 
months
ada 40 mg/ 2 
weeks, MTX 
25 mg/week, 
tapered† to MTX 
monotherapy
MTX 26 DAS44>1.6 35% (9)
/ 4 months
- - - 9, 12, 14, 19, 
27
Maneiro, 
2013 (13)
retrospective 
observational 
study
median 
10.6 years
early and 
established RA 
(≤ and > 2 years 
of diagnosis 
respectively)
early RA: 
sustained‡ 
DAS28<2.6; 
established 
RA: sustained‡ 
DAS28<3.2
ifx 5 to 3 mg/
kg and/or 6 to 8 
weeks
etn 7 to 10 days
ada 2 to 3 weeks
ctz 2 to 3 weeks
± sDMARDs 
± gcs
54 (ada 9,
ctz 7, etn 28, 
ifx 10)
DAS28 
increase >20% 
OR increase 
in dose or 
frequency of 
bDMARDs, 
sDMARDs or 
gcs
all 19,1% 
(ada 30,8%
ctz 50,0%
etn 11,1%
ifx 25,0%) / 
1 year
ada 19 m
etn 15,5 m
ifx 16,5 m
ctz not 
reported
- - 1, 5, 11-15, 
19, 27
Tanaka, 2010 
(RRR) (22)
single-arm 
trial
mean 5.9 
years
RA, 1987 ACR DAS28<3.2 for 
>24 weeks; 
prednisolone < 
5 mg/day
ifx, stop MTX 114 ifx restarted 
within 1 year; 
DAS28≥3.2 at 
year 1
40% (46)
/ 1 year
6.4 months 
(mean)
majority 
within 24 
weeks
- 11, 12, 19, 26; 
partly: 3, 9, 15
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Table 1. Overview of included studies.
first Author, 
year of 
publication
study design Disease 
duration
Patients Criteria used 
to initiate 
tapering / 
discontinuation
Medication 
tapered/
stopped 
Co-
medication
# patients 
tapered/
stopped
flare 
definition
flare % (n)
/ follow-up
Median / 
mean time 
to flare
Time to 
remission 
after flare
Radiological 
progression
study 
limitations 
(items)#
biological DMARDs: Tnf inhibitors
Smolen, 
2013 
(PRESERVE) 
(17)
RCT mean 6.9 
years
RA, 18-70 years 
old; etn+MTX 36 
weeks
DAS28≤3.2 for 
24 weeks
etn 50 mg / 
week + MTX, 
randomized 
1:1:1 to
A) etn 50 mg/
week +MTX, 
B) etn 25 mg/
week +MTX
 C) pbo + MTX
MTX ± gcs 202 (full 
dose etn), 
202 (half 
dose etn), 
200 (pbo)
DAS28>3.2 at 
52 weeks
50 mg: 
17.4% (35)
25 mg: 
20.9% (42)
placebo: 
57.4% (113) 
/ 1 year
- - group A: -0.06 
u/year, B: 0.05 
u/year, C: 0.60 
u/year; A vs C 
was significant 
9, 11, 12,26; 
partly: 1
van der 
Maas, 2012 
(21)
single-arm 
trial
median 
12 years
RA, 1987 ACR DAS28<3.2 for 6 
months
ifx, down- 
titration 3 mg/
kg every 8-12 
weeks
± sDMARDs 51 reversed 
EULAR 
response 
criteria¶
54% (28)
/ 1 year
200 days 
(median)
- - 9, 12,15,19, 26
Heimans, 
2013 
(IMPROVED) 
(5)
single-arm 
trial
8 months early RA (ACR 
2010) or 
undifferentiated 
arthritis
DAS44<1.6 for 4 
months
ada 40 mg/ 2 
weeks, MTX 
25 mg/week, 
tapered† to MTX 
monotherapy
MTX 26 DAS44>1.6 35% (9)
/ 4 months
- - - 9, 12, 14, 19, 
27
Maneiro, 
2013 (13)
retrospective 
observational 
study
median 
10.6 years
early and 
established RA 
(≤ and > 2 years 
of diagnosis 
respectively)
early RA: 
sustained‡ 
DAS28<2.6; 
established 
RA: sustained‡ 
DAS28<3.2
ifx 5 to 3 mg/
kg and/or 6 to 8 
weeks
etn 7 to 10 days
ada 2 to 3 weeks
ctz 2 to 3 weeks
± sDMARDs 
± gcs
54 (ada 9,
ctz 7, etn 28, 
ifx 10)
DAS28 
increase >20% 
OR increase 
in dose or 
frequency of 
bDMARDs, 
sDMARDs or 
gcs
all 19,1% 
(ada 30,8%
ctz 50,0%
etn 11,1%
ifx 25,0%) / 
1 year
ada 19 m
etn 15,5 m
ifx 16,5 m
ctz not 
reported
- - 1, 5, 11-15, 
19, 27
Tanaka, 2010 
(RRR) (22)
single-arm 
trial
mean 5.9 
years
RA, 1987 ACR DAS28<3.2 for 
>24 weeks; 
prednisolone < 
5 mg/day
ifx, stop MTX 114 ifx restarted 
within 1 year; 
DAS28≥3.2 at 
year 1
40% (46)
/ 1 year
6.4 months 
(mean)
majority 
within 24 
weeks
- 11, 12, 19, 26; 
partly: 3, 9, 15
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Table 1. Continued
first Author, 
year of 
publication
study design Disease 
duration
Patients Criteria used 
to initiate 
tapering / 
discontinuation
Medication 
tapered/
stopped 
Co-
medication
# patients 
tapered/
stopped
flare 
definition
flare % (n)
/ follow-up
Median / 
mean time 
to flare
Time to 
remission 
after flare
Radiological 
progression
study 
limitations 
(items)#
Van den 
Broek, 2011 
(BeSt) (20)
single-arm 
trial
median 23 
months
RA, 1987 ACR DAS44<2.4 for 6 
months
ifx, stop MTX 104 DAS44>2.4 20% (21) 
/ 1 year
17 months 
(median)
- - 9, 12,15,19, 
26; partly: 1
Brocq, 2009 
(8)
single-arm 
trial
mean 
11.3 years
Inflammatory 
joint disease; 
304/442 
fulfilling 1987 
ACR criteria
DAS28<2.6 
for 6 months; 
DMARDs stable 
for 6 months; 
no NSAIDs; 
prednisolone < 
5 mg
TNF-blocker (ifx, 
etn, ada), stop
sDMARDs 24 DAS28>3.2 63% (15)
/ 1 year
14.7 weeks 
(mean)
5.6 weeks 
(mean)
- 9, 12, 15, 19, 
26, 27; partly: 
11
Harigai, 2012 
(BRIGHT) 
(10)
retrospective 
cohort study
mean 
10.3 years
RA DAS28-CRP≤2.7 ada, stop MTX ± gcs 22 DAS28-CRP 
>2.7 or restart 
of bDMARDs
54% (12)
/ 1 year
- - - 8, 9, 12, 15, 
19, 23, 26, 27; 
partly: 5
Tanaka, 2015 
(HONOR) 
(19)
observational 
cohort (with 
control 
group)
mean 
7.5 years 
(sd 10.2 
years)
RA, 1987 ACR
Inadequate 
response to 
MTX and/or 
sDMARDs
DAS28<2.6 for 6 
months; Stable 
MTX dose ≥ 12 
weeks; no gcs; 
no NSAIDs
ada 40 mg/ 2 
weeks, stop
MTX A) 52
B) 23 
(control)
DAS28≥3.2 A) 40% (21)
B) 9% (2)
/ 1 year
- Restart ada ± 
mtx:
90% LDA 
within 6 
months; 
100% LDA 
within 9 
months
- 9,14, 15, 19, 
23, 27
Smolen, 
2014 
(OPTIMA) 
(16)
RCT < 1 year early RA, 1987 
ACR
DAS28-CRP<3.2 
at week 22 
and 26
ada 40 mg / 2 
weeks 
A) stop
B) continue
MTX 20 
mg/week 
±NSAIDs 
±gcs
A) 102
B) 105
DAS28-
CRP≥3.2
A) 19% (19)
B) 9% (9)
/ 1 year
- - radiographic 
non-
progression 
(ΔTSS≤0.05) 
from baseline 
to week 78:
A) 81%
B) 89%
(p=0.06)
9, 12, 19
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Table 1. Continued
first Author, 
year of 
publication
study design Disease 
duration
Patients Criteria used 
to initiate 
tapering / 
discontinuation
Medication 
tapered/
stopped 
Co-
medication
# patients 
tapered/
stopped
flare 
definition
flare % (n)
/ follow-up
Median / 
mean time 
to flare
Time to 
remission 
after flare
Radiological 
progression
study 
limitations 
(items)#
Van den 
Broek, 2011 
(BeSt) (20)
single-arm 
trial
median 23 
months
RA, 1987 ACR DAS44<2.4 for 6 
months
ifx, stop MTX 104 DAS44>2.4 20% (21) 
/ 1 year
17 months 
(median)
- - 9, 12,15,19, 
26; partly: 1
Brocq, 2009 
(8)
single-arm 
trial
mean 
11.3 years
Inflammatory 
joint disease; 
304/442 
fulfilling 1987 
ACR criteria
DAS28<2.6 
for 6 months; 
DMARDs stable 
for 6 months; 
no NSAIDs; 
prednisolone < 
5 mg
TNF-blocker (ifx, 
etn, ada), stop
sDMARDs 24 DAS28>3.2 63% (15)
/ 1 year
14.7 weeks 
(mean)
5.6 weeks 
(mean)
- 9, 12, 15, 19, 
26, 27; partly: 
11
Harigai, 2012 
(BRIGHT) 
(10)
retrospective 
cohort study
mean 
10.3 years
RA DAS28-CRP≤2.7 ada, stop MTX ± gcs 22 DAS28-CRP 
>2.7 or restart 
of bDMARDs
54% (12)
/ 1 year
- - - 8, 9, 12, 15, 
19, 23, 26, 27; 
partly: 5
Tanaka, 2015 
(HONOR) 
(19)
observational 
cohort (with 
control 
group)
mean 
7.5 years 
(sd 10.2 
years)
RA, 1987 ACR
Inadequate 
response to 
MTX and/or 
sDMARDs
DAS28<2.6 for 6 
months; Stable 
MTX dose ≥ 12 
weeks; no gcs; 
no NSAIDs
ada 40 mg/ 2 
weeks, stop
MTX A) 52
B) 23 
(control)
DAS28≥3.2 A) 40% (21)
B) 9% (2)
/ 1 year
- Restart ada ± 
mtx:
90% LDA 
within 6 
months; 
100% LDA 
within 9 
months
- 9,14, 15, 19, 
23, 27
Smolen, 
2014 
(OPTIMA) 
(16)
RCT < 1 year early RA, 1987 
ACR
DAS28-CRP<3.2 
at week 22 
and 26
ada 40 mg / 2 
weeks 
A) stop
B) continue
MTX 20 
mg/week 
±NSAIDs 
±gcs
A) 102
B) 105
DAS28-
CRP≥3.2
A) 19% (19)
B) 9% (9)
/ 1 year
- - radiographic 
non-
progression 
(ΔTSS≤0.05) 
from baseline 
to week 78:
A) 81%
B) 89%
(p=0.06)
9, 12, 19
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Table 1. Continued
first Author, 
year of 
publication
study design Disease 
duration
Patients Criteria used 
to initiate 
tapering / 
discontinuation
Medication 
tapered/
stopped 
Co-
medication
# patients 
tapered/
stopped
flare 
definition
flare % (n)
/ follow-up
Median / 
mean time 
to flare
Time to 
remission 
after flare
Radiological 
progression
study 
limitations 
(items)#
Iwamoto, 
2014 (11)
observational 
cohort
8.2 years RA, 1987 ACR 
OR 2010 ACR/
EULAR
DAS28<2.6 TNFi (ifx, etn, 
ada, gol, ctz), 
stop
±MTX ±gcs 32 DAS28>3.2 & 
escalation of 
anti-rheumatic 
treatment
38% (12)
/ 6 months
mean 14.8 
weeks
- - 9, 11, 12, 14, 
19, 26, 27; 
partly: 5, 15
Emery, 2014 
(9)
RCT 6.8 
months
early active 
disease;
RA, 1987 ACR;
MTX + biological 
naïve; etn + MTX 
for 52 weeks
DAS≤3.2 at 
week 39 AND 
DAS<2.6 at 
week 52
etn 50 mg / 
week + MTX 10 
-25 mg / week, 
randomized to:
A) etn 25 mg / 
week + MTX
B) MTX + pbo
C) pbo + pbo
for 39 weeks. 
Thereafter if 
DAS28≤3.2 all 
treatment was 
withdrawn. 
±gcs A) 63
B) 65
C) 65
DAS28≥2.6 A) 21% (13)
B) 46% (30)
C) 62% (40)
/ 39 weeks
- - ΔmTSS (mean 
±SE): 
A) 0.1 ±0.1
B) -0.0 ±0.2 
C) 0.4 ±0.2
/ 39 weeks
(p A vs B = 0.79
p A vs C = 0.48
p B vs C = 0.34)
9, 17c, 19
Marks, 2015 
(14)
prospective 
cohort
129.5 
months
RA, 2010 ACR/
EULAR; TNFi >1 
year
DAS28≤2.6 + 
PDUS=0 > 6 
months; no oral 
gcs
TNFi, tapered 
1/3 (increased 
interval)
±sDMARD 69 DAS28≥2.6 OR 
PDUS≥1 OR 
according to 
patient
63% (43)
/ 9 months
median 6 – 9 
months
- - 9, 12, 14, 
15, 17a, 18, 
19, 26, 27; 
partly: 3
Raffeiner, 
2014 (15)
RCT 14.3 years RA, 1987 
ACR; failure 
traditional 
DMARDs; etn 25 
mg 2x/week 
DAS28<2.6 for ≥ 
12 weeks
A) etn 25 mg / 
week
B) etn 25 mg 2x 
/ week
±sDMARD 
±NSAIDs 
±gcs
A) 159
B) 164
DAS28>2.6 A) 11% (18) 
B) (not 
reported)
/ 1 year
- - ΔTSS= 0; >0 ;≥5 
1 year:
A) 82%; 18%; 
1%
B) 82%; 18%; 
1%
2 years:
A) 85%; 16%; 
1%
B) 80%; 20%; 
1%
9, 12, 15, 19, 
24, 26
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Table 1. Continued
first Author, 
year of 
publication
study design Disease 
duration
Patients Criteria used 
to initiate 
tapering / 
discontinuation
Medication 
tapered/
stopped 
Co-
medication
# patients 
tapered/
stopped
flare 
definition
flare % (n)
/ follow-up
Median / 
mean time 
to flare
Time to 
remission 
after flare
Radiological 
progression
study 
limitations 
(items)#
Iwamoto, 
2014 (11)
observational 
cohort
8.2 years RA, 1987 ACR 
OR 2010 ACR/
EULAR
DAS28<2.6 TNFi (ifx, etn, 
ada, gol, ctz), 
stop
±MTX ±gcs 32 DAS28>3.2 & 
escalation of 
anti-rheumatic 
treatment
38% (12)
/ 6 months
mean 14.8 
weeks
- - 9, 11, 12, 14, 
19, 26, 27; 
partly: 5, 15
Emery, 2014 
(9)
RCT 6.8 
months
early active 
disease;
RA, 1987 ACR;
MTX + biological 
naïve; etn + MTX 
for 52 weeks
DAS≤3.2 at 
week 39 AND 
DAS<2.6 at 
week 52
etn 50 mg / 
week + MTX 10 
-25 mg / week, 
randomized to:
A) etn 25 mg / 
week + MTX
B) MTX + pbo
C) pbo + pbo
for 39 weeks. 
Thereafter if 
DAS28≤3.2 all 
treatment was 
withdrawn. 
±gcs A) 63
B) 65
C) 65
DAS28≥2.6 A) 21% (13)
B) 46% (30)
C) 62% (40)
/ 39 weeks
- - ΔmTSS (mean 
±SE): 
A) 0.1 ±0.1
B) -0.0 ±0.2 
C) 0.4 ±0.2
/ 39 weeks
(p A vs B = 0.79
p A vs C = 0.48
p B vs C = 0.34)
9, 17c, 19
Marks, 2015 
(14)
prospective 
cohort
129.5 
months
RA, 2010 ACR/
EULAR; TNFi >1 
year
DAS28≤2.6 + 
PDUS=0 > 6 
months; no oral 
gcs
TNFi, tapered 
1/3 (increased 
interval)
±sDMARD 69 DAS28≥2.6 OR 
PDUS≥1 OR 
according to 
patient
63% (43)
/ 9 months
median 6 – 9 
months
- - 9, 12, 14, 
15, 17a, 18, 
19, 26, 27; 
partly: 3
Raffeiner, 
2014 (15)
RCT 14.3 years RA, 1987 
ACR; failure 
traditional 
DMARDs; etn 25 
mg 2x/week 
DAS28<2.6 for ≥ 
12 weeks
A) etn 25 mg / 
week
B) etn 25 mg 2x 
/ week
±sDMARD 
±NSAIDs 
±gcs
A) 159
B) 164
DAS28>2.6 A) 11% (18) 
B) (not 
reported)
/ 1 year
- - ΔTSS= 0; >0 ;≥5 
1 year:
A) 82%; 18%; 
1%
B) 82%; 18%; 
1%
2 years:
A) 85%; 16%; 
1%
B) 80%; 20%; 
1%
9, 12, 15, 19, 
24, 26
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Table 1. Continued
first Author, 
year of 
publication
study design Disease 
duration
Patients Criteria used 
to initiate 
tapering / 
discontinuation
Medication 
tapered/
stopped 
Co-
medication
# patients 
tapered/
stopped
flare definition flare % (n)
/ follow-up
Median / 
mean time 
to flare
Time to 
remission 
after flare
Radiological 
progression
study 
limitations 
(items)#
Kavanaugh, 
2014 (12)
observational 
cohort
median 8 
years
RA, discontinued 
first TNFi, no 
other previous 
bDMARD
CDAI≤10 TNFi, stop ±sDMARDs 
±gcs
717 CDAI>10 OR 
bDMARD 
initiation 
OR sDMARD 
initiation / dose 
escalation OR 
gcs initiaton / 
dose escalation
26.6% (191)
/ 1 year
≥ 20 months 
(median)
- - 8, 9, 15, 19, 26
biological DMARDs: tocilizumab
Nishimoto, 
2013 
(DREAM/
RESTORE) 
(24, 26)
Single-arm 
trial
median 
7.8 years
RA, 1987 ACR;
 ≥20 years old
DAS28≤3.2 at 
2-3 consecutive 
time points
tcz ±NSAIDs ± 
oral gcs
187 DAS28>3.2 at 
2 consecutive 
observations
86.6 % 
(162)
/ 1 year
- 139 of 157 
(88.5%) 
retreated 
with TCZ 
achieved 
DAS28<2.6 
within 12 
weeks
- 12-15, 19
Aguilar, 2013 
(23)
prospective 
cohort
mean 
13.7 years
RA, MTX + tcz 
for 5 years
DAS28<2.6 & 
SJC=0
tcz 8mg/kg/4 
weeks, stop
MTX 45 SJC≥1 55% (25)
/ 1 year
3 months 
(median)
- - 9, 12-15, 26, 
27; partly: 3, 5
Van 
Herwaarden, 
2014 (25)
retrospective 
cohort
median 
10 years
RA, 1987 ACR 
OR 2010 ACR/
EULAR OR 
clinical diagnosis
DAS28<3.2 
OR judgement 
rheumatologist
tcz 8 mg/kg/4 
weeks to 4 mg/
kg/4 weeks 
±MTX 
±sDMARD 
±gcs
22 DAS28>3.2 
OR judgement 
rheumatologist
41% (9)
/ 6 months
7/9 (78%) 
within first 
16 weeks
after dose-
escalation 
8/9 achieved 
LDA (clinical 
judgement) 
within 6 
months; 1/9 
LDA after 6 
months
9, 12, 15, 26, 
27
Tapering or stopping DMARDs in patients in low disease activity or remission – a systematic review
115
7
Table 1. Continued
first Author, 
year of 
publication
study design Disease 
duration
Patients Criteria used 
to initiate 
tapering / 
discontinuation
Medication 
tapered/
stopped 
Co-
medication
# patients 
tapered/
stopped
flare definition flare % (n)
/ follow-up
Median / 
mean time 
to flare
Time to 
remission 
after flare
Radiological 
progression
study 
limitations 
(items)#
Kavanaugh, 
2014 (12)
observational 
cohort
median 8 
years
RA, discontinued 
first TNFi, no 
other previous 
bDMARD
CDAI≤10 TNFi, stop ±sDMARDs 
±gcs
717 CDAI>10 OR 
bDMARD 
initiation 
OR sDMARD 
initiation / dose 
escalation OR 
gcs initiaton / 
dose escalation
26.6% (191)
/ 1 year
≥ 20 months 
(median)
- - 8, 9, 15, 19, 26
biological DMARDs: tocilizumab
Nishimoto, 
2013 
(DREAM/
RESTORE) 
(24, 26)
Single-arm 
trial
median 
7.8 years
RA, 1987 ACR;
 ≥20 years old
DAS28≤3.2 at 
2-3 consecutive 
time points
tcz ±NSAIDs ± 
oral gcs
187 DAS28>3.2 at 
2 consecutive 
observations
86.6 % 
(162)
/ 1 year
- 139 of 157 
(88.5%) 
retreated 
with TCZ 
achieved 
DAS28<2.6 
within 12 
weeks
- 12-15, 19
Aguilar, 2013 
(23)
prospective 
cohort
mean 
13.7 years
RA, MTX + tcz 
for 5 years
DAS28<2.6 & 
SJC=0
tcz 8mg/kg/4 
weeks, stop
MTX 45 SJC≥1 55% (25)
/ 1 year
3 months 
(median)
- - 9, 12-15, 26, 
27; partly: 3, 5
Van 
Herwaarden, 
2014 (25)
retrospective 
cohort
median 
10 years
RA, 1987 ACR 
OR 2010 ACR/
EULAR OR 
clinical diagnosis
DAS28<3.2 
OR judgement 
rheumatologist
tcz 8 mg/kg/4 
weeks to 4 mg/
kg/4 weeks 
±MTX 
±sDMARD 
±gcs
22 DAS28>3.2 
OR judgement 
rheumatologist
41% (9)
/ 6 months
7/9 (78%) 
within first 
16 weeks
after dose-
escalation 
8/9 achieved 
LDA (clinical 
judgement) 
within 6 
months; 1/9 
LDA after 6 
months
9, 12, 15, 26, 
27
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Table 1. Continued
first Author, 
year of 
publication
study design Disease 
duration
Patients Criteria used 
to initiate 
tapering / 
discontinuation
Medication 
tapered/
stopped 
Co-
medication
# patients 
tapered/
stopped
flare 
definition
flare % (n)
/ follow-up
Median / 
mean time 
to flare
Time to 
remission 
after flare
Radiological 
progression
study 
limitations 
(items)#
biological DMARDs: abatacept
Emery, 2015 
(AVERT) (27)
single-arm 
trial
≤ 2years 
(symptoms)
clinical synovitis 
≥ 2 joints for ≥ 
8 weeks; ACPA 
positive; MTX 
naïve; ≥ 18 years
DAS28-CRP<3.2 
at month 12
A) aba 125 mg/ 
week + MTX 15-
20 mg/ week
B) aba 125 mg/ 
week
C) MTX 15 – 20 
mg/ week
Aba stopped 
immediately, 
MTX + steroids 
tapered over 1 
month
± gcs A) 84
B) 66
C) 73
DAS28-
CRP≥3.2
A) 75% (55)
B) 72% (36)
C) 83% (44)
/ 6 months
- - - 9, 12, 14, 15, 
17c, 19, 23, 
26, 27; partly: 
5, 8
Westhovens, 
2014 
(AGREE) (28)
RCT ≤ 2years early RA, 
seropositive, 
erosive
DAS28-ESR<2.6 
at 1 year
aba 10 mg / 
kg i.v.
A) 5 mg / kg i.v.
B) 10 mg / kg i.v.
±sDMARDs 
±gcs
A) 50
B) 58
DAS28-
CRP≥3.2 at 
2 visits OR 
additional 
DMARD 
required OR 
aba 10 mg 
required OR 
≥2 courses 
of gcs
A) 34% (17)
B) 31% (18)
/ 1 year
- restart aba 
10 mg / kg: 
3/4 remission 
within 1 year
- 9, 27
Takeuchi, 
2014 (18)
prospective 
cohort with 
control
9.6 years 
(A); 15.3 
years (B)
RA, 1987 ACR; 
age ≥ 20 years; 
aba > 2 years
DAS28-CRP<2.3 aba 10 mg/kg/ 4 
weeks:
A) stop
B) continue
±sDMARDs 
±NSAIDs 
±gcs
A) 34
B) 17
DAS28-
CRP>2.7
A) 41% (14)
B) 6% (1)
/ 1 year
- - ΔmTSS: 
A) 0.80 / year
B) 0.32 / year 
(p=0.37)
9, 12, 14, 15, 
23, 27
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Table 1. Continued
first Author, 
year of 
publication
study design Disease 
duration
Patients Criteria used 
to initiate 
tapering / 
discontinuation
Medication 
tapered/
stopped 
Co-
medication
# patients 
tapered/
stopped
flare 
definition
flare % (n)
/ follow-up
Median / 
mean time 
to flare
Time to 
remission 
after flare
Radiological 
progression
study 
limitations 
(items)#
biological DMARDs: abatacept
Emery, 2015 
(AVERT) (27)
single-arm 
trial
≤ 2years 
(symptoms)
clinical synovitis 
≥ 2 joints for ≥ 
8 weeks; ACPA 
positive; MTX 
naïve; ≥ 18 years
DAS28-CRP<3.2 
at month 12
A) aba 125 mg/ 
week + MTX 15-
20 mg/ week
B) aba 125 mg/ 
week
C) MTX 15 – 20 
mg/ week
Aba stopped 
immediately, 
MTX + steroids 
tapered over 1 
month
± gcs A) 84
B) 66
C) 73
DAS28-
CRP≥3.2
A) 75% (55)
B) 72% (36)
C) 83% (44)
/ 6 months
- - - 9, 12, 14, 15, 
17c, 19, 23, 
26, 27; partly: 
5, 8
Westhovens, 
2014 
(AGREE) (28)
RCT ≤ 2years early RA, 
seropositive, 
erosive
DAS28-ESR<2.6 
at 1 year
aba 10 mg / 
kg i.v.
A) 5 mg / kg i.v.
B) 10 mg / kg i.v.
±sDMARDs 
±gcs
A) 50
B) 58
DAS28-
CRP≥3.2 at 
2 visits OR 
additional 
DMARD 
required OR 
aba 10 mg 
required OR 
≥2 courses 
of gcs
A) 34% (17)
B) 31% (18)
/ 1 year
- restart aba 
10 mg / kg: 
3/4 remission 
within 1 year
- 9, 27
Takeuchi, 
2014 (18)
prospective 
cohort with 
control
9.6 years 
(A); 15.3 
years (B)
RA, 1987 ACR; 
age ≥ 20 years; 
aba > 2 years
DAS28-CRP<2.3 aba 10 mg/kg/ 4 
weeks:
A) stop
B) continue
±sDMARDs 
±NSAIDs 
±gcs
A) 34
B) 17
DAS28-
CRP>2.7
A) 41% (14)
B) 6% (1)
/ 1 year
- - ΔmTSS: 
A) 0.80 / year
B) 0.32 / year 
(p=0.37)
9, 12, 14, 15, 
23, 27
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Table 1. Continued
first Author, 
year of 
publication
study 
design
Disease 
duration
Patients Criteria used to 
initiate tapering / 
discontinuation
Medication 
tapered/
stopped 
Co-
medication
# patients 
tapered/
stopped
flare definition flare % (n)
/ follow-up
Median / 
mean time to 
flare
Time to 
remission 
after flare
Radiological 
progression
study 
limitations 
(items)#
synthetic DMARDs
Fleischmann, 
2005 
(iRAMT) (4)
single-
arm 
trial
mean 10.4 
years
RA,1987 ACR 40% reduction in TJC 
+ SJC
MTX, tapering 5 
mg/8 weeks to 
minimum of 5 
mg/week
ifx ± gcs 159 loss of response 
(response defined 
as 40% reduction 
in TJC + SJC 
compared to 
baseline)
42% (67)
/ 32 weeks
- - - 9, 12, 15, 19; 
partly: 1, 5
Heimans, 
2013 
(IMPROVED) 
(5)
single-
arm 
trial
8 months early RA (ACR 
2010) or 
undifferentiated 
arthritis
DAS44<1.6 for 4 
months
prednisone 7.5 
mg/day, ssz 
2000 mg/day, 
hcq 400 mg/day, 
MTX 25 mg/
week; tapered 
in above 
order to MTX 
monotherapy
MTX 30 DAS44>1.6 63% (19)
/ 4 months
- - - 9, 12, 14, 19, 
27
Luis, 1999 (6) RCT mean 2.8 
years
RA, 1987 ACR; 
functional class 
I or II; disease 
duration < 15 
years
Clinical remission ACR 
criteria ≥ 6 months; 
stable dose weekly MTX 
≥9 months
MTX, weekly -> 
2-weekly
±hcq ± gcs 25 loss of remission 
(clinical criteria)
8% (2)
/ 24 weeks
- - - 2, 12, 14, 19, 
27; partly: 3, 
5, 24
Ten Wolde, 
1996 (7)
RCT median 9 
years
RA, 1987 ACR; 
age 18-85 years
Good therapeutic 
response ARA criteria 
(5/6); stable disease for 
1 year; RX second-line 
drugs for 2 years; no 
previous unsuccessful 
attempt to discontinue 
second line drugs
sDMARDs (chl, 
hcq, pg, dpen, 
ssz, aza, MTX), 
stop
± NSAIDs 143 SJC≥3 and 
≥2 additional 
criteria; 
clear clinical 
recurrence 
of synovitis
Overall: 37% (53)
hcq/chl: 33% (26)
pg: 33% (11)
ssz: 47% (8)
pen: 40% (4)
aza: 67% (2)
MTX 100% (2)
/ 1 year
- 24/51 ( 47%) 
patients 
retreated with 
same cDMARD 
achieved 
ACR20 
response within 
3 months
- 12, 19; partly: 
3
¶ DAS28 increase ≥ 1.2 compared to baseline at two consecutive visits with at least two weeks in between 
or DAS28 increase ≥ 0.6 if DAS28>3.2
† Mode of tapering was not described
‡ Remission duration was not further specified
# Study limitations (also see Supplement 3): reporting: items 1-9; external validity: items 11-13; internal 
validity/bias: items14-20; internal validity/confounding: items 21-26; power: item 27
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Table 1. Continued
first Author, 
year of 
publication
study 
design
Disease 
duration
Patients Criteria used to 
initiate tapering / 
discontinuation
Medication 
tapered/
stopped 
Co-
medication
# patients 
tapered/
stopped
flare definition flare % (n)
/ follow-up
Median / 
mean time to 
flare
Time to 
remission 
after flare
Radiological 
progression
study 
limitations 
(items)#
synthetic DMARDs
Fleischmann, 
2005 
(iRAMT) (4)
single-
arm 
trial
mean 10.4 
years
RA,1987 ACR 40% reduction in TJC 
+ SJC
MTX, tapering 5 
mg/8 weeks to 
minimum of 5 
mg/week
ifx ± gcs 159 loss of response 
(response defined 
as 40% reduction 
in TJC + SJC 
compared to 
baseline)
42% (67)
/ 32 weeks
- - - 9, 12, 15, 19; 
partly: 1, 5
Heimans, 
2013 
(IMPROVED) 
(5)
single-
arm 
trial
8 months early RA (ACR 
2010) or 
undifferentiated 
arthritis
DAS44<1.6 for 4 
months
prednisone 7.5 
mg/day, ssz 
2000 mg/day, 
hcq 400 mg/day, 
MTX 25 mg/
week; tapered 
in above 
order to MTX 
monotherapy
MTX 30 DAS44>1.6 63% (19)
/ 4 months
- - - 9, 12, 14, 19, 
27
Luis, 1999 (6) RCT mean 2.8 
years
RA, 1987 ACR; 
functional class 
I or II; disease 
duration < 15 
years
Clinical remission ACR 
criteria ≥ 6 months; 
stable dose weekly MTX 
≥9 months
MTX, weekly -> 
2-weekly
±hcq ± gcs 25 loss of remission 
(clinical criteria)
8% (2)
/ 24 weeks
- - - 2, 12, 14, 19, 
27; partly: 3, 
5, 24
Ten Wolde, 
1996 (7)
RCT median 9 
years
RA, 1987 ACR; 
age 18-85 years
Good therapeutic 
response ARA criteria 
(5/6); stable disease for 
1 year; RX second-line 
drugs for 2 years; no 
previous unsuccessful 
attempt to discontinue 
second line drugs
sDMARDs (chl, 
hcq, pg, dpen, 
ssz, aza, MTX), 
stop
± NSAIDs 143 SJC≥3 and 
≥2 additional 
criteria; 
clear clinical 
recurrence 
of synovitis
Overall: 37% (53)
hcq/chl: 33% (26)
pg: 33% (11)
ssz: 47% (8)
pen: 40% (4)
aza: 67% (2)
MTX 100% (2)
/ 1 year
- 24/51 ( 47%) 
patients 
retreated with 
same cDMARD 
achieved 
ACR20 
response within 
3 months
- 12, 19; partly: 
3
¶ DAS28 increase ≥ 1.2 compared to baseline at two consecutive visits with at least two weeks in between 
or DAS28 increase ≥ 0.6 if DAS28>3.2
† Mode of tapering was not described
‡ Remission duration was not further specified
# Study limitations (also see Supplement 3): reporting: items 1-9; external validity: items 11-13; internal 
validity/bias: items14-20; internal validity/confounding: items 21-26; power: item 27
Abbreviations
aba = abatacept
ada = adalimumab
aza = azathioprine
bDMARDs = biologic disease modifying antirheumatic 
drugs
CDAI = clinical disease activity index
chl = chloroquine
CRP = C-reactive protein
ctz = certolizumab pegol
DAS = disease activity score
dpen = d-penicillamine
etn= etanercept 
gcs = glucocorticoids
hcq = hydroxychloroquine
ifx = infliximab
mTSS = modified Total Sharp Score
MTX = methotrexate
NSAIDS = non-steroidal anti-inflammatory drug
pbo = placebo
PDUS = power doppler ultrasound
pen = penicillamine
pg = parenteral gold
RA = rheumatoid arthritis
RCT = randomized controlled trial
sDMARDs = synthetic disease modifying 
antirheumatic drugs
SJC = swollen joint count
ssz = sulphasalazine
TJC = tender joint count
TNFi = tumor necrosis factor inhibitor
tcz = tocilizumab
TSS = Total Sharp Score
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synthetic DMARDs
Risk of disease flare
Four studies (two RCTs, two single-arm trials) evaluated the de-escalation of sDMARDs 
(Table 1) (4-7). Reported flare rates after tapering methotrexate (MTX) ranged from 8% at 
24 weeks (flare defined on clinical criteria) (6) to 42% at 32 weeks (loss of 40% reduction 
in swollen and tender joint counts compared to baseline) (4). In patients on triple DMARD 
therapy with prednisone, tapering of subsequent DMARDs (prednisone, sulphasalazine 
and hydroxychloroquine) to MTX monotherapy was evaluated (5). Sixty-three percent of 
patients lost response to therapy (defined as DAS>1.6) after 4 months (5). Ten Wolde et 
al. (7) defined flare as having ≥3 swollen joints while fulfilling ≥2 additional criteria (7) 
and found an overall flare rate of 37% at 1 year (see Table 1 for flare rates specified by 
sDMARD).
Radiographic progression
None of the included studies evaluated radiographic progression for sDMARDs.
Time-to-flare
None of the included studies evaluated time-to-flare for sDMARDs.
Time-to-remission
No data on time-to-remission was available. Ten Wolde found that 47% of patients re-
treated with the same sDMARD achieved ACR20 response within 3 months (7). 
biologic DMARDs: Tnf inhibitors
Risk of disease flare
Fifteen studies (five single-arm trials, two retrospective cohort studies, four prospective 
cohort studies and four RCTs) evaluated the tapering or stopping of TNF-blockers (Table 1) 
(5, 8-21), four of which were in early RA (5, 9, 16, 20). A meta-analysis was performed on 
the 11 studies (10 study arms) de-escalating TNF-blockers reporting a flare rate at 1 year 
(Table 2). Overall heterogeneity was high (I2: 93.1) with respect to patients (early versus 
established RA), de-escalation strategy, type of TNF-blocker, co-medication with sDMARDs. 
Pooled flare rates for the studies with a good (12, 15-17, 19, 20, 22) and moderate (8, 10, 
13, 21) quality scores were 0.28 (95% CI 0.19-0.40) and 0.49 (95% CI 0.27-0.73) respectively 
and the overall flare rate was 0.34 (95% CI 0.25-0.45). Pooling studies on tapering versus 
stopping of TNF-blockers did not lead to different flare rates (Supplemental Table 1).
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Radiographic progression
Three studies evaluated radiological progression by directly comparing groups of pa-
tients continuing and stopping treatment (16, 17) or de-escalating treatment to various 
extents (9). The PRESERVE study compared radiological progression between groups of 
patients continuing full-dose etanercept to patients switching to half-dose or stopping of 
etanercept (17). ΔmTSS was significantly higher in the group stopping etanercept (0.60 
units/year) compared to the group continuing etanercept 50 mg/week (-0.06 units/year, 
p=0.026)). However, no significant difference was found between the group receiving 
etanercept 25 mg/week (0.05 units/year) compared to the full-dose or placebo groups 
(17). In the OPTIMA trial, patients with early RA were randomized to stop or continue 
adalimumab. After 1 year, there was no significant difference in the percentage of non-
progressors (ΔTSS≤0.05) between groups (stop 81%, continue 89%, p=0.06) (16). Emery 
et al. compared three de-escalation strategies in early RA patients treated with MTX and 
etanercept: reducing etanercept to half dose, stopping etanercept and stopping both 
etanercept and MTX (9). After 39 weeks, mean ΔmTSS (±SE) were similar for all groups 
0.1 (0.1), -0.0 (0.2) and 0.4 (0.2) respectively. 
Three studies (19, 20, 22) evaluated radiographic progression by comparing patients 
experiencing a flare to those with sustained LDA/remission after stopping infliximab (20, 
22) or adalimumab (19). The BeSt study reported a median damage progression of 0 
units/year at 1 year in both groups (20), while the RRR study reported similar progression 
for the flare group (1.6 units/year) and the non-flare group (0.3 units/year, p=0.11) at 28 
weeks (22). The HONOR study found that ΔmTSS increased from -0.74 to 0.85 / year in 
patients with a flare. Those with sustained LDA had equal ΔmTSS regardless of whether 
adalimumab was continued (19).
Time-to-flare
Eight studies de-escalating TNF-blockers (8, 11-14, 20-22)reported on the mean or 
median time-to-flare. Reported times-to-flare ranged from 14.7 weeks (mean) (8) to ≥20 
months (median) (gentle tapering scheme) (12). 
Time-to-remission
Three studies stopping TNF-blockers evaluated time-to-remission (8, 19, 22). In the RRR 
study restart of infliximab was effective in 70% of patients, of whom the majority reached 
DAS28<3.2 within 24 weeks (22). Brocq et al. found that all 15 patients regained remis-
sion after restarting the same TNF-blocker, 87% within 2 months (8). In the HONOR study, 
MTX dose-escalation was not effective in 75% of patients experiencing a flare, but after 
re-administration of adalimumab those patients regained LDA, 90% within 6 months (19).
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biologic DMARDs: tocilizumab
Risk of disease flare
Three studies reported on the de-escalation of tocilizumab (23-25). The DREAM study 
reported a flare rate of 87% at 1 year for patients with low disease activity stopping tocili-
zumab and not using any concurrent DMARDs (24). Aguilar et al. found a flare rate of 55% 
one year after stopping tocilizumab in patients in remission with combination therapy of 
tocilizumab and MTX (23). Van Herwaarden et al. reported that after 6 months, 41% of 
patients lost LDA after dose reduction of tocilizumab from 8 mg/kg to 4 mg/kg every 4 
weeks (25).
Radiographic progression
None of the included studies evaluated radiographic progression for tocilizumab.
Time-to-flare
Two studies de-escalating tocilizumab (23, 25) reported on time to flare. After stopping 
tocilizumab, 50% of flares occurred within 3 months (23), while in another study 78% of 
flares occurred within the first 4 months after dose reduction of tocilizumab (25).
Time-to-remission
In the DREAM/RESTORE study (88%), achieved DAS28 remission within 12 weeks after re-
starting tocilizumab (24, 26). In the dose reduction study by van Herwaarden, all patients 
who experienced a flare achieved LDA after dose escalation, 89% within 6 months (25).
biologic DMARDs: abatacept
Risk of disease flare
De-escalation of abatacept was evaluated in 3 studies (18, 27, 28). In the AVERT study 
early initially active RA patients with LDA at one year entered the treatment withdrawal 
period in which all treatment was stopped. After 6 months, flare rates were 75% and 
72% in the abatacept + MTX and abatacept monotherapy arms respectively (27). Dose 
reduction of abatacept to half dose in early RA patients was evaluated in the AGREE study 
(28). At 1 year 34% (half dose) and 31% (full dose) of patients experienced a flare (28). In 
a cohort of patients with established RA, Takeuchi et al. compared stopping and continu-
ing abatacept (18). Flare rates at 1 year were 41% (stop) versus 6% (continuation) (18).
Radiographic progression
Only one study presented radiological data. Takeuchi et al. found no difference in ra-
diographic progression after 1 year between the groups stopping (ΔmTSS = 0.80) and 
continuing (ΔmTSS = 0.32) abatacept (p=0.37) (18).
Tapering or stopping DMARDs in patients in low disease activity or remission – a systematic review
125
7
Time-to-flare
None of the included studies evaluated time-to-flare for abatacept.
Time-to-remission
Increasing abatacept from half dose to full dose after flare resulted in 75% of patients 
regaining remission within 1 year (28).
DIsCUssIOn
Despite a large heterogeneity in primary studies, tapering down or stopping synthetic or 
biologic DMARD therapy without experiencing an immediate flare of disease is possible 
in more than one third of patients with low disease activity or remission. De-escalation of 
TNF-blockers suggest even better results with flare rates at 1 year of 0.26 (95% CI 0.17-
0.39) for good quality studies and 0.49 (95% CI 0.27-0.73) for moderate quality studies in 
the pooled analysis. Furthermore, evidence from two well executed RCTs suggests that 
reducing TNF-inhibitors to half dose results in a lower risk of flare (≈20%) compared to 
stopping (≈50%) (9, 17) and is possibly non-inferior to full dose continuation (17). Precau-
tion should be taken in the decision to taper medication as evidence on radiographic 
progression is limited. Only 5 studies presented radiographic data comparing patients 
continuing and stopping bDMARDs, of which the PRESERVE study found a significantly 
higher rate of radiographic progression in the stop group versus the continuation group 
(17). In three other studies (9, 16, 18), a trend for slightly more progression was found for 
the discontinuation versus the continuation arms, but differences were not significant. 
However, it should be emphasized that included studies were not powered to detect 
differences in radiographic progression.
Time needed to regain remission after the occurrence of a flare was evaluated in six 
studies stopping bDMARDs (8, 19, 22, 24, 25, 28). The majority of patients regained a 
state of low disease activity within 2-6 months after reinitiating therapy with the same 
bDMARD. No data were available for sDMARDs. Whether de-escalation of TNF-blockers 
leads to increased immunogenicity and formation anti-drug antibodies remains unclear 
and should be subject of further study, as the formation of such antibodies could lead to 
treatment inefficacy on re-introducing the TNF-blocker after a flare (29).
Two RCTs found a lower risk of flare for dose reduction versus complete stop of etan-
ercept (9, 17) This was less clear when we pooled the flare rates among study arms 
tapering versus immediately stopping TNF-blockers. Pooling resulted in a small but 
insignificant difference (flare rate of 0.31 versus 0.38 respectively), but a difference may 
well have been missed because of heterogeneity among studies. Among included studies 
in early RA patients, flare rates for bDMARDs (9, 16, 20, 27, 28) are not consistently lower 
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compared to those in studies in patients with established RA. A discussion on risk factors 
for flare that were addressed in the primary studies is provided in Supplement 4.
Time to flare was assessed in studies de-escalating bDMARDs only and ranged widely 
(mean 14.7 weeks – median ≥20 months) across studies (8, 11-14, 20-23, 25). No relation 
could be observed between use of concomitant DMARDs or de-escalation strategy and 
time to flare.
A risk of bias assessment was performed (3) (see Supplement 3) to assess the internal 
validity of the primary studies and to see whether this would influence the observed flare 
rate. In the meta-analysis of TNF de-escalation, good quality studies showed lower flare 
rates compared to moderate quality studies. No single quality assessment item discrimi-
nated well between good and moderate quality studies, except for sample size, which 
was consistently larger in good quality studies. Higher study quality was observed in the 
more recent studies as they were more often randomized controlled trials compared to 
earlier cohort studies that were using existing data not necessarily collected with the aim 
to evaluate de-escalation strategies.
Three systematic (30-32) and two narrative (33, 34) reviews have previously been 
published on the de-escalation of both bDMARDs (30, 32, 34) and sDMARDs (31, 33). 
While overlap exists between our review and those previously published, we are the first 
systematic review with quality assessment addressing both sDMARDs and bDMARDs, 
performing a pooled analysis on TNF-inhibitors. Regarding sDMARDs the authors were 
reluctant to say that part of the patients could de-escalate treatment given the higher 
flare rates compared to treatment continuation (31, 33). Considering bDMARDs, in line 
with our findings, Yoshida (32) reported that studies showed large heterogeneity, Tanaka 
(34) and Navarro-Millan (30) concluded that discontinuation is possible in RA patients.
This review has several strengths and weaknesses. We synthesized all available data 
to be able to answer clinically relevant questions regarding de-escalation of DMARDs, 
despite the underlying heterogeneity in the primary studies. For de-escalation of TNF-
blockers data was meta-analyzed, resulting in a different flare rate between good and 
moderate quality studies. This should be interpreted with caution due to underlying 
differences in study designs. Relevant publications could have been missed, although we 
performed an extensive systematic search in various database without the use of lan-
guage restrictions. Regarding radiographic progression, a major limitation of the primary 
studies is that they were not powered to detect differences in progression rates among 
groups. To address this, data from adequately powered cohort studies and RCTs, using 
uniform definitions for initiation of de-escalation and flare, is needed.
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COnClUsIOn
Despite a large heterogeneity between studies, our overall results suggest that more 
than one third of patients with low disease activity or remission may taper or stop 
DMARD treatment without experiencing a flare within the first year. Limited radiological 
data suggests progression after treatment de-escalation remains low, but data is needed 
from adequately powered cohorts or RCTs.
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supplement 1. Search strategies.
Embase (including Medline)
(‘rheumatoid arthritis’/de OR ((rheuma* NEXT/1 arthrit*) OR (RA AND (rheuma* OR arthrit*))):ab,ti) AND (‘disease 
modifying antirheumatic drug’/exp OR (DMARD* OR (disease NEAR/3 modif*) OR methotrexat* OR metotrex* OR 
mexate OR amethopterin* OR ametopterin* OR emthexat* OR emtrexat* OR ledertrexat* OR MTX OR novatrex OR 
rheumatrex OR leflunomide OR Arava OR arabloc OR salazosulfapyridin* OR salicylazosulfapyridin* OR sulfasalazin* OR 
Azulfidin* OR Sulfazin* OR Salazopyrin* OR sulphasalazin* OR sulphazin* OR chloroquin* OR aralen* OR arthrochin* 
OR nivaquin* OR hydroxychloroquin* OR hydroxychlorochin* OR HCQ OR plaquenil* OR ercoquin* OR chlorochin* 
OR quinolin* OR quensyl* OR penicillamin* OR dimethylcystein* OR cuprimin* OR depen* OR gold* OR monogold* 
OR aurothiomalat* OR myochrysin* OR tauredon* OR organogold* OR azathioprin* OR azothioprin* OR imuran* OR 
immuran* OR cyclosporin* OR Neoral* OR Gengraf* OR Sandimmun* OR CyA OR etanercept* OR Enbrel* OR ((TNF* 
OR factor*) NEAR/3 (block* OR antagon* OR anti* OR inhibit* OR ‘fusion protein’)) OR TNFis* OR adalimumab* OR 
Humira* OR Trudexa* OR certolizumab* OR Cimzia* OR CDP870 OR ‘CDP 870’ OR golimumab* OR Simponi OR inflix-
imab* OR ((Mab OR monoclonal) NEAR/3 cA2) OR Remicade OR Avakine OR Revellex OR abatacept* OR Orencia* OR 
‘BMS 188667’ OR BMS188667 OR CTLA4 OR ‘CTLA 4’ OR belatacept* OR BMS224818 OR ‘BMS 224818’ OR Nulojix* 
OR ((‘interleukin 1’ OR interleukin1 OR ‘il 1’ OR Il1 OR ‘interleukin 6’ OR interleukin6 OR ‘il 6’ OR Il6) NEAR/3 (block* OR 
antagon* OR anti* OR inhibit*)) OR Antril* OR Kineret* OR Anakinra* OR rituximab* OR Mabthera OR Rituxan OR Redi-
tux* OR CD20 OR ‘CD 20’ OR tocilizumab* OR Actemra* OR Roactemra* OR Atlizumab* OR biological* OR Tetracyclin* 
OR Minocyclin* OR Azithromycin* OR Doxycyclin* OR cyclophosphamid* OR Cytoxan* OR Endoxan* OR tacrolimus* 
OR Prograf):ab,ti,de) AND (‘drug dose reduction’/de OR ‘drug dose titration’/de OR ‘treatment withdrawal’/de OR 
((dos* OR treatm* OR therap* OR medic*) NEAR/5 (reduc* OR adjust* OR withdraw* OR withhold* OR withheld* OR 
stop* OR taper* OR titrat* OR discontin* OR cessat* OR lower* OR retract* OR ceas* OR diminish* OR deescal* OR 
‘de escalation’ OR ‘de escalations’ OR ‘de escalating’ OR ‘de escalate’ OR ‘de escalated’)):ab,ti)
OVID-SP (Medline)
(“Arthritis, Rheumatoid”/ OR ((rheuma* ADJ arthrit*) OR (RA AND (rheuma* OR arthrit*))).ab,ti.) AND ((DMARD* OR 
(disease ADJ3 modif*) OR methotrexat* OR metotrex* OR mexate OR amethopterin* OR ametopterin* OR emthexat* 
OR emtrexat* OR ledertrexat* OR MTX OR novatrex OR rheumatrex OR leflunomide OR Arava OR arabloc OR salazosul-
fapyridin* OR salicylazosulfapyridin* OR sulfasalazin* OR Azulfidin* OR Sulfazin* OR Salazopyrin* OR sulphasalazin* 
OR sulphazin* OR chloroquin* OR aralen* OR arthrochin* OR nivaquin* OR hydroxychloroquin* OR hydroxychloro-
chin* OR HCQ OR plaquenil* OR ercoquin* OR chlorochin* OR quinolin* OR quensyl* OR penicillamin* OR dimethyl-
cystein* OR cuprimin* OR depen* OR gold* OR aurothiomalat* OR myochrysin* OR tauredon* OR organogold* OR 
azathioprin* OR azothioprin* OR imuran* OR immuran* OR cyclosporin* OR Neoral* OR Gengraf* OR Sandimmun* 
OR CyA OR etanercept* OR Enbrel* OR “TNFR-Fc fusion protein” OR ((TNF* OR factor*) ADJ3 (block* OR antagon* OR 
anti* OR inhibit*)) OR TNFis* OR adalimumab* OR Humira* OR Trudexa* OR certolizumab* OR Cimzia* OR CDP870 OR 
“CDP 870” OR golimumab* OR Simponi OR infliximab* OR ((Mab OR monoclonal) ADJ3 cA2) OR Remicade OR Avakine 
OR Revellex OR abatacept* OR Orencia* OR “BMS 188667” OR BMS188667 OR CTLA4 OR “CTLA 4” OR belatacept* OR 
BMS224818 OR “BMS 224818” OR Nulojix* OR ((“interleukin 1” OR interleukin1 OR “il 1” OR Il1 OR “interleukin 6” OR 
interleukin6 OR “il 6” OR Il6) ADJ3 (block* OR antagon* OR anti* OR inhibit*)) OR Antril* OR Kineret* OR Anakinra* 
OR rituximab* OR Mabthera OR Rituxan OR Reditux* OR CD20 OR “CD 20” OR tocilizumab* OR Actemra* OR Ro-
actemra* OR Atlizumab* OR biological* OR Tetracyclin* OR Minocyclin* OR Azithromycin* OR Doxycyclin* OR cyclo-
phosphamid* OR Cytoxan* OR Endoxan* OR tacrolimus* OR Prograf).mp.) AND (“Dose response relationship, Drug”/ 
OR “Withholding Treatment”/ OR ((dos* OR treatm* OR therap* OR medic*) ADJ5 (reduc* OR adjust* OR withdraw* 
OR withhold* OR withheld* OR stop* OR taper* OR titrat* OR discontin* OR cessat* OR lower* OR retract* OR ceas* 
OR diminish* OR (de ADJ escalat*))).ab,ti.)
Cochrane Central
(((rheuma* NEXT/1 arthrit*) OR (RA AND (rheuma* OR arthrit*))):ab,ti) AND ((DMARD* OR (disease NEAR/3 modif*) 
OR methotrexat* OR metotrex* OR mexate OR amethopterin* OR ametopterin* OR emthexat* OR emtrexat* OR 
ledertrexat* OR MTX OR novatrex OR rheumatrex OR leflunomide OR Arava OR arabloc OR salazosulfapyridin* OR 
salicylazosulfapyridin* OR sulfasalazin* OR Azulfidin* OR Sulfazin* OR Salazopyrin* OR sulphasalazin* OR sulphazin* 
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OR chloroquin* OR aralen* OR arthrochin* OR nivaquin* OR hydroxychloroquin* OR hydroxychlorochin* OR HCQ OR 
plaquenil* OR ercoquin* OR chlorochin* OR quinolin* OR quensyl* OR penicillamin* OR dimethylcystein* OR cupri-
min* OR depen* OR gold* OR monogold* OR aurothiomalat* OR myochrysin* OR tauredon* OR organogold* OR aza-
thioprin* OR azothioprin* OR imuran* OR immuran* OR cyclosporin* OR Neoral* OR Gengraf* OR Sandimmun* OR 
CyA OR etanercept* OR Enbrel* OR ((TNF* OR factor*) NEAR/3 (block* OR antagon* OR anti* OR inhibit* OR “fusion 
protein”)) OR TNFis* OR adalimumab* OR Humira* OR Trudexa* OR certolizumab* OR Cimzia* OR CDP870 OR “CDP 
870” OR golimumab* OR Simponi OR infliximab* OR ((Mab OR monoclonal) NEAR/3 cA2) OR Remicade OR Avakine 
OR Revellex OR abatacept* OR Orencia* OR “BMS 188667” OR BMS188667 OR CTLA4 OR “CTLA 4” OR belatacept* OR 
BMS224818 OR “BMS 224818” OR Nulojix* OR ((“interleukin 1” OR interleukin1 OR “il 1” OR Il1 OR “interleukin 6” OR 
interleukin6 OR “il 6” OR Il6) NEAR/3 (block* OR antagon* OR anti* OR inhibit*)) OR Antril* OR Kineret* OR Anakinra* 
OR rituximab* OR Mabthera OR Rituxan OR Reditux* OR CD20 OR “CD 20” OR tocilizumab* OR Actemra* OR Roactem-
ra* OR Atlizumab* OR biological* OR Tetracyclin* OR Minocyclin* OR Azithromycin* OR Doxycyclin* OR cyclophospha-
mid* OR Cytoxan* OR Endoxan* OR tacrolimus* OR Prograf):ab,ti,kw) AND (((dos* OR treatm* OR therap* OR medic*) 
NEAR/5 (reduc* OR adjust* OR withdraw* OR withhold* OR withheld* OR stop* OR taper* OR titrat* OR discontin* 
OR cessat* OR lower* OR retract* OR ceas* OR diminish* OR deescal* OR “de escalation” OR “de escalations” OR “de 
escalating” OR “de escalate” OR “de escalated”)):ab,ti)
PubMed
(((rheuma*[tiab] AND arthrit*[tiab]) OR (RA[tiab] AND (rheuma*[tiab] OR arthrit*[tiab])))) AND ((DMARD*[tiab] OR 
(disease[tiab] AND modif*[tiab]) OR methotrexat*[tiab] OR metotrex*[tiab] OR mexate OR amethopterin*[tiab] OR 
ametopterin*[tiab] OR emthexat*[tiab] OR emtrexat*[tiab] OR ledertrexat*[tiab] OR MTX[tiab] OR novatrex[tiab] 
OR rheumatrex[tiab] OR leflunomide[tiab] OR Arava[tiab] OR arabloc[tiab] OR salazosulfapyridin*[tiab] OR 
salicylazosulfapyridin*[tiab] OR sulfasalazin*[tiab] OR Azulfidin*[tiab] OR Sulfazin*[tiab] OR Salazopyrin*[tiab] OR 
sulphasalazin*[tiab] OR sulphazin*[tiab] OR chloroquin*[tiab] OR aralen*[tiab] OR arthrochin*[tiab] OR nivaquin*[tiab] 
OR hydroxychloroquin*[tiab] OR hydroxychlorochin*[tiab] OR HCQ OR plaquenil*[tiab] OR ercoquin*[tiab] OR 
chlorochin*[tiab] OR quinolin*[tiab] OR quensyl*[tiab] OR penicillamin*[tiab] OR dimethylcystein*[tiab] OR 
cuprimin*[tiab] OR depen*[tiab] OR gold[tiab] OR aurothiomalat*[tiab] OR myochrysin*[tiab] OR tauredon*[tiab] 
OR organogold*[tiab] OR azathioprin*[tiab] OR azothioprin*[tiab] OR imuran*[tiab] OR immuran*[tiab] OR 
cyclosporin*[tiab] OR Neoral*[tiab] OR Gengraf*[tiab] OR Sandimmun*[tiab] OR CyA OR etanercept*[tiab] OR 
Enbrel*[tiab] OR TNFR-Fc fusion protein[tiab] OR ((TNF*[tiab] OR factor*[tiab]) AND (block*[tiab] OR antagon*[tiab] 
OR anti*[tiab] OR inhibit*[tiab])) OR TNFis*[tiab] OR adalimumab*[tiab] OR Humira*[tiab] OR Trudexa*[tiab] 
OR certolizumab*[tiab] OR Cimzia*[tiab] OR CDP870 OR CDP 870 OR golimumab*[tiab] OR Simponi[tiab] OR 
infliximab*[tiab] OR ((Mab[tiab] OR monoclonal[tiab]) AND cA2[tiab]) OR Remicade[tiab] OR Avakine[tiab] OR 
Revellex[tiab] OR abatacept*[tiab] OR Orencia*[tiab] OR BMS 188667[tiab] OR BMS188667[tiab] OR CTLA4[tiab] 
OR CTLA 4[tiab] OR belatacept*[tiab] OR BMS224818[tiab] OR BMS 224818[tiab] OR Nulojix*[tiab] OR ((interleu-
kin 1[tiab] OR interleukin1[tiab] OR il 1[tiab] OR Il1[tiab] OR interleukin 6[tiab] OR interleukin6[tiab] OR il 6[tiab] OR 
Il6[tiab]) AND (block*[tiab] OR antagon*[tiab] OR anti*[tiab] OR inhibit*[tiab])) OR Antril*[tiab] OR Kineret*[tiab] 
OR Anakinra*[tiab] OR rituximab*[tiab] OR Mabthera[tiab] OR Rituxan[tiab] OR Reditux*[tiab] OR CD20[tiab] OR CD 
20[tiab] OR tocilizumab*[tiab] OR Actemra*[tiab] OR Roactemra*[tiab] OR Atlizumab*[tiab] OR biological*[tiab] OR 
Tetracyclin*[tiab] OR Minocyclin*[tiab] OR Azithromycin*[tiab] OR Doxycyclin*[tiab] OR cyclophosphamid*[tiab] OR 
Cytoxan*[tiab] OR Endoxan*[tiab] OR tacrolimus*[tiab] OR Prograf)) AND (((dos*[tiab] OR treatm*[tiab] OR therap*[tiab] 
OR medic*[tiab]) AND (reduc*[tiab] OR adjust*[tiab] OR withdraw*[tiab] OR withhold*[tiab] OR withheld*[tiab] OR 
stop*[tiab] OR taper*[tiab] OR titrat*[tiab] OR discontin*[tiab] OR cessat*[tiab] OR lower*[tiab] OR retract*[tiab] OR 
ceas*[tiab] OR diminish*[tiab] OR (de escalat*[tiab])))) AND (publisher[sb] OR 2012/11/20:3000[mhda])
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supplement 2. Modification to Downs and Black’s list (3) used for quality assessment.
1) Is the hypothesis/aim/objective of the study clearly described?
 yes/no/partly/unclear
2)  Are the main outcomes to be measured clearly described in the introduction or methods section?
 yes/no/partly/unclear
3) Are the characteristics of the patients included in the study clearly described?
 yes/no/partly/unclear
4) Are the interventions of interest clearly described?
 yes/no/partly/unclear
5) Are the distributions of principal confounders in each group of subjects clearly described?
 yes/no/partly/unclear
6) Are the main findings of the study clearly described?
 yes/no/partly/unclear
7) [Omitted, not relevant for outcome flare rate]
8) Have all important adverse events that may be a consequence of the intervention been reported?
 yes/no/partly/unclear/NA
9) Have the characteristics of patients lost to follow-up been reported?
 yes/no/partly/unclear
10) [Omitted, not relevant for outcome flare rate]
11)  Were the studies asked to participate in the study representative of the entire population from 
which they were recruited?
 yes/no/partly/unclear
12)  Were those subjects who were prepared to participate representative of the entire population from 
which they were recruited?
 yes/no/partly/unclear
13)  Were the staff, places and facilities where patients were treated, representative of the treatment 
the majority of patients receive?
 yes/no/partly/unclear
14) Was an attempt made to blind study subjects to the intervention they received?
 yes/no/partly/unclear/NA
15) Was an attempt made to blind those measuring the main outcomes of the intervention?
 yes/no/partly/unclear
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16) [Omitted, not relevant for de-escalation studies]
17) a)  In trials and cohort studies, doe the analyses adjust for different lengths of follow-up of pa-
tients, (…)?
 yes/no/partly/unclear/NA
 b) Was the follow-up time with respect to flares adequate?
  yes/no/partly/unclear
 c) Was the follow-up time with respect to radiological progression adequate?
  yes/no/partly/unclear/NA
18) Were the statistical tests used to assess the main outcomes appropriate?
 yes/no/partly/unclear
19) Was compliance with the intervention reliable?
 yes/no/partly/unclear
20) Were the main outcome measures used accurate (valid and reliable?)
 yes/no/partly/unclear
21) Were the patients in different intervention groups (…) recruited from the same population?
 yes/no/partly/unclear/NA
22)  Were the study subjects in different intervention groups (…) recruited over the same period of 
time?
 yes/no/partly/unclear/NA
23) Were the study subjects randomized to intervention groups?
 yes/no/partly/unclear/NA
24)  Was the randomized intervention assignment concealed from both patients and health care staff 
until recruitment was complete and irrevocable?
 yes/no/partly/unclear/NA
25) [Omitted, not relevant for de-escalation studies]
26) Were losses of patients to follow-up taken into account?
 yes/no/partly/unclear
27)  Was the study sample size ≥ 100, so that a flare rate of 0.5 could be estimated with such precision 
that the size of the 95% confidence interval is less than 0.2?
 yes/no/partly/unclear
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supplement 3. Quality Assessment.
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sDMARDs 
 
(6) (4) (5) (7) 
Luis Fleischmann Heimans ten Wolde 
1999 2005 2013 1996 
Flare rate 8% 42% 35% 37% 
Study design RCT single-arm single-arm RCT 
DMARD conventional conventional conventional/ TNF-blocker conventional 
1 yes Partially yes yes 
2 no Yes yes yes 
3 partially Yes yes partially 
4 yes Yes yes yes 
5 partly Partially yes yes 
6 yes Yes yes yes 
7 xxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxx 
8 yes Yes NA yes 
9 yes Unclear no yes 
10 xxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxx 
11 yes Yes yes yes 
12 unclear unclear unclear unclear 
13 yes Yes yes yes 
14 no NA no yes 
15 yes Unclear yes yes 
16 xxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxx 
17a yes NA yes yes 
17b yes Yes yes yes 
17c NA NA yes NA 
18 yes Yes yes yes 
19 unclear Unclear unclear unclear 
20 yes Yes yes yes 
21 yes NA yes yes 
22 yes NA yes yes 
23 yes NA yes yes 
24 partly NA yes Yes 
25 xxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxx Xxxxxxxxxxxx 
26 yes Yes yes Yes 
27 no yes no Yes 
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Item Legend 
 
Item  Description 
1 Is the hypothesis/aim/objective of the study clearly described? 
2 Are the main outcomes to be measured clearly described in the introduction or methods section? 
3 Are the characteristics of the patients included in the study clearly described? 
4 Are the interventions of interest clearly described? 
5 Are the distributions of principal confounders in each group of subjects clearly described? 
6 Are the main findings of the study clearly described? 
7 Does the study provide estimates of the random variability in the data for the main outcomes? 
8 Have all important adverse events that may be a consequence of the intervention been reported? 
9 Have the characteristics of patients lost to follow-up been reported 
10 Have actual probability values been reported (e.g. 0.035 rather than <0.05) for the main outcomes except where the probability value is less than 0.001 
11 Were the subjects asked to participate in the study representative of the entire population from which they were recruited? 
12 Were those subjects who were prepared to participate representative of the entire population from which they were recruited? 
13 Were the staff, places, and facilities where the patients were treated, representative of the treatment the majority of patients receive? 
14 Was an attempt made to blind study subjects to the intervention they received? 
15 Was an attempt made to blind those measuring the main outcomes of the intervention 
16 If any of the results of the study were based on data dredging, was this made clear? 
17a In trials and cohort studies, do the analyses adjust for different lengths of follow-up of patients, (…)? 
17b Was the follow-up time with respect to flares adequate? 
17c Was the follow-up time with respect to radiological progression adequate? 
18 Were the statistical tests used to assess the main outcomes appropriate? 
19 Was compliance with the intervention reliable? 
20 Were the main outcome measures used accurate (valid and reliable)? 
21 Were the patients in different intervention groups (…) recruited from the same population 
22 Were the study subjects in different intervention groups (…) recruited over the same period of time? 
23 Were the study subjects randomized to intervention groups? 
24 Was the randomized intervention assignment concealed from both patients and health care staff until recruitment was complete and irrevocable? 
25 Was there adequate adjustment for confounding in the analyses from which the main findings were drawn? 
26 Were losses of patients to follow-up taken into account? 
27 Did the study have sufficient power to detect a clinically important effect where the probability value for a difference being due to chance is less than 5%? (n≥100 order to obtain CI smaller than 0.2) 
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supplement 4. Risk factors for flare addressed in primary studies.
Several studies looked at risk factors for flare. Six studies evaluated the effect of using concomitant sD-
MARDs on flare risk after stopping the TNF-blocker, but found no significant association (8, 11, 12, 14, 21, 
25). Of three studies (8, 11, 12) one found a lower risk of disease flare for a longer duration of remission 
(8). Of 12 studies evaluating the effect of disease duration (7, 8, 11, 12, 18-22, 24, 25, 27), 4 found a sig-
nificant association between a longer disease duration and an increased risk of flare (19, 20, 22, 27) and 
8 found no association (7, 8, 11, 12, 18, 21, 24, 25). Eleven studies assessed the effect of disease activity 
score on flare rate (8, 11, 12, 18-22, 24, 25, 27), five of which found a significant association for a higher 
disease activity score at moment of de-escalation (12, 18, 19, 24, 27). Other factors that could influence 
flare rates that were not addressed in the primary studies are taper or stop criterion (e.g. remission or 
LDA), follow-up time and monitoring frequency of disease activity.
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supplemental Table 1. Reported flare rates among studies de-escalating TNF-blockers. Pooled estimates 
were calculated for studies discontinuing and tapering TNF-blockers.
study (arm), year Medication Charac-
teristics
follow-up n flare rate 
(95% CI)
Stop
Smolen (stop), 2013 (17) etn s, a 1 year 200 0.57 (0.50-0.64)
Tanaka, 2010 (22) ifx s, a 1 year 114 0.45 (0.36-0.54)
van den Broek, 2011 (20) ifx s, a, e 1 year 104 0.20 (0.13-0.29)
Maneiro, 2013 (13) ada, ctz, etn, ifx s, p 1 year 52 0.19 (0.11-0.32)
Brocq, 2009 (6) ifx, etn, ada s, a 1 year 21 0.75 (0.53-0.89)
Harigai, 2012 (10) ada s, a 1 year 22 0.55 (0.34-0.74)
Smolen, 2014 (17) ada s, a, e 1 year 102 0.19 (0.12-0.27)
Kavanaugh, 2014 (12) TNFi s, p 1 year 717 0.27 (0.24-0.30)
Tanaka, 2015 (19) ada s, a 24 weeks 52 0.40 (0.28-0.54)
Iwamoto, 2014 (11) TNFi s, p 6 months 32 32 0.38 (0.23-0.55)
Emery (etn stop), 2014 (9) etn s, a, e 39 weeks 65 0.46 (0.35-0.58)
Emery (etn + MTX stop), 2014 (9) etn s, a, e 39 weeks 65 0.62 (0.49-0.73)
Pooled estimate 1546 0.38 (0.29-0.48)
Tapering
Smolen (half dose), 2013 (17) etn r1, a 1 year 202 0.19 (0.14-0.25)
Maneiro, 2013 (35) ada, ctz, etn, ifx s, p 1 year 52 0.19 (0.11-0.32)
van der Maas, 2012 (21) ifx r2, p 1 year 51 0.55 (0.41-0.68)
Heimans, 2013 (5) ada r3, a 4 months 26 0.35 (0.19-0.55)
Raffeiner, 2014 (15) etn r4,p 1 year 159 0.11 (0.07-0.17)
Emery (etn half dose), 2014 (9) etn r1, a, e 39 weeks 63 0.21 (0.12-0.32)
Marks, 2015 (14) TNFi r5, p 9 months 69 0.62 (0.50-0.73)
Pooled estimate 570 0.31 (0.16-0.51)
a = co-medication with sDMARDs in all patients 
e = early RA 
p = co-medication with sDMARDs in selected patients 
r1 = dose reduction: etn 50 mg/week, dose reduced to etn 25 
mg/week
r2 = dose reduction: ifx 3 mg/kg, tapered down 0.75 mg/kg every 
8-12 weeks
r3 = dose reduction: ada 40 mg/2 weeks, tapered down to MTX 
monotherapy
r4 = dose reduction: etn 2x 25mg/week, dose reduced to etn 
25mg/week
r5 = dose reduction with 1/3 (by increasing interval *1.5)
s = stop
ada = adalimumab
ctz = certolizumab pegol
etn = etanercept
ifx = infliximab
MTX = methotrexate
sDMARDs = synthetic disease modifying 
anti-rheumatic drugs
TNFi = tumor necrosis factor inhibitor
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AbsTRACT
background
Current guidelines suggest reduction of DMARDs can be considered in RA patients in re-
mission. Objectives were 1) to estimate the relative importance of patient characteristics 
rheumatologists consider in their decision to de-escalate 2) to assess whether heteroge-
neity exists among rheumatologists with respect to de-escalation and 3) to identify the 
preferred de-escalation strategy.
Methods
A discrete choice experiment (DCE) was conducted. All rheumatologists and trainees in 
The Netherlands were invited to participate. A conditional logit model was estimated 
to assess overall preference for de-escalation and its determinants. Heterogeneity was 
estimated by latent class analysis.
Results
The DCE questionnaire was completed by 156 doctors. This questionnaire was con-
structed using the results of semi-structured interviews with 12 rheumatologists that 
identified 5 patient characteristics relevant for de-escalation: Number of swollen joints 
(SJC), presence of DAS remission/low disease activity (LDA), patient history, duration of 
remission/LDA and patient willingness to de-escalate DMARDs. Overall SJC and patient 
history were most important. Latent class analysis revealed 5 subgroups of doctors, 
showing differences regarding willingness to de-escalate and relative importance of 
patient characteristics. De-escalation of the TNF-inhibitor rather than methotrexate first 
was the most preferred strategy.
Conclusion
Rheumatologists are not uniform in their decision in whom to de-escalate. Differences 
emerged in which characteristics they traded off resulting in 5 subgroups: Those that 
taper 1) always, 2) in absence of swollen joints, 3) in absence of swollen joints and pres-
ence of favorable patient history, 4) in DAS remission and favorable patient history and 5) 
taking into account all factors.
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bACKGROUnD
Treatment of rheumatoid arthritis (RA) has advanced greatly during the past decades. 
The introduction of combination therapy with disease modifying anti-rheumatic drugs 
(DMARDs), the recognition of early, tight controlled treatment and the introduction of 
biologic agents have contributed to improved outcomes for patients suffering from RA 
(1). With intensive use of (a combination of) DMARDs, a state of low disease activity 
(LDA) or remission can be achieved by many patients while preventing erosions and 
functional impairment (2, 3). Although DMARD therapy is essential to obtain disease 
control, continuous use comes with several disadvantages. Apart from obvious draw-
backs such as drug toxicity and side effects, medication use by itself may be perceived 
as burdensome and unhealthy by patients. Hence many patients view medication use as 
a necessary burden and wish to minimize its use. Also medication costs, especially for 
expensive biological treatments, are of increasing concern for governments. From this 
viewpoint tapering or discontinuation of DMARDs is preferable once disease control has 
been obtained.
Current guidelines suggest that reduction of biological DMARDs can be considered, 
especially if this treatment is combined with a conventional synthetic (cs)DMARD, once 
sustained remission has been achieved and glucocorticoids have been tapered first (4, 5). 
In addition, guidelines state that a cautious reduction of csDMARDs could be considered, 
as a shared decision between patient and physician, after glucocorticoids and bDMARDs 
have been succesfully withdrawn (5). Furthermore, a general recommendation is in-
cluded that, apart from disease activity, other factors should be taken into account such 
as progression of structural damage, comorbidities and safety issues (5).
Indeed, evidence from a range of clinical studies suggests that de-escalation of DMARDs 
is feasible in a large number of patients in LDA or disease remission. (6-8) However, to 
date there is no standardized way to determine the patient for whom de-escalation of 
DMARD therapy is appropriate. (8) Also, adherence of rheumatologists to the guidelines 
that are currently available for de-escalation may not be optimal. (9) Therefore large dif-
ferences are expected to exist between rheumatologists with respect to whether, when, 
and in which patients they will de-escalate therapy. Obtaining insight in these differences 
may assist in future guideline development and guide further research into this topic. 
In the assessment whether a patient is suitable candidate for treatment de-escalation, 
rheumatologists weigh several patient characteristics together at the same time. Hence 
a simple questionnaire in which the importance of patient characteristics are rated 
separately does not reflect a real-life decision. A discrete choice experiment (DCE) is a 
method that allows for the analysis of such complex decisions. It does so by presenting a 
series of “choice tasks” to the participant. Each choice task consists of two hypothetical 
patients with varying characteristics. The participant must then choose the patient with 
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the most favorable combination of characteristics. By analyzing the choices participants 
made based on the characteristics, the relative importance of patient characteristics on 
the decision to de-escalate treatment can be assessed. A technique very similar to that 
of a discrete choice experiment was used in the process of the development of the ACR/
EULAR 2010 criteria for RA (10).
Objectives of this study were (1) to estimate the relative importance of patient 
characteristics rheumatologists consider in their decision to de-escalate medication, (2) 
to quantify how these characteristics influence doctor’s preferences for de-escalating 
DMARDs, (3) to assess whether heterogeneity exists among rheumatologists with re-
spect to their preference for de-escalation and the patient characteristics influencing this 
decision and (4) to identify the most preferred de-escalation strategy.
MATeRIAls AnD MeTHODs
DCe
In a DCE it is assumed that the analyzing process leading to a decision to medically inter-
vene, such as de-escalation of medication, can be described by features relevant for mak-
ing that decision (patient and disease characteristics) (11, 12). In case of a rheumatolo-
gist deciding whether to de-escalate DMARDs for a certain patient, these characteristics 
are likely disease related (e.g. presence of swollen joints indicating active disease). Each 
characteristic can then be further described by specific variants or levels (e.g. presence 
of 0, 1 or 2 swollen joints) (11, 12). Another assumption is that an individual’s preference 
for the intervention is determined by the levels of these characteristics (11, 12). By offer-
ing a series of choices between two options with different characteristics (patients with 
different characteristics), the relative importance of the characteristics on the decision 
can be determined (11).
Questionnaire design
To identify patient characteristics that determine the decision making for DMARD 
de-escalation, 12 rheumatologists were randomly selected for interviews stratified by 
region and type of hospital (university or general). A semi-structured interview schedule 
(Supplement 1) was designed based on characteristics identified by pilot interviews 
of rheumatologists and literature (7). During the semi-structured interviews, rheuma-
tologists were questioned by telephone about their personal opinion and attitude with 
respect to DMARD de-escalation. The number of interviews was deemed sufficient as 
no new themes were mentioned during the final interviews, and therefore no other 
rheumatologists were approached. Based on the interviews, five patient characteristics 
with corresponding levels were developed (Table 1).
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study design and questionnaire
A questionnaire containing 16 choice tasks, each consisting of two hypothetical patients, 
was deemed feasible to complete by rheumatologists attending the annual convention of 
the Dutch Society of Rheumatology (Nederlandse Vereniging voor Reumatologie, NVR). 
All hypothetical patients were assumed to use the combination of methotrexate 20-25 
mg / week and a TNF-blocker, without additional glucocorticoids. In order to gain as much 
information as possible (enhancing precision) from a limited number of choice sets and 
sample size, computer software using experimental design theory (NGENE 1.1.2, 2014 
ChoiceMetrics software) was used to generate the most efficient sets of choices given 
the characteristics as defined previously (optimized for a main effect model with full 
dummy specification). To further optimize this process, priors were chosen reflecting the 
expected direction of characteristic levels on preference (Supplemental Table 1) but not 
imposing any strong assumptions about the weight of each characteristic in the decision 
that might (dis)favor identification of some effects over others.
Choice sets consisted of two hypothetical patients and an opt-out option (Supplemen-
tal Table 2). From each choice set, rheumatologists were asked to choose the patient 
they deemed most suitable to de-escalate DMARDs. The opt-out option was included in 
case respondents deemed neither patient suitable for de-escalation, resembling real-life 
decision-making. Of note, only after rheumatologists chose to de-escalate treatment 
in either patient they were offered a second question to select the strategy they most 
preferred. If de-escalation was deemed appropriate, a second choice was given on how 
Table 1. Choice task example. Participants were required to choose the patient they deemed most suit-
able for de-escalation or neither (opt-out). For each choice task patient characteristics were varied by 
assigning different levels. Possible levels are indicated in the subscript. All patients were assumed to use 
the combination of methotrexate 20-25 mg / week and a TNF-blocker.
Patient A Patient b
Duration of remission1 6 months 1 year
Patient preference for de-
escalation at the start of the 
consult2
Patient is not willing to de-escalate Patient is willing to de-escalate
Number of swollen joints3 1 2
DAS284 ≤ 3.2 < 2.6
Medical history5 Difficult to accomplish remission Easy to accomplish remission
Non-erosive Erosive
1 Levels were “6 months” and “12 months”
2 Levels were “patient is not willing to de-escalate” and “patient is willing to de-escalate”
3 Levels were “0”, “1” and “2”
4 Levels were “≤ 3.2” and “< 2.6”
5 Levels were “difficult to accomplish remission, erosive”, “difficult to accomplish remission, non-erosive”, 
“easy to accomplish remission, erosive” and “easy to accomplish remission, non-erosive”
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they would de-escalate DMARDs. To make respondents familiar with the concept of DCE, 
two introductory questions were included. To avoid bias by presentation, the order of 
choice sets and order of attributes were randomized for each participant (13).
study sample
All rheumatologists and rheumatology trainees active in the Netherlands were eligible 
for participation. 
Invitation of subjects
A list of active rheumatologists was kindly provided by the Dutch Society of Rheumatol-
ogy (NVR). Doctors were recruited during the annual meeting of the NVR 25 and 26 
September 2014. Questionnaires were provided electronically on iPads. Non-attending 
rheumatologists received an invitation by e-mail to complete the questionnaire at their 
own computer.
statistical analyses
We estimated a conditional logit model to assess overall preference for de-escalation of 
DMARDs and its determinants (Supplement 2).
To assess whether preferences for de-escalation and relative importance of patient 
characteristics determining this decision differed among rheumatologists, a subgroup 
analysis (latent class model) was performed as well (Supplement 2). With this model 
subgroups of rheumatologists (clusters or classes) can be identified. To determine the 
optimal number of classes we selected the model with the best fit on the consistent 
Akaike information criterion (CAIC). This measure deals with the trade-off between 
increase in goodness of fit of the model and the increase in complexity by the addition of 
clusters. Analyses were performed using the clogit and lclogit function in STATA (version 
13.1, StataCorp, 4905 Lakeway Drive, College Station, Texas, USA).
ResUlTs
In total 156 doctors completed the questionnaire (128 rheumatologists and 28 trainees), 
128 of which completed the questionnaire at the annual conference Of 174 rheumatolo-
gists that had not yet participated at the annual conference and received an invitation 
by e-mail, 28 (16%) completed the questionnaire online. Eleven rheumatologists did 
not provide demographic data because of technical problems or by their own wishes. 
Characteristics of the study sample are shown in Table 2.
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Table 2. Characteristics of study sample.
Rheumatologists (n=117)* Trainee (n=28)
Age (years) median (IQR) 47 (40-57) 34 (31-36)
Female, n (%) 60 (51%) 20 (71%)
Work experience (years), median (IQR) 10 (5 – 23) -
Self-reported number of RA patients in 
practice, median (IQR)
350 (200 – 1000) 70 (25-100)
Self-reported prevalence of biological 
among RA patients in practice, median 
(IQR)
25 (20 – 30) 30 (20 – 35)
Working in academic hospital, n (%) 19 (16%) 10 (36%)
*11 out of 128 rheumatologists did not provide information due to technical problems or by their own wish.
De-escalation of therapy was preferred in 74% of the patient choice sets evaluated by 
the rheumatologists. To quantify how patient characteristics influence doctor’s prefer-
ences for de-escalating DMARDs, a conditional logit model was estimated (Table 3). The 
interpretation of such a model is somewhat different than of a linear or logit regression 
model. Each of the patient characteristics played a role in the decision to de-escalate 
DMARDs, as all coefficients of the model showed significance. The opt-out option was 
chosen if a rheumatologist deemed neither patient of a pair suitable for treatment de-
escalation. De-escalation was chosen in 74% of cases, while the opt-out was chosen in 
26% of cases. Therefore, in general, the opt-out was less preferred than de-escalation 
(the reference category), which is reflected by a negative sign for the opt-out (Table 3). 
Coefficients for the other factors have a similar interpretation, as will be further explained.
For each characteristic, we chose the level we expected to be most preferable for 
de-escalation to be the reference level, e.g. no swollen joints, DAS<2.6 (see footnotes 
Table 3). Therefore, the ideal patient that doctors would like to consider for de-escalation 
of DMARDs is a patient having all the reference characteristics, i.e.: came in remission 
easily, has no erosions, a remission duration of one year, no swollen joints and has DAS 
remission rather than DAS LDA. Hence, the coefficients represent the relative decrease in 
de-escalation preference when a patient presents with that feature (e.g. 2 swollen joints) 
relative to the reference of that feature (0 swollen joints). Presence of 2 swollen joints 
(-1.68, p<0.001) and a patient history of erosive disease in combination with difficulties 
achieving remission (-1.64, p<0.001) had the strongest influence on the decision not to 
de-escalate (Table 3). It should be emphasized that above results did not depend on the 
fashion in which DMARDs were de-escalated, as this was not specified in the question-
naire. Only after rheumatologists chose to de-escalate treatment in either patient they 
were offered a second question to select the strategy they most preferred (see below).
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Table 3. Overall preference of doctors for de-escalation based on a conditional logit model.
Overall
n=156
β se
Opt out1 chosen 26%
Opt out1 -2.96*** 0.11
DAS ≤ 3.22 -0.98*** 0.07
Swollen joint count
13 -1.15*** 0.08
23 -1.68*** 0.09
Patient history
Erosive disease4 -0.69*** 0.11
Remission difficult4 -0.80*** 0.09
Erosive + remission difficult4 -1.64*** 0.10
Remission duration 6 months5 -0.52*** 0.06
Patient not willing to de-escalate at start of visit6 -1.09*** 0.07
1: this option was included in case a rheumatologist did not want to de-escalate DMARDs in either of the 
patients presented in a pair
2: reference DAS<2.6
3: reference no swollen joints
4: reference easy remission and no erosions
5: reference remission duration 1 year
6: reference patient willing to de-escalate DMARDs at start of visit
*  p<0.05
**  p<0.01
***  p<0.001
Abbreviations:
β = Beta coefficient
SE = Standard Error
Although this model describes the preferences of rheumatologists for de-escalation 
of DMARDs on average, in reality subgroups of doctors may exist that weigh patient 
characteristics differently. Therefore we looked whether we could distinguish subgroups 
based on answering patterns. Using a latent class model, we identified 5 subgroups of 
rheumatologists as shown in Table 4. Each of the groups made different tradeoffs whom 
to de-escalate DMARDs in given the relative weight in the patient characteristics and opt 
out. Opt-out preference ranged from 1% in class 4 to 53% in class 5. For each subgroup 
the relative weights of the patient characteristics that drove de-escalation were analyzed 
(absolute weights of coefficients cannot be directly compared between subgroups be-
cause coefficients are on different scales). Table 4 shows that presence of swollen joints 
was the most important characteristic for rheumatologists to consider in subgroups 2 
and 5, whereas in subgroups 1 and 3 patient history was most important. Of note, in 
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subgroup 4 none of the patient characteristics dominated the decision to de-escalate, 
while their preference for de-escalation was strong. To further illustrate differences 
between the subgroups, 96 unique patient profiles were created, using the character-
istics and levels as defined in Table 1. As shown in Figure 1, overall, patients 1-10 had 
a high probability to be considered for de-escalation (>80%) and patients 83-96 had a 
low probability (<20%). For the other patients (11-82), probabilities to be considered 
for de-escalation were variable among subgroups. Comparing subgroups with respect to 
Table 4. Preference of doctors for de-escalation of DMARDs by subgroups based on answering patterns.
Group 1
n=48
Group 2
n=22
Group 3
n=26
Group 4
n=30
Group 5
n=30
β se β se β se β se β se
Opt out1 chosen 38% 21% 9% 1% 53%
Opt out1 -2.78*** 0.23 -5.33*** 0.97 -4.98*** 0.83 -5.70*** 0.64 -4.72*** 0.41
DAS ≤ 3.22 -0.59*** 0.15 -1.60** 0.49 -2.55*** 0.57 -0.59*** 0.15 -1.87*** 0.27
Swollen joint count
13 -1.01*** 0.19 -3.24*** 0.59 -1.02 0.53 -0.79*** 0.19 -3.53*** 0.48
23 -1.90*** 0.22 -6.06*** 0.99 -0.63* 0.28 -1.25*** 0.21 -3.92*** 0.51
Patient history
Erosive disease4 -1.27*** 0.20 -0.73 0.40 -1.23** 0.38 -0.58* 0.24 -1.29*** 0.43
Remission difficult4 -1.08*** 0.20 -0.95* 0.46 -1.42** 0.42 -0.44 0.27 -1.79*** 0.37
Erosive + remission 
difficult4
-2.80*** 0.25 -1.14 0.62 -2.99*** 0.60 -1.29*** 0.30 -2.79*** 0.40
Remission duration 
6 months5
-0.41* 0.16 -1.17*** 0.40 -0.52 0.31 -0.17 0.14 -3.74 -
Patient not willing 
to de-escalate at 
start of visit6
-1.61*** 0.20 -1.05*** 0.30 -0.98** 0.30 -1.14*** 0.13 -1.49*** 0.27
Class probabilities,
median (range)
0.99
(0.55 – 0.99)
0.99
(0.55 – 0.99)
0.94
(0.58 – 0.99)
0.99
(0.77 – 0.99)
0.98
(0.57 – 0.99)
1: this option was included in case a rheumatologist did not want to de-escalate DMARDs in either of the 
patients presented in a pair
2: reference DAS<2.6
3: reference no swollen joints
4: reference easy remission and no erosions
5: reference remission duration 1 year
6: reference patient willing to de-escalate DMARDs at start of visit
*  p<0.05
**  p<0.01
***  p<0.001
Abbreviations:
β = Beta coefficient
SE = Standard Error
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their willingness to de-escalation, group 4 had the greatest willingness to de-escalate and 
group 5 was least willing to de-escalate medication. Given the diagonal in Figure 1, group 
3 had above average willingness to de-escalate, whereas group 1 was somewhat below 
average. Willingness to de-escalate for group 2 was in general above average for patients 
at the left side of the figure (patients 1-48) and less than average for patients at the right 
side (patients 49-96). A simple analysis to see whether differences related to age, sex 
or practice-related factors (Table 5) did not reveal particular characteristics of doctors. 
Being trainee was associated with lower preference to de-escalate.
After the decision whether to de-escalate or not the rheumatologists were presented 
with the choice which DMARDs to de-escalate. Three options were presented: de-
escalating the TNF-blocker, de-escalating MTX or de-escalating MTX to half the dose 
followed by de-escalating the TNF-blocker. Of de-escalation strategies, rheumatologists 
chose de-escalating the TNF-blocker in majority of cases (61%), followed by de-escalating 
the TNF-blocker after de-escalating MTX to half dosage (33%).
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52 54 56 58 60 62 64 66 68 70 72 74 76 78 80 82 84 86 88 90 92 94 96
Ch
oi
ce
 p
ro
ba
bi
lit
y 
to
 ta
pe
r 
Patient profile 
Group 1
Group 2
Group 3
Group 4
Group 5
Overall
figure 1. The probability rheumatologists choose to taper specific patients, shown for 96 unique pa-
tient profiles. Overall probability (average for all rheumatologists, orange rounds) and probabilities by 
subgroups (other shapes) are shown.
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Table 5. Characteristics of subgroups.
Group 1
n=48
Group 2
n=22
Group 3
n=26
Group 4
n=30
Group 5
n=30
P-value*
Age (years) median (IQR) 43 (35 – 51) 49 (40 – 56) 39 (35 – 45) 50 (40 – 60) 41 (37 – 52) 0.038
Female, n (%) 22 (51%) 12 (55%) 15 (60%) 15 (50%) 20 (67%) 0.663
Trainee, n (%) 11 (26%) 2 (9%) 7 (29%) 1 (3%) 7 (26%) 0.051
Work experience (years), 
median (IQR)
7 (0 – 15) 13 (5 – 25) 5 (0 – 8) 12 (5 – 25) 4 (0 – 18) 0.027
Self-reported number of 
RA patients in practice, 
median (IQR)
375
(100 – 800)
425
(200 – 
1100)
450
(100 – 
2000)
300
(200 – 
1000)
300
(100 – 500)
0.492
Self-reported prevalence 
of biological among RA 
patients in practice, 
median (IQR)
23 (20 – 30) 20 (20 – 33) 30 (20 – 30) 29 (20 – 33) 20 (15 – 30) 0.641
Working in academic 
hospital, n (%)
9 (21%) 4 (18%) 6 (24%) 5 (17%) 7 (23%) 0.955
No data, n(%) 5 (10%) 0 (0%) 2 (8%) 1 (3%) 3 (10%) <0.001
* Kruskall – Wallis test
DIsCUssIOn
By semi-structured interviews, we identified 5 patient characteristics rheumatologists 
take into account in their decision to de-escalate DMARDs: number of swollen joints, 
presence of DAS remission/LDA, patient history, duration of remission/LDA and patient 
willingness to de-escalate. Using a discrete choice experiment among Dutch rheuma-
tologists, number of swollen joints and patient history were identified as factors of 
greatest importance. However, rheumatologists were not uniform in their decision to 
de-escalate DMARDs. Based on a further (latent class) analysis of the answering patterns, 
five subgroups of rheumatologists were identified that traded off patient characteristics 
differently in their decision to de-escalate: 1) rheumatologists that always tapered 2) 
rheumatologists tapering in the absence of swollen joints 3) rheumatologists tapering 
in the absence of swollen joints and in the presence of a favorable patient history 4) 
rheumatologists tapering in case of DAS remission and favorable patient history and 
5) rheumatologists taking into account all factors. That heterogeneity among rheuma-
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tologists exists with respect to decision-making was further demonstrated by calculating 
the probability rheumatologists would decide to de-escalate medication for 96 unique 
patient profiles (figure 1). This showed that subgroup probabilities were highly variable 
for most of the profiles, especially those for which one or more characteristics were 
less favorable (e.g. presence of 1 rather than 0 swollen joints or DAS LDA rather than 
DAS remission). This means that no general consensus exists on which patients are suit-
able for de-escalation. Eliciting details on rheumatologist subgroups resulted in mixed 
demographic characteristics, so other person related factors are likely to play a role. We 
only observed that trainees were less willing to taper, possibly due to lack of experi-
ence and confidence. Of de-escalation strategies rheumatologists could choose from, 
de-escalating the TNF-blocker first and de-escalating the TNF-blocker after reducing MTX 
to half dosage were chosen in 94% of cases.
To date there is no standardized way to determine the patient for whom de-escalation 
of DMARD therapy is appropriate. (8) Of clinical factors, conflicting results have been 
reported for deeper remission (14, 15) and shorter disease duration (14-16) to be associ-
ated with successful tapering, while observations from CORRONA registry suggested that 
a rapid response to DMARDs is associated with better maintenance of remission when 
the agents are tapered later on (8, 17). In this DCE, rheumatologists regarded presence of 
swollen joints, a patient history of erosive disease and difficulties achieving remission and 
patient fulfilling DAS LDA rather than remission as most important factors to not de-esca-
late. Although swollen joints may be regarded as a direct indication of inflammation and 
contra-indication for de-escalation, this is not necessarily true for the DAS28 score itself, 
which could be high because of psychosocial distress or comorbidities. Rheumatologists 
in clinical practice may therefore sometimes decide to de-escalate in case of DAS LDA 
in the absence of other signs of inflammation. Future research, may aid to clarify which 
clinical factors are really important for predicting successful de-escalation. Ultrasound 
(18-20) or biomarkers (14, 21) may have an additional role in detecting in which patients 
subclinical synovitis is still present increasing the risk of flare after treatment withdrawal. 
It would also be of interest to study whether (a combination of) clinical, ultrasonographic 
and/or serum factors can adequately predict which patients can successfully de-escalate 
treatment.
This study was conducted using a DCE, which in comparison to other quantified 
preference techniques, bears most resemblance to real-world decision-making (22). A 
strength of this design is that several patient characteristics can be evaluated at once 
in which the weight of each characteristic contributes to the decision to de-escalate 
medication. Another strength of this study is that we identified relevant characteristics 
using semi-structured interviews with a random sample of rheumatologists to identify 
relevant factors (characteristics and levels) for the DCE questionnaire. As no new factors 
were mentioned during the final interviews, we assumed that saturation was reached 
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and hence no important factors had been missed. One inherent limitation of a DCE is 
that rheumatologists were asked to evaluate virtual RA patients on screen. Consequently, 
as the decision to de-escalate does not have real clinical implications, rheumatologists 
may have been more risks taking than they would be when dealing with real patients. 
This could then have resulted in an over-estimation of rheumatologists’ willingness to 
de-escalate. Another limitation of this study is that, although the majority of rheumatolo-
gists attending the annual conference participated in the study, response rates were low 
for rheumatologists not attending the conference that were invited to participate from 
home. Although this could for a large part be explained by the method of recruitment, 
we could not fully exclude the possibility of a relationship between non-responders and 
tendency to de-escalate DMARDs.
In designing the questions for the DCE we made several choices that need clarifica-
tion. We refrained from including side effects in the decision to de-escalate. Several 
rheumatologists remarked that presence of side-effects is relevant in the decision of 
de-escalation therapy. Although we agree this is likely to influence the decision to de-
escalate a particular medicine first due to side-effects, it not necessarily relates to the 
decision of de-escalation in patients achieving LDA or remission. The presence of severe 
side-effects would likely result in de-escalation or switching medication before sustained 
remission or LDA is achieved.
Second, a simple choice was given on what to de-escalate. Rheumatologists could 
choose between de-escalating the TNF-inhibitor or MTX completely, or to de-escalate 
the TNF-inhibitor completely after reducing MTX to half dosage. As more strategies are 
imaginable, different strategies can and will be adopted in reality. Therefore, more work 
on preference of what to de-escalate first given both the medication characteristics and 
patient characteristics would help to further understand de-escalation of therapy deci-
sions.
Third, due to the definition of levels assigned to the disease characteristics, the relative 
importance of characteristics could change if levels had been defined differently (e.g. 
remission duration of 2 years rather than 1 year). Therefore, the relative importance of 
characteristics can only be interpreted taking the definition of the levels into consider-
ation.
COnClUsIOn
Swollen joint count and patient history were the most important characteristics rheuma-
tologists take into consideration in the decision to de-escalate. However rheumatologists 
are not uniform in their decision in whom to de-escalate. Five subgroups of rheumatolo-
gists could be identified: Those that taper 1) always, 2) in absence of swollen joints, 3) in 
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absence of swollen joints and favorable patient history, 4) if DAS remission and favorable 
patient history and 5) taking into account all factors.
To improve uniform decision-making in the future, more research is needed assessing 
the predictive value of patient characteristics for successful de-escalation of DMARDs. 
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supplement 1. Topics for semi-structured interview.
Introduction: 
Thank you for cooperating with this interview.
We would like to get ourselves an idea about how rheumatologists de-escalate DMARDs in clinical prac-
tice in patients with RA.
The following questions will focus on the de-escalation of conventional and biological DMARDs in pa-
tients with RA in remission.
Topics to discuss:
· Age/gender/years of clinical practice of rheumatologist
· Have you ever de-escalated biological or conventional DMARDs?
· What are, in your opinion, advantages of de-escalation?
· And disadvantages?
· Which factors make that you consider treatment de-escalation for a certain patient?
(first have rheumatologist come with an answer by himself, thereafter check whether any of below topics 
are relevant as well)
	 § Disease duration of RA
 § Severity and course of disease
 § DMARD history
 § “Difficulties” to achieve remission in a patient
 § Remission duration
 §  Doctor-patient relationship (mutual trust, extent to which shared decision making is possible
 § Other
 o  Do you sometimes de-escalate medication for a patient for whom it was difficult to achieve a 
state of remission.
 o  In your opinion, how long should a patient be in remission before one should consider tapering 
or stopping medication?
 o  How do you evaluate whether a patient is in remission and can commence de-escalation (DAS, 
other factors?)
 o  If you were to assess remission exclusively by using the DAS28, then which value of the DAS28 
would, in your opinion, reflect remission? (Officially 2.6, but especially the feeling of the doctor 
is relevant here)
 o  In clinical practice, the DAS is not always a perfect measure to assess remission. Are there per-
haps components of the DAS you feel are a decisive factor to indicate remission.
 o  In case you de-escalate etanercept (Enbrel) in patients that use the regular dose (50 mg/ week), 
then in what fashion do you generally do this? (extending the dose interval, half the dose, stop 
immediately).
 o  Are you aware that etanercept (Enbrel) is also available as a 25 mg injection? Do you sometimes 
prescribe it?
 o  Which would have your preference? De-escalating etanercept (Enbrel) by doubling the interval 
or by halving the dose by prescribing the 25 mg / week injection?
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 o  Whenever you de-escalate methotrexate in patients using the full dose (20-25 mg/week), how 
do you usually do this? (half the dosage at once, taper by 1-2 tablets each time? Stop at once?)
 o  In case a patient uses the combination of etanercept (Enbrel) and methotrexate, do you have a 
preference which agent to de-escalate (first)? How would you de-escalate?
 o What makes that you have a preference?
 § Adverse effects
 § Co-morbidity
 § Preference of the patient
 § Other
 o  In case a patient uses the combination of adalimumab (Humira) and methotrexate, do you have 
a preference which agent to de-escalate first? Why? (does the formation of anti-drug antibodies 
play a role?) How would you de-escalate?
 o  In case a patient uses another TNF blocker (certolizumab (Cimzia) 200mg/2 weeks or golim-
umab (Simponi) 50mg/month), how would you commence de-escalation? (would you then use 
another de-escalation strategy?)
-  Can you imagine that you would decide not to de-escalate medication in a patient that has reached 
a state of low disease activity or remission for a long period of time? What are the reasons?
-  Are there any non-medical reasons that play a role in your decision to de-escalate, such as biological 
costs or branch recommendations? 
- Are there patients whom you never de-escalate after negotiation?
- How many patients do you estimate are in your practice and how many use a biological?
Doctor’s preferences in de-escalating DMARDs in RA – a discrete choice experiment
159
8
supplement 2. Utility functions for the conditional logit and latent class models.
Utility function for the conditional logit model:
  V = β0 + β1*opt out + β2*DAS28≤3.2 + β3*SJC=1 + β4*SJC=2 + β5*history erosive disease + β6*history 
difficult achieving remission + β7*history erosive disease and difficult achieving remission + 
β8*remission duration 1 year + β9*patient unwilling to taper 
V: Observable utility that rheumatologists have for tapering medication in a patient.
β1-β9: Coefficients for the patient characteristics. These represent the relative weight doctors attach to a 
certain characteristics when it comes to their decision to taper medication
Utility function for the cluster (latent class) model: 
  V|c = β0|c + β1|c*opt out + β2|c*DAS28≤3.2 + β3|c*SJC=1 + β4|c*SJC=2 + β5|c*history erosive disease + 
β6|c*history difficult achieving remission + β7|c*history erosive disease and difficult achieving remis-
sion + β8|c*remission duration 1 year + β9|c*patient unwilling to taper
V|c: Observable utility for tapering medication for doctors belonging to that class.
  β1-β9: Represent the coefficients of the attributes indicating the relative weight rheumatologists of a 
class place on a certain attribute level.
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supplemental Table 1. Priors used in the design of the questionnaire.
Characteristic levels Priors
Duration of remission - 1 year
- 6 months
0 (ref)
-0.1
Patient preference for tapering at the start of the consult - Patient is not willing to taper
- Patient is willing to taper
0.15
0 (ref)
Number of swollen joints - 0
- 1
- 2
0.2
0.1
0 (ref)
DAS28 - < 2.6
- ≤ 3.2
0.1
0 (ref)
Medical history - Difficult to accomplish remission
- Easy to accomplish remission
-0.1
0 (ref)
- Non-erosive
- Erosive
0 (ref)
-0.15
supplemental Table 2. Example of a choice set as presented in the questionnaire.
Patient A Patient b Opt-out
Duration of remission 1 year 6 months -
Patient preference for 
tapering at start of visit
Patient is not willing to 
taper
Patient is willing to taper -
Number of swollen joints 1 0 -
DAS28 < 2.6 ≤ 3.2 -
Medical history Difficult to accomplish 
remission
Non-erosive
Easy to accomplish 
remission
-
In case A or B was 
chosen:
strategy A strategy b strategy C
Preferred tapering 
strategy
Tapering MTX to 0 mg Tapering biological to 
0 mg
Decrease MTX (50% of 
initial dosage), then taper 
biological to 0 mg
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GeneRAl DIsCUssIOn
The medical treatment of RA has improved greatly over the previous two decades (1). 
As a result, disabling joint deformations, once the hallmark of the disease, have become 
a rare manifestation that the new generation of rheumatologists will mainly know from 
medical textbooks. Nonetheless since RA is a chronic non-curable disease, challenges 
to further optimize care for patients remain and two main challenges have been the 
focus of this work. First, despite the better medical outcomes the burden of disease in 
RA patients is still higher compared to the general population, which may be attributed, 
at least in part, to higher levels of psychological distress patients experience (2). Second, 
continuous medical drug treatment for patients in remission is only justified if the ben-
efits outweigh the disadvantages such as potential overtreatment, safety considerations 
and treatment costs (3). These challenges resulted in the main objectives of this thesis:
 1.  To study the impact of psychosocial factors on patients with early RA, with 
special interest in the relationships between psychosocial factors and disease 
activity score and achievement of treatment goals
 2.  To study the effects of treatment de-escalation in patients with low disease 
activity or remission and aid rheumatologists in making informed decisions with 
regard to treatment de-escalation
In this chapter, I will discuss how the findings of this thesis may aid in tackling these chal-
lenges and which issues remain unresolved. I will address methodological considerations 
and finally make recommendations for further research.
Impact of psychological factors
In chapter 2 we showed that RA patients experience a quality of life that is substantially 
lower than the general population. Furthermore, this difference remains after the first 
year of medical treatment. Of course, many factors could be responsible for this differ-
ence in quality of life. The most obvious being that the disease is not yet adequately 
controlled. However, in tREACH, at 12 months 81% of patients had achieved their treat-
ment goal of DAS<2.4 and 53% of patients were in DAS remission (4). Although residual 
disease activity with associated pain and disability may explain part of the difference in 
quality of life, it is probably not the only factor at play. As I described in the introduction, 
RA has previously been associated with psychological distress such as anxiety, depression 
and fatigue (2, 5). Likely, these factors contribute to the lower feeling of well-being of RA 
patients.
The relationship between psychosocial factors and RA is likely bidirectional (6, 7). On 
the one hand rheumatoid arthritis may result in higher levels of anxiety and depression 
because of pain and disability associated with the disease. On the other hand, higher 
levels of psychosocial distress may result in higher disease activity measures like the 
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DAS, by patients scoring higher on subjective components tender joint count and global 
health (6). A bidirectional relationship between RA and depression by inflammatory 
pathways is also possible. Depression and depressed mood have been associated with a 
pro-inflammatory cytokine spectrum. In this light, the higher prevalence of depression in 
RA may also be explained by higher levels of inflammation present in these patients (6). 
Reversely, depression might cause higher levels of inflammation leading to higher disease 
activity measures because of increased swollen joint count and ESR. Placing these theo-
ries in light with my own findings in chapters 3 and 5, the psychosocial factors appear to 
be associated with disease activity measures at the subsequent visit mostly by their as-
sociation with the more subjective components of the disease activity score tender joint 
count and VAS global health, although some associations with objective components 
(ESR and swollen joint count) were also observed. Therefore, effects through subjective 
components and through a direct inflammatory pathway may both take place, although 
indirect mechanisms, such as non-adherence, could also be responsible for an increase 
in inflammatory parameters (6).
Over the first year of disease, a shift in relative importance of individual psychosocial 
factors influencing DAS during the chronic phase of the disease was observed as well. 
At baseline, anxiety and coping with pain were the most important psychosocial factors 
affecting DAS at subsequent visit, while at 12 months, fatigue came out as independent 
predictor. Care should be taken in drawing definitive conclusions from this observed 
shift, as results are from one sample only and psychosocial factors are highly correlated. 
However, from the perspective of disease progression, the shift may be plausible from 
a psychological point of view. At baseline, when disease is active and patients need to 
cope with a new situation of having a chronic disease it is imaginable that coping with 
pain and anxiety play a large role, whereas at 12 months, when disease is under control 
and patients have adapted more to their new situation, the fatigue that remains comes 
to the foreground.
In chapter 4 we showed the patterns of fatigue during the first year after diagnosis of 
RA. Fatigue is a common symptom in auto-immune disorders (8) and cancer (9) and is 
often notoriously unresponsive to drug treatment. This is also the case in RA. Although 
intensive treatment with a combination of conventional DMARDs or biologic agents 
are effective in reducing pain and disability and stopping progression of joint damage 
(10), a recent meta-analysis found that they only have a very limited effect in reducing 
fatigue (11). In cancer, however, physical therapy (12) and cognitive behavioral therapy 
(13) have been shown to be effective in part of the patients. From meta-analyses it 
was concluded that these interventions have a small benefit on self-reported fatigue 
in patients with rheumatoid arthritis as well (14). However, fatigue is a complex entity 
that may encompass both physical and mental aspects (8). Measuring these aspects of 
fatigue more specifically may also aid in deciding which intervention is most appropriate 
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for individual patients and understanding why certain interventions may work in some 
but not in others.
In conclusion, we found that RA patients experience a lower quality of life compared 
to the general population, which may in part be attributed to a higher burden of psy-
chosocial distress. We found that higher levels of psychosocial factors are associated 
with higher disease activity scores at subsequent visits. The nature of this relationship 
was mainly explained by an association between psychosocial factors and the subjective 
components of the disease activity score. However, as some associations with objective 
components were observed as well, the existence of an association by a direct inflam-
matory pathway cannot be ruled out. In addition a shift was observed in the relative 
importance of psychosocial aspects during the first year of follow-up. With respect to 
fatigue, almost half of patients classify as being fatigued during the first year of follow-up, 
despite a tight controlled treatment strategy. One third of fatigued patients at baseline 
classify as being suspect for clinical depression. Monitoring for symptoms of depression 
and fatigue should be considered in newly diagnosed RA patients, so that appropriate 
interventions can be performed.
Aspects of remission and tapering
Identifying patients that are not likely to respond to initial treatment with (combination) 
DMARD therapy could aid in developing a more personalized treatment regimen in which 
such patients can be switched early to a more intensive therapy, for instance with TNF-
blocking agents. Although clinical factors are able to predict differences in response at 
group level, predictions are not accurate enough at the individual level to base treatment 
decisions on. In chapter 5 we identified predictors for attaining remission in early RA. 
We found that, in addition to clinical factors, psychosocial factors have additional value 
in predicting which patients attain the treatment goal. However, as the association is 
likely to take place mainly through the subjective components of DAS (chapter 3), adding 
the psychosocial factors to a predictive model that is used to inform decisions on treat-
ment intensification may not be desirable. Therefore, enhancement of the predictive 
abilities of such a model may be better sought by, for instance, the inclusion of genetic 
factors or biomarkers. Nonetheless, the association we observed between psychosocial 
factors and treatment response should make clinicians aware that patients with high 
levels of psychological distress can affect outcome measures used for making treatment 
decisions. Therefore, in some patients with high DAS, psychological rather than medical 
interventions may be warranted.
Once remission has been achieved, a new question emerges whether DMARD therapy 
may be safely de-escalated or should be continued for an unlimited period of time. 
Evidence from this thesis and recent literature (3, 15) suggests that a substantial part 
of patients can de-escalate biological DMARDs (chapter 7) and conventional DMARDs 
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(chapter 6) without experiencing a flare within the first year of follow-up. Furthermore, 
treatment de-escalation appears to be reasonably safe: Of patients that do experience 
a flare, the majority regains remission within 6 months of follow-up. With respect to 
structural damage, the studies evaluating this outcome in the systematic review found 
limited to no progression.
Although our results suggest that treatment de-escalation may be safely attempted, 
several aspects warrant future research. Although the studies evaluating joint damage 
under treatment de-escalation found limited to no progression, this outcome was only 
investigated in a limited number of studies. Although not significant, some studies in 
the systematic review showed a non-significant trend towards more progression in the 
group de-escalating therapy. A question of specific interest would be if such damage 
progression occurs at all and if so, whether it can be prevented if therapy is reinitiated 
immediately after relapse.
Another area of interest lies in the identification of patients that may successfully de-
escalate DMARDs without experiencing a subsequent flare. As was mentioned in the 
introduction, identifying these patients by clinical factors alone is not yet possible (3). As 
a consequence, rheumatologists in clinical practice differ greatly in their assessments of 
which patients are eligible for treatment de-escalation (chapter 8). Addition of imaging 
data and/or biomarkers might improve this identification, but is not guaranteed to be 
successful.
In conclusion, we found that in addition to clinical factors, psychosocial factors are 
associated with treatment response. Rheumatologists should be aware that patients that 
psychological distress can affect outcome measures like the DAS and take this fact into 
consideration in the decision of treatment intensification. We found evidence that de-
escalation of biological and conventional DMARDs without a short-term flare is possible 
in a substantial part of patients in remission or low disease activity. In patients that do 
experience a flare available evidence suggests that the majority of patients regains a state 
of remission within 6 months after treatment intensification with little or no progression 
of joint damage. Identification of patients that can successfully de-escalate medication 
is not yet possible. As a consequence, we found that rheumatologists in clinical practice 
differ greatly in their assessment which patients are eligible for treatment de-escalation.
Methodological considerations
When it comes to study limitations, three issues may affect validity that I will further 
discuss: Selection bias, information bias, confounding and generalizability.
Selection bias
Selection bias is a distortion of the results because the sample obtained for the analysis 
is not a representative sample of the target population.
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Most of the studies included in this work were based on data obtained from the tREACH 
study (4). The tREACH study was a randomized clinical trial in patients with arthritis in 
at least one joint and a duration of complaints shorter than 1 year. Based on the risk of 
developing persistent arthritis (Visser model (16)) patients were categorized into three 
groups (Low, Intermediate, High), each of which had three treatment arms. Primary aim 
of the tREACH study was to compare the response treatment response of different initial 
treatment strategies. In this work, all data from tREACH comprises the High risk group, of 
which 98% of patients fulfilled the later developed 2010 classification criteria for RA (4). 
Therefore, with respect to the 2010 classification criteria (17), patients in tREACH High 
may be assumed to be representative.
The target population of tREACH may be defined as all patients fulfilling the inclusion 
criteria being referred to a rheumatologist in a participating hospital during the inclusion 
time of the study. A distortion in this selection may be caused by rheumatologists not 
asking eligible patients to participate or by eligible patients not willing to participate 
themselves. As long as these effects play completely at random, a representative sample 
will still be obtained. However, in clinical trials, usually some systematic effects are at 
play. In general, patients willing to participate in clinical trials tend to be more highly edu-
cated, have more free time and are more adherent to therapy. Furthermore, in tREACH 
a tendency by rheumatologists to select patients with a typical presentation of RA was 
observed, as inclusion rate in the High group was much higher compared to the Low 
group. As focus of this work has been on the High group, of which 98% (4) fulfill the 
2010 classification criteria for RA (17) and the target population of this work are newly 
diagnosed patients with RA, this tendency is not likely to have much affected the results. 
On the other hand, certain groups (lower educated, non-Dutch ethnicity, people with 
very demanding jobs or familial obligations) may have been underrepresented in the 
trial, which could have implications for the generalizability of results to these groups. 
However, the mere inclusion of members of such subgroups in the study sample does 
not mean that the overall results automatically hold for these subgroups. For instance, 
in a clinical trial studying the effects of a certain drug, the inclusion of two 90 year olds 
in the sample does not mean that overall trial results can be applied to a population 
of 90 year olds. Therefore, if there is doubt whether results can be applied to certain 
subgroups, this should be the focus of a separate study or analysis.
Information bias
Information bias is a distortion in the results by measurement error or misclassification. In 
the tREACH trial and this work, the main outcome studied was the disease activity score 
(DAS). Although the DAS is measured using certain guidelines, there is large potential 
for variability between raters, especially in their assessment of presence of joint swell-
ing and tenderness. As in tREACH, the DAS was directly used to steer treatment, raters 
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scoring overly liberal or sensitive may result in the under- and overtreatment of patients 
respectively. To make sure the different raters evaluate the DAS in a similar fashion (i.e. 
to increase the inter-rater reliability), annual training sessions were organized in which 
trainers all rated the same set of patients, after which scores were compared. Raters 
rating too sensitive or liberal were encouraged to adjust their evaluation of DAS. Despite 
the annual training sessions, some inter-rater variability will always remain. Furthermore, 
by increasing the inter-rater variability, the internal validity of the study will increase, 
but variability between different studies may remain and hence affect generalizability. 
For instance, part of the heterogeneity in flare rates observed in the systematic review 
may be explained by inter-rater variability in assessing the disease activity across studies. 
However, it should be remarked that in this example, most heterogeneity is likely to be 
caused by differences in studies with respect to remission criteria, included patients and 
therapeutic management. Another potential source of information bias is the registra-
tion of DMARDs in tREACH. These were extracted from the paper or electronic patient 
records (most hospitals changed from paper to electronic patient records during the 
inclusion and follow-up period of tREACH). Because of their busy practice, rheumatolo-
gists sometimes fail to register the exact medication used by a patient at certain visits. 
In the case of paper patient records, sometimes the medication used is registered but 
difficult to decipher. Especially small changes in medication, such as performed when 
tapering or de-escalating therapy, may have been missed. This could lead to some over 
or under-estimation of the occurrence of tapering or flare at these time points. However, 
in most cases, registration at subsequent visits will be adequate, so that these events 
will be detected later in time. A more serious problem may be patient non-adherence. 
Generally, non-adhering patients use less than the prescribed dosage of the drugs, but 
in de-escalation studies the opposite may occur as well. Underuse of DMARDs may de-
crease remission rates and increase flare rates, while overuse of DMARDs during taper-
ing my decrease flare rates. Although non-adherence affects the outcomes, one could 
argue that non-adherence takes place in the general population as well (likely even more 
so than in clinical trial), making the outcomes of the study more similar to its expected 
efficacy when the intervention would be implemented in clinical practice.
Confounding
Confounding is a distortion of the observed association between a certain factor of 
interest and outcome by a (often unobserved) third factor, called the confounder. The 
confounder and the factor of interest need to be associated to each other and to the 
outcome. My father used to tell a practical joke on statistics about a research on fire 
damage. The researchers had found that the more fire trucks were sent to a fire, the 
larger was the damage. So they concluded that only one fire trucks should be sent to 
a fires to prevent damage. The example shows that if we are naive and only study the 
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relationship between the confounder (number of fire trucks) and outcome (fire damage), 
this can lead us to draw false conclusions. Although this example is of course a bit silly, in 
reality confounding factors are often not so easily identified. For this reason, in medical 
research, identifying and adjusting for confounders is of great importance to be able to 
find the true relationships of interest.
There are several ways to deal with confounding, so that the true association between 
the factor of interest is observed. One of these methods, which was also applied in 
this work, is to control for confounding by using multivariable regression models. By 
regressing the relationship of the confounder and factor if interest simultaneously on the 
outcome, one can control for the confounder so that the relationship between factor of 
interest, conditional on the confounders can be observed. In chapter 3, interest lied in the 
independent effects of psychosocial factors measured at the current visit on the DAS 3 
months later. Therefore, other factors having a relationship with DAS (confounders), age, 
sex, RF status ACPA status and DAS at the current visit, were adjusted for in the model. 
Similarly, in chapter 5 these factors were controlled for to assess the additional effect of 
psychosocial factors on attaining remission. Although confounders can be controlled for 
in statistical models, the method is still no absolute guarantee that the true relationship 
between the factor of interest and outcome is observed. This is because the model can 
only adjust for confounders that were observed. If important confounders were left out 
of the model, either because they were not measured or because they are unknown, the 
observed relationship will still be biased. 
Taking all methodological considerations into account, I feel that the conclusions pre-
sented in this work are likely to be applicable to the general population of RA patients. 
Although not used as an inclusion criterion, almost all patients in tREACH fulfilled the 
ACR/EULAR 2010 criteria for RA. Information bias by misclassification of medication use 
or inter-rater variability in DAS scores, may have occurred, but the impact is not likely 
to be large. Known potential confounders were adjusted for in the analyses. Hence, this 
work can provide more insight in the impact of psychosocial factors on patients with 
early RA and aid rheumatologists in making more informed decisions with respect to 
treatment de-escalation. Nonetheless, many questions remain that warrant future re-
search, for which I will make recommendations in the section that follows.
future recommendations
The medical treatment of RA has improved greatly over the previous two decades. This 
success may for a great part be attributed to two factors. First, a paradigm shift in the way 
the disease is managed in which early and tight-controlled are paramount (1). Second, 
the development of a wide spectrum of therapeutic agents, all of which have shown to 
be effective at the group level (1). Yet, further improvement may be realized in several 
ways. As already noted in the introduction, guidelines are frequently not adhered to by 
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rheumatologists in clinical practice, even if they do agree with the recommendations 
(18). A seemingly obvious, but important recommendation is to make sure that guide-
lines are more strictly implemented in clinical practice.
A second opportunity to further optimize care in rheumatoid arthritis may be per-
sonalized health care. Although treatments may be effective when studied at the group 
level, this does not mean that they are equally effective for every patient. While some 
patients may benefit a lot, other patients may not benefit at all, but may still be exposed 
to (serious) side effects. Hence, identification of subgroups of patients that are likely, or 
unlikely, to respond to a certain therapy may lead to a more effective, safe and efficient 
use of therapeutics. Personalized healthcare is most suited for therapeutic areas that 
are characterized by highly heterogeneous patient populations, low response rates, 
high burden of side effects originating from traditional trial and error prescription and a 
high cost of the given therapy (19). Arguably, rheumatoid arthritis fulfills most of these 
criteria. As we showed in chapter 6, only 27% of patients achieved sustained remission 
within 6 months and 57% within 2 years of follow-up period in tREACH. This may indicate 
that part of the patients are unsatisfactorily treated. Furthermore, the heterogeneity in 
response may suggest different underlying molecular etiology in the disease may exist, 
even though presenting as the same disease (19). Also, the costs of biological treat-
ments for RA are high and DMARD treatment often comes with side-effects. Therefore, 
a personalized health care approach could be of great interest for RA. However, such 
an approach would require that the individual response to certain treatments can be 
accurately predicted. The model presented in chapter 5 allowed us to associate baseline 
patient and disease characteristics to treatment response (remission) in treated with 
(combination) DMARD therapy. Despite several strong associations, the predictive 
power of the model was not adequate to allow for accurate individual predictions. To 
get closer to a personalized health care approach, studies looking to identify genetic 
factors and biomarkers associated with treatment response are emerging, some with 
promising results (19). Unfortunately, the predictive power of these technologies have 
mostly been investigated independently, while optimal prediction may be achieved by 
the combination of clinical, genomic and serologic biomarkers. Successful combination 
and validation of these modalities will require increased collaboration across research 
groups and consortiums (19).
A third challenge lies in the further optimization of rheumatoid arthritis care to patient 
needs. While rheumatologists often mainly focus on treatment targets, patients’ needs 
remain unmet across domains such as pain, physical function, mental function and 
fatigue (20). Therefore, it is important that doctors recognize these needs and address 
them, where possible, with appropriate interventions (20). Some of these interventions, 
that have shown to be effective in other areas, may require further evaluation in rheu-
matoid arthritis before they are offered to patients on a large scale. As an example, both 
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cognitive behavioral therapy and physical therapy have shown to be effective in reducing 
fatigue in cancer patients. Fatigue continues to have a considerable negative impact on 
more than half of patients with RA (21) and DMARD treatment often fails to produce 
meaningful improvements in levels of fatigue in RA patients. Therefore, it could be of 
interest to investigate whether cognitive behavioral therapy and physical therapy are ef-
fective in reducing levels of fatigue in RA patients in a randomized controlled clinical trial.
At last, while current evidence seems to indicate that for the average patient in clinical 
remission, treatment de-escalation may be safely attempted in shared decision with the 
patient, it is possible that there is a small subgroup of that experiences a dispropor-
tionally high burden of negative effects. Therefore, it may be worthwile to more closely 
study the effects of treatment de-escalation on individual patients. Outcomes of interest 
could for instance be radiographic progression and functional limitations (e.g. limitations 
at work) during flare. While the randomized controlled trial is still te gold standard to 
measure causal effects of an intervention such as treatment de-escalation, it may not 
be feasible to address these questions for practical reasons. While patient inclusion 
is known to be difficult in treatment de-escalation studies in general, this will be an 
even a bigger problem when studying rare outcomes that only occur in a small subset 
of patients. Furthermore, now that treatment de-escalation has been included in the 
guidelines and is more common in daily clinical practice, it may be even more difficult 
to find eligible patients willing to participate. Either because patients have a very strong 
wish have an to attempt to de-escalate treatment, or because they already had such an 
attempt that failed and do not wish to have another attempt. Therefore, it is possible 
that these questions may only be adequately addressed by means of observational data. 
To this end, hospital registries should be built, in which relevant patient and disease 
characteristics are stored. Such a database should minimally include relevant patient 
characteristics such as disease duration and RF/ACPA status, as well as outcomes such 
as DAS, X-ray data and patient-reported outomes that are measured at a regular basis, 
as well as adequate prescription data on DMARDs. Ideally, concensus should be reached 
by different hospitals on the set of data that is gathered so that registries from different 
hospitals can be combined. Because of the observational and repeated nature of the 
data, combinations of more advanced statistical methods such as multiple imputation, 
longitudinal models and causal inference methods may be used to gain maximal insight 
from these data.
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sUMMARY
Although many advances have been made in the medical treatment of RA, challenges to 
further optimize care for patients remain. One of these challenges is that, despite medical 
outcomes have improved, the burden of disease in RA patients is still higher compared 
to the general population. This may be attributed, at least in part, to higher levels of 
psychological distress patients experience. Another challenge is the question whether 
or not medical drug treatment with DMARDs should be continued in patients that have 
reached a disease state of remission, or that treatment may be de-escalated. Continuous 
medical drug treatment for patients in remission is only justified if the benefits outweigh 
the disadvantages such as potential overtreatment, safety considerations and treatment 
costs. These challenges resulted in the main objectives of this thesis:
1. To study the impact of psychosocial factors on patients with early RA, with special 
interest in the relationships between psychosocial factors and disease activity score 
and achievement of treatment goals
2. To study the effects of treatment de-escalation in patients with low disease activity 
or remission and aid rheumatologists in making informed decisions with regard to 
treatment de-escalation
In chapter 2 we showed that health related quality of life in newly diagnosed RA patients 
improves over time, but remains lower than that of the general population. A similar 
pattern was observed for patients with joint complaints without synovitis. Improvements 
over time were also observed for pain scores and functional ability, whereas fatigues 
score remained relatively constant over time in both groups. Health care consumption 
levels were comparable between groups. In RA patients, more health care consumption 
was associated with a shorter time since diagnose, shorter duration of complaints, higher 
baseline physical health and lower chance locus of control.
In chapter 3 we investigated whether psychosocial factors have an additional effect 
on the disease activity score measured 3 months later and which compounds of psycho-
social factors are the most influencing ones during the first year of follow-up. We found 
that baseline anxiety and coping with pain were associated with DAS at 3 months, coping 
with pain at 6 months was associated with DAS at 9 months and fatigue at 12 months 
was associated with DAS at 15 months. Psychosocial factors were moderately correlated 
to each other. Effects on DAS appeared to occur mainly through subjective components 
of the DAS: Tender joint count and global health.
In chapter 4 we investigated the prevalence and course of fatigue over time in newly 
diagnosed RA patients during the first year of follow-up. We found that, despite a treat 
to target strategy, almost half of the early rheumatoid arthritis patients show high levels 
of fatigue over the first year of diagnosis. On group level, fatigue only decreased slightly, 
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while on individual level fluctuation was seen. Predictors for the course of fatigue over 
time were also investigated. In the group with low fatigue at baseline, univariable analyses 
revealed tender joints, VAS global, DAS, anxiety, depression and SF36 mental component 
score to be associated with development of fatigue, of which depression and coping with 
limitations remained as independent predictors in multivariable analysis.
In chapter 5, we explored which factors predict early remission within 6 months and 
sustained remission at 6 and 9 months of follow-up in RA patients initiating DMARD 
therapy. We identified younger age, male sex, lower baseline DAS and lower levels of 
baseline anxiety as independent predictors for remission within 6 months. Younger age, 
male sex, ACPA negativity, and lower levels of baseline fatigue were independent predic-
tors for sustained remission at 6 and 9 months.
In chapter 6, we investigated the tapering of DMARDs in patients with early arthritis 
in sustained remission, with a focus on conventional synthetic DMARDs. We found that, 
during 2 years of follow-up, sustained remission (DAS<1.6 at 2 consecutive visits) was 
achieved at least once by 159 (57%) of patients. Of these patients, 118 and 23 initiated 
tapering of conventional synthetic and biologic DMARDs respectively. Estimated flare 
rates at 1 year were 41% and 37% respectively. After flare, re-remission was achieved 
within 6 months by 65% of patients tapering csDMARDs after treatment intensification. 
In chapter 7, we performed a systematic literature review about tapering or de-
escalation of synthetic and biologic DMARDs in RA patients in a state of low disease 
activity or remission. Only four, mostly dated studies, evaluated synthetic DMARDs, in 
which flare rates ranged from 8% at 24 weeks to 63% at 4 months after de-escalation. On 
fifteen studies reporting on TNF-blockers we performed a meta-analysis and obtained a 
pooled 1-year flare rate of 33% (95% CI 23% – 73%). For other biologicals like abatacept 
and tocilizumab, flare rates ranged from 34% at 1 year to 72% at 6 months. Only 5 studies 
evaluated radiographic progression, all of which found limited to no progression. In 7 
studies evaluating time to remission after flare, the majority of patients achieved re-
remission within 6 months after treatment intensification.
In chapter 8, we explored the preferences of rheumatologists with respect their deci-
sion to de-escalate DMARDs in patients with rheumatoid arthritis. In semi-structured 
interviews of 12 randomly selected rheumatologists, the number of swollen joints, pres-
ence of DAS remission or low disease activity, patient history, duration of remission/LDA 
and patient willingness to de-escalate DMARDs were mentioned as being relevant for the 
decision to de-escalate DMARDs. These factors were incorporated into the DCE question-
naire, which was completed by 156 rheumatologists from across The Netherlands. In the 
analysis, all identified factors were significant, of which swollen joint count and patient 
history were most important. In a subsequent latent class analyses we explored hetero-
geneity. We found 5 different subgroups of doctors, showing differences with respect to 
willingness to de-escalate and the relative importance of the 5 patient characteristics. 
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For the majority of hypothetical patients, little consensus was observed among doctors 
with respect to the feasibility of tapering.
Chapter 9 provides a general discussion of the main findings of this thesis and their 
relevance to clinical practice. Methodological considerations and their potential implica-
tions on the findings are discussed. Finally, several recommendations for future research 
are presented.
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sAMenVATTInG
De laatste jaren is veel vooruitgang geboekt in de medicamenteuze behandeling van RA. 
Echter, uitdagingen om de behandeling verder te verbeteren zijn er nog steeds. Eén van 
deze uitdagingen is dat patiënten, ondanks dat ziekte uitkomsten zijn verbeterd, nog 
steeds een slechtere kwaliteit van leven ervaren vergeleken met de algehele populatie. 
Dit kan onder meer worden toegeschreven aan een hogere mate van psychisch on-
welbevinden bij deze patiënten. Een tweede uitdaging is de vraag of medicamenteuze 
behandeling met DMARDs moet worden voortgezet bij patiënten bij wie de ziekte tot 
rust is gekomen (remissie), of dat moet worden geprobeerd om de behandeling met 
medicijnen te verminderen. Het doorgaan met medicamenteuze behandeling bij patiënt-
en in remissie is alleen gerechtvaardigd als de voordelen opwegen tegen de nadelen, 
waaronder mogelijke overbehandeling, veiligheidsrisico’s en kosten van de behandeling. 
Deze uitdagingen hebben geleid tot de volgende doelstellingen van dit proefschrift:
1. Het onderzoeken van de impact van psychosociale factoren op patiënten met vroege 
RA, met als specifiek aandachtspunt de relaties tussen psychosociale factoren en de 
ziekte acitiviteitsscore (DAS) en het bereiken van behandeldoelen.
2. Het onderzoeken van de gevolgen van het afbouwen van medicijnen in patiënten met 
RA, wiens ziekte in een staat is van lage ziekteactiviteit of remissie en om reumatolo-
gen te helpen bij het maken van geïnformeerde beslissingen met betrekking tot het 
afbouwen van medicijnen.
In hoofdstuk 2 lieten we zien dat de kwaliteit van leven van patiënten met reumatoïde 
artritis, bij wie pas de diagnose is gesteld, verbetert met de tijd. Echter, de kwaliteit van 
deze patiënten blijft lager wanneer je die vergelijkt met die in van de algehele populatie. 
Een vergelijkbaar beeld kwam naar voren bij patiënten die zich presenteerden met 
gewrichtsklachten, maar bij wie de reumatoloog geen zwelling van de gewrichten 
(synovitis) vast kon stellen. Verbeteringen met de tijd werden ook gezien bij pijnscores 
en fysiek functioneren, terwijl scores voor vermoeidheid in beide groepen nauwelijks 
verbeterden. De twee groepen hadden een verglijkbare mate van gebruik van gezond-
heidszorg. Bij patiënten met reumatoïde artritis waren een kortere tijd sinds de diagnose, 
een kortere klachtenduur, een hogere score voor fysieke gezondheid en een lagere score 
voor “chance locus of control” geassocieerd met een hoger zorggebruik.
In hoofdstuk 3 onderzochten we of psychosociale factoren een toegevoegde waarde 
hebben in het kunnen verklaren van de ziekte activiteit score (DAS) 3 maanden later. 
Tevens onderzochten we welke psychosociale factoren het meeste invloed hadden op de 
DAS gedurende het eerste jaar dat de diagnose RA is gesteld. We vonden dat angst en 
coping met pijn op het moment van diagnose waren geassocieerd met de DAS 3 maan-
den later. Coping met pijn op 6 maanden was geassocieerd met de DAS na 9 maanden 
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en vermoeidheid op 12 maanden was geassocieerd met de DAS na 15 maanden. De psy-
chosociale factoren waren matig gecorreleerd met elkaar. De effecten van psychosociale 
factoren op de DAS leken vooral plaats te vinden door beïnvloeding van de subjectieve 
componenten van de DAS: Tender joint count (aantal pijnlijke gewrichten bij lichamelijk 
onderzoek door de arts) en global health (algehele gezondheid volgens de patiënt).
In hoofdstuk 4 hebben we gekeken naar het voorkomen van (prevalentie) en het beloop 
over de tijd van vermoeidheid bij RA patiënten tijdens het eerste jaar nadat de diagnose 
is gesteld. We vonden dat, ondanks een behandelwijze waarbij wordt gestreefd naar 
een lage score voor de ziekteactiviteit (treat-to-target), bijna de helft van de patiënten 
hoge scores voor vermoeidheid hadden gedurende het eerste jaar na de diagnose. Op 
groepsniveau verbeterde de vermoeidheid maar minimaal, terwijl op individueel niveau 
schommelingen werden gezien. Voorspellende factoren voor het beloop van vermoe-
idheid over de tijd werden eveneens onderzocht. In de groep met een lage score voor 
vermoeidheid op het moment van diagnose waren het aantal pijnlijke gewrichten, VAS 
global, ziekteactiviteitsscore (DAS), angst, depressie en de SF36 mental component scale 
geassocieerd met het ontwikkelen van vermoeidheid. In multivariable analyses bleken 
depressie en coping met beperkingen onafhankelijke voorspellers te zijn voor vermoe-
idheid.
In hoofdstuk 5 verkenden we welke factoren vroege remissie (minimale ziekteactivit-
eit) binnen 6 maanden en remissie op zowel 6 als 9 maanden na diagnose voorspelden 
bij RA patiënten die begonnen met een behandeling met “disease modifying anti-
rheumatic drugs” (DMARDs). We vonden dat een jongere leeftijd, mannelijk geslacht, 
een lagere DAS op het moment van diagnose en lagere scores voor angst op het moment 
van diagnose onafhankelijke voorspellers waren voor het bereiken van remissie binnen 6 
maanden. Een jongere leeftijd, mannelijk geslacht, negatieve anti-CCP en lagere scores 
voor vermoeidheid op het moment van diagnose waren onafhankelijke voorspellers voor 
remissie op zowel 6 als 9 maanden.
In hoofdstuk 6 onderzochten we het afbouwen van DMARDs bij patiënten met reuma-
toïde artrtitis in persisterende remissie (DAS<1.6) op 2 of meer opéénvolgende 3-maan-
delijkse bezoeken, met speciale aandacht voor synthetische DMARDs. We vonden dat, 
gedurende 2 jaar na de diagnose, persisterende remissie tenminste 1 maal werd behaald 
door 159 (57%) van de patiënten. Van deze patiënten begonnen er respectievelijk 118 
en 23 met het afbouwen van conventionele synthetische DMARDs (csDMARDs) en biolo-
gische DMARDs. Het risico op opvlammen van de ziekte binnen 1 jaar werd geschat op 
respectievelijk 41% en 37%. Na het optreden van een opvlamming van de ziekte werd 
remissie opnieuw behaald binnen 6 maanden door 65% van de patiënten die csDMARDs 
afbouwden na het intensiveren van de behandeling.
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In hoofdstuk 7 verrichtten we een systematisch literatuuronderzoek naar het afbouwen 
van synthetische en biologische DMARDs bij RA patiënten die in een staat van remissie 
of lage ziekteactiviteit verkeerden. In slechts 4, veelal gedateerde, publicaties werden 
synthetische DMARDs onderzocht, waarbij het risico op een opvlamming varieerde van 
8% 24 weken tot 63% 4 maanden nadat werd begonnen met afbouwen. Op 15 studies 
die rapporteerden over TNF-blockers verrichtten we een meta-analyse en vonden een 
gezamenlijk risico op opvlamming binnen 1 jaar van 33% (95% betrouwbaarheidsinterval 
23%-73%). Voor andere biologische DMARDs, zoals abatacept en tocilizumab, varieerden 
de risico’s op een opvlamming van 34% na 1 jaar tot 72% na 6 maanden. Slechts 5 
onderzoeken keken naar het voortschrijden van gewrichtsschade op röntgenfoto’s, allen 
vonden weinig tot geen toename. In 7 onderzoeken die de tijd tot het opnieuw bereiken 
van remissie bekeken, behaalde het merendeel van de patiënten opnieuw remissie na 
het intensiveren van de behandeling.
In hoofdstuk 8 onderzochten we de voorkeuren van reumatologen met betrekking 
tot het besluit om DMARDs af te bouwen bij patiënten met RA. Uit interviews met 12 
willekeurig gekozen reumatologen kwamen het aantal gezwollen gewrichten bij licha-
melijk onderzoek, het hebben van remissie of lage ziekteactiviteit volgens de DAS, voorge-
schiedenis van de patiënt, duur van remissie of lage ziekteactiviteit en de bereidheid van 
de patiënt zelf om af te bouwen naar voren als relevante factoren in de overweging van 
de reumatologen om DMARDs af te bouwen. Deze factoren weden opgenomen in de 
DCE (discrete choice experiment) vragenlijst, die werd ingevuld door 156 reumatologen 
afkomstig uit heel Nederland. In de analyse hiervan waren alle eerder genoemde facto-
ren significant, waarvan het aantal gezwollen gewrichten en de voorgeschiedenis van de 
patiënt het belangrijkste bleken. In een vervolganalyse (latent class analyse) keken we of 
er sprake kon zijn van heterogeniteit (dat reumatologen verschillen in de afwegingen die 
ze maken). We vonden 5 subgroepen van dokters, die verschilden van elkaar wat betreft 
hun algehele bereidheid om af te bouwen en de mate waarin zij belang hechtten aan de 
5 verschillende factoren. Bij het merendeel van de denkbeeldige patiënten voor wie de 
reumatologen moesten besluiten, werd er weinig overeenstemming gezien tussen de 
dokters of zij wel of niet gingen afbouwen.
Hoofdstuk 9 betreft een algehele discussie van de belangrijkste bevindingen van dit 
proefschrift en hun relevantie voor de klinische praktijk. Methodologische overwegingen 
en hun mogelijke consequenties voor bevindingen worden besproken. Als laatste worden 
enkele aanbevelingen voor toekomstig onderzoek gepresenteerd.
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DAnKWOORD
Na alle voorgaande hoofdstukken zijn we nu dan eindelijk aanbeland bij het hoofdstuk 
waar het uiteindelijk allemaal om gaat... Het dankwoord! Over de jaren heb ik ondertus-
sen met vele mensen mogen samenwerken en het zal moeilijk zijn om iedereen hier 
persoonlijk te bedanken. Maar ik zal in ieder geval een poging wagen.
Terugkijkend op mijn promotietraject is het voor mij zeker niet altijd een makkelijke pe-
riode geweest. Behalve problemen met de inclusies van de TARA studie, waar ik aanvan-
kelijk op zou gaan promoveren, kreeg ik op persoonlijk vlak ook de nodige uitdagingen 
te verwerken. Bovendien bleek een carrière als medisch specialist, die ik sinds ik begon 
met de studie geneeskunde voor ogen had gehad, toch minder goed bij mij te passen dan 
ik had gehoopt. Maar tot zover het droevige gedeelte. Inmiddels heb ik helemaal mijn 
weg gevonden in de data analyse statistiek. En ik kan toch wel zeggen dat mijn promo-
tieonderzoek aan de basis heeft gestaan van waar ik nu sta en ik er op meerdere vlakken 
enorm veel van heb geleerd. Iets waar ik nu met dankbaarheid op kan terugkijken. Graag 
zou ik daarom hier een aantal mensen met name bedanken die een belangrijke rol heb-
ben gespeeld bij het tot stand komen van dit proefschrift of die mij anderszins bijzonder 
tot steun zijn geweest.
Allereerst mijn promotor, professor Hazes. Beste Mieke, ondanks je overvolle agenda 
wist je, samen met Joyce, toch altijd wel een moment te vinden om me op weg te helpen 
als dat nodig was. Je was altijd  enthousiast als ik nieuwe resultaten kwam laten zien 
en toonde daarnaast ook persoonlijke belangstelling. Je hebt me geleerd om met een 
kritische houding onderzoek te doen, maar ook dat goed soms goed genoeg is en dat wat 
algemeen als wetenschappelijke waarheid wordt aangenomen vaak minder hard is dan 
je op het eerste gezicht zou denken.
Beste Jolanda, mijn copromotor. Behalve je kritische blik die vaak wordt genoemd, heb 
ik je  leren kennen als iemand met veel humor en een overvloed aan originele ideeën. 
Een mooi voorbeeld hiervan is het DCE onderzoek bij de reumatologen, wat tot één van 
mijn persoonlijk favoriete hoofdstukken van dit boekje heeft geleid. Daarnaast ben jij 
het geweest die mijn interesse heeft gewekt in statistiek en het succesvol toepassen van 
alternatieve statistische methoden in mijn eigen onderzoek en inmiddels ook bij dat van 
anderen.
Beste Angelique, mijn andere copromotor. Door mijn onderzoek op de tREACH data ben 
je betrokken geraakt bij mijn promotietraject en ben je hierin een steeds grotere rol gaan 
spelen. Ik weet nog goed dat toen je me probeerde over te halen om mijn promotietra-
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ject in het Maasstad ziekenhuis af te ronden ik hier aanvankelijk mijn bedenkingen bij 
had. Voor onderzoek en complexe analyses moest je toch immers niet in een perifeer 
ziekenhuis zijn? Ik ben blij dat ik  toch naar je heb geluisterd. Het Maasstad ziekenhuis 
bleek zo’n vervelende plek nog niet en ik werd enthousiast ontvangen door de vakgroep 
reumatologie. Niet alleen kreeg ik de gelegenheid om dit proefschrift af te ronden, ook 
kon ik mijn analytische vaardigheden inzetten bij nieuwe en lopende onderzoeken op 
de afdeling, waaronder de Impact, Joint Care en het value-based healthcare project. 
Daarnaast reed ik ook nog 2 of 3 keer in de week op en neer naar Gent om in deeltijd een 
master statistiek te volgen kon ik meteen het geleerde in de praktijk toepassen met het 
geven van statistische consulten in het ziekenhuis. Achteraf gezien had ik me geen betere 
werkplek kunnen wensen en daarvoor ben ik jou (en Marc en de rest van de vakgroep 
reumatologie natuurlijk) enorm dankbaar voor de kans die jullie mij gegeven hebben. 
Daarbij was (en is) het altijd prettig om met je te werken. Je gaf me de ruimte en door je 
enthousiasme en positieve instelling wist je me toch altijd te motiveren en te inspireren 
om door te zetten en de zaken af te maken.
Pascal, de tREACH-man mag uiteraard ook niet ontbreken in dit dankwoord! Een groot 
deel van dit boekje gaat over de tREACH studie welke jij vanaf het begin zo succesvol hebt 
opgezet en gecoördineerd! Toen ik de taken van je overnam was je altijd bereid om me 
op weg te helpen en adviezen te geven. Daarbij was het altijd leuk om met je samen te 
werken zoals bij het organiseren van het “Future of RA” symposium!
Myrthe, het coördineren van de TARA was best een klus met zoveel ziekenhuizen en 
alsmaar  tegenvallende inclusies, maar samen hebben we er toch het beste van gemaakt! 
Het was altijd fijn om met je te werken en je had altijd leuke ideeën voor acties om de 
dokters tot includeren aan te moedigen. Ik wens je heel veel geluk toe met je lieve kleine 
(en grote) man en hoop op een mooi vervolg van je carrière met je PhD titel!
Maar natuurlijk zat ik niet alleen met Myrthe op de kamer. Annelieke, om je grappige 
uitspraken (zowel tegen mensen als computers) moest ik altijd lachen! En ook David, 
Sjel, Hilal, Jenny,  Florentien, Marie-Louise en Albert wil ik bedanken voor de leuke en 
gezellige tijd op de kamers. En natuurlijk ook onze buren, Esther, Kim en Lonneke. En 
Maren, dank je voor je geduldige uitleg hoe ik nu eindelijk de plakjes kaas op de goede 
manier uit het plastic krijg. :)
Ook heb ik twee studenten begeleid die ik graag in dit dankwoord wil vermelden, 
aangezien zij hebben bijgedragen aan twee artikelen in dit proefschrift. Hong, het was 
altijd fijn om met je te werken en het was opvallend hoe zelfstandig je was. Je scriptie 
heeft de basis gevormd voor hoofdstuk 3 en is onlangs gepubliceerd! Riëtte, dankzij jouw 
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organisatorische skills hebben we in korte tijd een heel discrete choice experiment kun-
nen opzetten en uitvoeren onder alle reumatologen op tijdens de NVR najaarsdagen. 
Als team vulden we elkaar perfect aan, wat heeft geleid tot hoofdstuk 8 van dit boekje 
en een publicatie. En Margot, bedankt voor de fijne samenwerking aan hoofdstuk 4, 
waar we veel werk aan hebben gehad, maar waar we binnenkort hopelijk ook een mooi 
journal voor zullen vinden.
Voor de ondersteuning van het onderzoek dat ik heb gecoördineerd wil ik ook graag 
Anke en Sjaan vermelden, die diverse ziekenhuizen in de omgeving afreisden om maar 
patiënten te zien voor de studies. Daarnaast wil ik natuurlijk ook Connie bedanken en de 
research verpleegkundigen en medewerkers uit de andere ziekenhuizen die zich hebben 
ingezet voor het onderzoek: Tania, Gera, Joanne en Mireille (Maasstad ziekenhuis), Ari-
anne en Liesbeth (Albert Schweitzer ziekenhuis), Lida (Amphia ziekenhuis), Anneke en Lia 
(Groene Hart ziekenhuis) en Louisa (Haga ziekenhuis). Van het studenteam wil ik graag 
Nigara bedanken op wie ik altijd kon rekenen en Vera voor het opvragen en verwerken 
van alle röntgenfoto’s en natuurlijk alle andere studenten uit het team die over de jaren 
het werk hebben ondersteund en gegevens hebben opgezocht in alle ziekenhuizen.
Verder wil ik graag alle reumatologen en andere medewerkers uit de ziekenhuizen be-
danken, zonder wiens inzet mijn onderzoek niet mogelijk was geweest en uiteraard ook 
alle patiënten die zich alle jaren belangeloos hebben ingezet om de kennis rondom hun 
ziekte te vergroten en de zorg een stukje beter te  maken.
Ron, bij vragen en problemen met de database kon ik altijd bij jou terecht en meestal wist 
je met wat speurwerk het probleem ook nog snel te verhelpen. Joyce, jou wil ik bedanken 
voor het organiseren van de leuke uitjes, waarvan met name de eendenrace me nog 
goed bij staat! En voor dat je altijd wel iets wist te verzinnen als Miekes agenda helemaal 
vol stond, maar ik haar toch echt even nodig had.
Het laatste deel van mijn promotie heb ik vanuit het Maasstad ziekenhuis afgerond. 
De afdeling reumatologie van het Maasstad ziekenhuis heb ik leren kennen als een 
ambitieuze afdeling met een  fijne werksfeer, waar hard gewerkt wordt maar zeker ook 
met elkaar gelachen. Daarbij wordt er flink aan de weg getimmerd op het gebied van 
wetenschappelijk onderzoek en value-based healthcare. Ik vind dat best iets om trots op 
te zijn en ben dan ook blij dat ik hier aan heb mogen bijdragen en nog steeds mag doen.
Met veel plezier heb ik er samengewerkt met de andere onderzoekers op de verdieping, 
eerst Sandhya en later Arno, Deirisa, Nienke en Maha en de research verpleegkundigen 
Iris en Elise. En bovendien heb ik hier ook mijn twee prachtige paranimfen gevonden! 
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Tessa en Daisy, meer dan jullie beseffen zijn jullie me tot steun geweest in deze laatste 
fase, waarin ik er na wat grapjes met elkaar, een hiphop nummer  van Daisy en een snack 
uit Tessa’s la weer even tegenaan kon! Ik ben dan ook zeer verheugd dat jullie mij bij 
willen staan bij mijn verdediging.
Maar natuurlijk hebben ook buiten mijn werkkring mensen mij gesteund bij de totstand-
koming van dit proefschrift die ik hier graag wil bedanken.
Lieve pap en mam, dank voor jullie onvoorwaardelijke steun en begrip. Met alle verschil-
lende studiekeuzes en carrière switchen hebben jullie je vast meer dan eens afgevraagd 
of ik zelf eigenlijk wel wist wat ik wilde gaan doen. Toch heb ik daar nooit iets van gemerkt 
en hebben jullie me altijd zelf mijn weg laten kiezen. Gelukkig maar, want ik heb nu 
toch mijn weg gevonden en van alle stukjes heb ik nu profijt! Ik hoop dat er nu een iets 
rustigere periode zal aanbreken en kijk al uit naar onze reis naar Spitsbergen deze zomer!
Lieve Francisca, dankjewel dat je er altijd voor mij bent.
Mijn lieve buren Robert en Christina, bij jullie voel ik mij altijd welkom en thuis. Na een 
lange dag werken is het altijd fijn om bij jullie te zijn. Lieve Mika, niks kan me meer 
opvrolijken dan om samen met jou te spelen! Voor je aanstaande verjaardag krijg je in 
ieder geval een boekje met je naam erin (maar ook een over de brandweer als je die 
liever wilt lezen)!
Stephanie, dank je voor je steun als ik er weer eens helemaal klaar mee was. Ook jij mag 
trots zijn op wat je hebt bereikt! 
Dear Marta, It was always fun playing tennis with you. Now that we have both finished 
our PhD’s, I hope we will find the time to meet and play again soon! And I would love to 
see Heidelberg too!
Thomas, het was altijd plezant om samen te studeren en aan de groepsopdrachten te 
werken voor de statistiek master. Heel veel geluk gewenst met je nieuwe functie!
Fien, je grappige berichtjes vrolijken me altijd op! Heel veel succes met het afronden van 
je studie en je PhD! Het is nu veel werk, maar het komt goed!
